CA2260973C - Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon - Google Patents

Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon Download PDF

Info

Publication number
CA2260973C
CA2260973C CA002260973A CA2260973A CA2260973C CA 2260973 C CA2260973 C CA 2260973C CA 002260973 A CA002260973 A CA 002260973A CA 2260973 A CA2260973 A CA 2260973A CA 2260973 C CA2260973 C CA 2260973C
Authority
CA
Canada
Prior art keywords
oligonucleotide
nucleotide sequence
strand
nucleotide
extended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002260973A
Other languages
French (fr)
Other versions
CA2260973A1 (en
Inventor
Irina A. Nazarenko
Satish K. Bhatnagar
Emily S. Winn-Deen
Robert J. Hohman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EMD Millipore Corp
Original Assignee
Intergen Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/778,487 external-priority patent/US5866336A/en
Application filed by Intergen Co filed Critical Intergen Co
Publication of CA2260973A1 publication Critical patent/CA2260973A1/en
Application granted granted Critical
Publication of CA2260973C publication Critical patent/CA2260973C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6818Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]

Abstract

The present invention provides labeled nucleic acid amplification oligonucleotides, which can be linear or hairpin primers or blocking oligonucleotides. The oligonucleotides of the invention are labeled with donor and/or acceptor moieties of molecular energy transfer pairs. The moieties can be fluorophores, such that fluorescent energy emitted by the donor is absorbed by the acceptor. The acceptor may be a fluorophore that fluoresces at a wavelength different from the donor moiety, or it may be a quencher. The oligonucleotides of the invention are configured so that a donor moiety and an acceptor moiety are incorporated into the amplification product. The invention also provides methods and kits for directly detecting amplification products employing the nucleic acid amplification primers. When labeled linear primers are used, treatment with exonuclease or by using specific temperature eliminates the need for separation of unincorporated primers. This "closed-tube" format greatly reduces the possibility of carryover contamination with amplification products, provides for high throughput of samples, and may be totally automated.

Description

NUCLEIC ACID AMPLIFICATION
OLIGONUCLEOTIDES WITH MOLECULAR ENERGY
TRANSFER LABELS AND METHODS BASED THEREON
This application is a continuation-in-part of U.S. Patent No 6,117,E;35 dated ~;eptenber 12, 2000, which in turn is a continuation-in-part of U.S. Patent No.
5,866,336, which in turn is a continuation-in-part of PCT
International Publication WO 98C2449.
1. INTRODUCTION
The present. invention relates to oligonucleotides for amplification of nucleic acids that are detestably labeled with molecular energy transfer (MET) labels. It also relates to methods for detecting the products of nucleic acid amplification using these oligonucleotides. It further relates.to a rapid, sensitive, and reliable method for detecting amplification products that greatly decreases the possibility of carryover contamination with amplification products and that is adaptable to many methods for amplification of nucleic acid sequences, including polymerase chain reaction (PCR), triamplification, and other amplification systems.
2. BACKGROUND OF THE INVENTION
2.1. FLUORESCENCE RESONANCE ENERGY TRANSFER (FRETI
Molecular energy transfer (MET) is a process by which energy is passed non-radiatively between a donor 3o molecule and an acceF~tor molecule. Fluorescence resonance energy transfer (FREE) is a form of MET. FRET arises from the properties of certain chemical compounds; when excited by exposure to particular wavelengths of light, they emit light (i.e., they fluoresce.) at a different wavelength. Such compounds are termed fluorophores. In FRET, energy is passed non-radiatively over a long distance (10-100A) between a WO 98!02449 . PCT/US97112315 donor molecule, which is a fluorophore, and an acceptor molecule. The donor absorbs a photon and transfers this energy nonradiatively to the acceptor (Forster, 1949, Z.
Naturforsch. A4: 323-327; Clegg, 1992, Methods Enzymol. 211:
353-388).
When two fluorophores whose excitation and emission spectra overlap are in close proximity, excitation of one fluorophore will cause it to emit light at wavelengths that are absorbed by and that stimulate the second fluorophore, causing it in turn to fluoresce. In other words, the excited-state energy of the first (donor) fluorophore is transferred by a resonance induced dipole - dipole interaction to the neighboring second (acceptor) fluorophore.
As a result, the lifetime of the donor molecule is decreased and its fluorescence is quenched, while the fluorescence intensity of the acceptor molecule is enhanced and depolarized. When the excited-state energy of the donor is transferred to a non-fluorophore acceptor, the fluorescence of the donor is quenched without subsequent emission of fluorescence by the acceptor. In this case, the acceptor functions as a quencher.
Pairs of molecules that can engage in fluorescence resonance energy transfer (FRET) are termed FRET pairs. In order for energy transfer to occur, the donor and acceptor molecules must typically be in close proximity (up to 70 to 100 A)(Clegg, 1992, Methods Enzymol. 211: 353-388; Selvin, 1995, Methods Enzymol. 246: 300-334). The efficiency of energy transfer falls off rapidly with the distance between the donor and acceptor molecules. According to Forster (1949, Z. Naturforsch. A4:321-327), the efficiency of energy transfer is proportional to D x 10-6, where D is the distance between the donor and acceptor. Effectively, this means that FRET can most efficiently occur up to distances of about 70 A.
Molecules that are commonly used in FRET include fluorescein, 5-carboxyfluorescein (FAM), 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE), rhodamine, 6-WO 98!02449 . PCTIUS97/12315 carboxyrhodamine (R6G), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA), 6-carboxy-X-rhodamine (ROX), 4-(4'-dimethylaminophenylazo) benzoic acid (DABCYL), and 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS).
Whether a fluorophore is a donor or an acceptor is defined by its excitation and emission spectra, and the fluorophore with which it is paired. For example, FAM is most efficiently excited by light with a wavelength of 488 nm, and emits light with a spectrum of 500 to 650 nm, and an emission maximum of 525 nm. FAM is a suitable donor fluorophore for use with JOE, TAMRA, and ROX (all of which have their excitation maximum at 514 nm).
In the 1970's, FRET labels were incorporated into immunofluorescent assays used to detect specific antigens (Ullman et al. U.S. Patents 2,998,943; 3,996,345; 4,160,016;
4,174,384; and 4,199,559). Later, in the early 1980's, several patents were received by Heller and coworkers concerning the application of energy transfer for polynucleotide hybridization (U. S. Patent Nos. 4,996,143, 5,532,129, and 5,565,322). In European Patent Application 82303699.1 (publication number EP 0 070 685 A2 dated January 26, 1983), "Homogeneous nucleic acid hybridization diagnostics by non-radioactive energy transfer," the inventors claim that they can detect a unique single stranded polynucleotide sequence with two oligonucleotides: one containing the donor fluorophore, the other, an acceptor.
When both oligonucleotides hybridize to adjacent fragments of analyzed DNA at a certain distance, energy transfer can be detected.
In European Patent Application 86116652.8 (publication number EP 0 229 943 A2 dated July 29, 1987; "EP
'943"), entitled "Fluorescent Stokes shift probes for polynucleotide hybridization assays," Heller et al. propose . the same schema, but with specified distances between donor and acceptor for maximum FRET. They also disclose that the donor and acceptor labels can be located on the same probe (see, e.g., EP '943: Claim 2 and Figure 1).
- 3 -A similar application of energy transfer was disclosed by Cardullo et al. in a method of detecting nucleic acid hybridization (1988, Proc. Natl. Acad. Sci. USA 85:
8790-8794). Fluorescein (donor) and rhodamine (acceptor) are attached to 5' ends of complementary oligodeoxynucleotides.
Upon hybridization, FRET may be detected. In other experiments, FRET occurred after hybridization of two fluorophore-labeled oligonucleotides to a longer unlabeled DNA. This system is the subject of PCT Application PCT/TJS92/1591, ~crrespon..ding to Publication No. WO 92/14845 dated September 3, 1992 ("PCT
'845," entitled "Diagnosing cystic fibrosis and other genetic diseases using fluorescence resonance energy transfer"). PCT
'845 discloses a metlhod for dete=ction of abnormalities in human chromosomal DN;?~ associated with cystic fibrosis by hybridization. The :FRET signal used in this method is generated in a manner similar to that disclosed by Heller et al. (see PCT '845 Figure 1) . Ot=her publications have disclosed the use of energy transfer in a method for the estimation of distances between specific sites in DNA (Ozaki and McLaughlin, 1992,, Nucl. Acids Res. 20:_ 5205-5214), in a method for _the analy;~is of strucaure of four way DNA junction (Clegg et al. 1992, Biochem. 31: 4846-4856), and in a method for observing the he:Lical geometry of DNA (Clegg et al. , ,.:
1993, Proc. Natl. Acad.~Sci. USA 90: 2994-2998).
2.2. OTHER TYPES OF MOLECUI:,AR ENERGY TRANSFER (MET) As described in Section 2.1, fluorescence resonance energy transfer (FRET) is one form of molecular energy transfer (MET) . In FRET, the er.~ergy donor is fluorescent, but the energy acceptor may be fluorescent or non-fluorescent. In the case of a fluorescent energy acceptor, energy transfer results in a decrease in the emission of the donor or an increase in emission. of the acceptor (Clegg, 1992, Methods Enzymol.. 211: 353-388; Selvin, 1995, Methods Enzymol. 246: 300-334; Stryer, 1978, Ann. Rev. Biochem.
47:819-846). In the case of a non-fluorescent acceptor,
- 4 -WO 98/02449 . PCTIUS97112~15 e.g., a chromophore or a quencher, energy transfer results in an increase in the emission of the donor (Matayoshi, et al., 1990, Science 247: 954-958; Tyagi and Kramer, 1996, Nature Biotech. 14:303-309; Steinberg, 1991, Ann. Rev. Biochem.
40:83-114).
In another form of MET, the energy donor is non-fluorescent, e.g., a chromophore, and the energy acceptor is fluorescent. In this case, energy transfer results in an increase in the emission of the acceptor (Heller, U.S. Patent Nos. 5,532,129 and 5,565,322; Steinberg, 1991, Ann. Rev.
Biochem. 40:83-114).
In yet another form of MET, the energy donor is luminescent, e.g. bioluminescent, chemiluminescent, electrochemiluminescent, and the acceptor is fluorescent. In this case, energy transfer results in an increase in the emission of the acceptor (Selvin, 1995, Methods Enzymol. 246:
300-334, Heller European Patent Publication 0070685A2, dated January 26, 1993; Schutzbank and Smith, 1995, J. Clin.
Microbiol. 33:2036-2041). An example of such an energy transfer system is described by Selvin (supra), wherein a luminescent lanthanide chelate, e.g., terbium chelate or lanthanide chelate, is the donor, and an organic dye such as fluorescein, rhodamine or CY-5, is the acceptor.
Particularly efficient MET systems using this strategy include terbium as a donor and fluorescein or rhodamine as an acceptor, and europium as a donor and CY-5 as an acceptor.
The reverse situation, i.e., wherein the donor is fluorescent and the acceptor is luminescent, is termed "sensitized luminescence," and energy transfer results in an increase in emission of the acceptor (Dexter, 1953, J. Chem. Physics 21:
836-850).
In a theoretically possible form of MET, the energy donor may be luminescent and the energy acceptor may be non-fluorescent. Energy transfer results in a decrease in the emission of the donor.
2.3. METHODS OF MONITORING NUCLEIC ACID AMPLIFICATION
- 5 -WO 98/02449 , PCTIUS97112315 Prior to the present invention, application of energy transfer to the direct detection of genetic amplification products had not been attempted. In prior art methods of monitoring amplification reactions using energy transfer, a label is not incorporated into the amplification product. As a result, these methods have relied on indirect measurement of the amplification reaction.
Commonly used methods for detecting nucleic acid amplification products require that the amplified product be separated from unreacted primers. This is commonly achieved either through the use of gel electrophoresis, which separates the amplification product from the primers on the basis of a size differential, or through the immobilization of the product, allowing washing away of free primer.
However, three methods for monitoring the amplification process without prior separation of primer have been described. All of them are based on FRET, and none of them detect the amplified product directly. Instead, all three methods detect some event related to amplification. For that reason, they are accompanied by problems of high background, and are not quantitative, as discussed below.
One method, described in Wang et al. (U. S. Patent 5,348,853; Wang et al., 1995, Anal. Chem. 67: 1197-1203), uses an energy transfer system in which energy transfer occurs between two fluorophores on the probe. In this method, detection of the amplified molecule takes place in the amplification reaction vessel, without the need for a separation step. This method results in higher sensitivity than methods that rely on monolabeled primers.
The Wang et al. method uses an "energy-sink"
oligonucleotide complementary to the reverse primer. The "energy-sink" and reverse-primer oligonucleotides have donor and acceptor labels, respectively. Prior to amplification, the labeled oligonucleotides form a primer duplex in which energy transfer occurs freely. Then, asymmetric PCR is carried out to its late-log phase before one of the target strands is significantly overproduced.
- 6 -WO 98/02449 PCTIUS97I12~15 A primer duplex complementary to the overproduced target strand is added to prime a semi-nested reaction in concert with the excess primer. As the semi-nested amplification proceeds, the primer duplex starts to dissociate as the target sequence is duplicated. As a result, the fluorophores configured for energy transfer are disengaged from each other, causing the energy transfer process preestablished in all of the primer duplexes to be disrupted for those primers involved in the amplification process. The measured fluorescence intensity is proportional to the amount of primer duplex left at the end of each amplification cycle. The decrease in the fluorescence intensity correlates proportionately to the initial target dosage and the extent of amplification.
This method, however, does not detect the amplified product, but instead detects the dissociation of primer from the "energy-sink" oligonucleotide. Thus, this method is dependent on detection of a decrease in emissions; a significant portion of labeled primer must be utilized in order to achieve a reliable difference between the signals before and after the reaction. This problem was apparently noted by Wang et al., who attempted to compensate by adding a preliminary amplification step (asymmetric PCR) that is supposed to increase the initial target concentration and consequently the usage of labeled primer, but also complicates the process.
A second method for detection of amplification product without prior separation of primer and product is the 5' nuclease PCR assay (also referred to as the TaqMan° assay) (Holland et al., 1991, Proc. Natl. Acad. Sci. USA 88: 7276 -728~; Lee et al., 1993, Nucleic Acids Res. 21: 3761-3766).
This assay detects the accumulation of a specific PCR product by hybridization and cleavage of a doubly labeled fluorogenic probe (the "TaqMan" probe) during the amplification reaction.
The fluorogenic probe consists of an oligonucleotide labeled with both a fluorescent reporter dye and a quencher dye.
During PCR, this probe is cleaved by the 5'-exonuclease _ 7 _ activity of DNA polymerase if, and only if, it hybridizes to the segment being amplified. Cleavage of the probe generates an increase in the fluorescence intensity of the reporter dye.
In the TaqMan assay, the donor and quencher are preferably located on the 3' and 5'-ends of the probe, because the requirement that 5'-3' hydrolysis be performed between the fluorophore and quencher may be met only when these two moieties are not too close to each other (Lyamichev et al., 1993, Science 250:778-783). However, this requirement is a serious drawback of the assay, since the efficiency of energy transfer decreases with the inverse sixth power of the distance between the reporter and quencher. In other words, the TaqMan assay does not permit the quencher to be close enough to the reporter to achieve the most efficient quenching. As a consequence, the background emissions from unhybridized probe can be quite high.
Furthermore, the TaqMan assay does not measure the amplification product directly, because the amplification primers are not labeled. This assay measures an event related to amplification: the hydrolysis of the probe that hybridizes to the target DNA between the primer sequences.
As a result, this assay method is accompanied by significant problems.
First, hybridization will never be quantitative unless the labeled oligonucleotide is present in great excess. However, this results in high background (because the quenching is never quantitative). In addition, a great excess of oligonucleotide hybridized to the middle of the target DNA will decrease PCR efficiency. Furthermore, not all of the oligonucleotides hybridized to the DNA will be the subject of 5'-3' exonuclease hydrolysis: some will be displaced without hydrolysis, resulting in a loss of signal.
Another method of detecting amplification products that relies on the use of energy transfer is the "beacon probe" method described by Tyagi and Kramer (1996, Nature _ g _ WO 98102449 PCTIUS97/12~15 Biotech. 14:303-309) which is also the subject of U.S. Patent Nos. 5,119,801 and 5,312,728 to Lizardi et al. This method employs oligonucleotide hybridization probes that can form hairpin structures. On one end of the hybridization probe (either the 5' or 3' end) there is a donor fluorophore, and on the other end, an acceptor moiety. In the case of the Tyagi and Kramer method, this acceptor moiety is a quencher, that is, the acceptor absorbs energy released by the donor, but then does not itself fluoresce. Thus when the beacon is in the open conformation, the fluorescence of the donor fluorophore is detectable, whereas when the beacon is in hairpin (closed) conformation, the fluorescence of the donor fluorophore is quenched. When employed in PCR, the molecular beacon probe, which hybridizes to one of the strands of the PCR product, is in "open conformation," and fluorescence is detected, while those that remain unhybridized will not fluoresce (Tyagi and Kramer, 1996, Nature Biotechnol. 14:
303-306. As a result, the amount of fluorescence will increase as the amount of PCR product increases, and thus may be used as a measure of the progress of the PCR.
However, since this method is based on hybridization of the probe to template between the primer sequences, it has a number of problems associated with it, some of which are similar to those described above in connection with the TaqMan method. First, it is unlikely that the beacon probes will hybridize quantitatively to one strand of double-stranded PCR product, especially when the amplification product is much longer than the beacon probe.
Even those probes that are hybridized could be displaced by the second DNA strand over a short period of time; as a result, this method cannot be quantitative.
Efforts to increase the hybridization efficiency by increasing the concentration of beacon probe will result in decreased amplification efficiency, since the necessity for DNA polymerase to displace hybridized beacons during the _ reaction will slow down the rate of polymerization. An excess of probe will also increase the background. In WO 98/02449 , PCTIUS97/12315 addition, the ratio between the amplification product and the beacon probes will change as amplification proceeds, and so will change the efficiency of hybridization. Thus the detection of the amplified product may not be quantitative.
Therefore, in view of the deficiencies in prior art methods of detecting amplification products, it is clear that there exists in the art a need for an improved method of detecting amplification products rapidly, sensitively, reliably and quantitatively. The present invention solves this problem by providing nucleic acid amplification primers that are detestably labeled with energy-transfer labels. It also solves this problem by providing methods for detecting amplification products that are adaptable to many methods for amplification of nucleic acid sequences and that greatly decrease the possibility of carryover contamination with amplification products.
Citation of references herein shall not be construed as an admission that such references are prior art 2o to the present invention.
3. SUMMARY OF THE INVENTION
The present invention relates to oligonucleotides for amplification of nucleic acids that are detestably labeled with molecular energy transfer (MET) labels. One or more oligonucleotides of the invention containing a donor and/or acceptor moiety of a MET pair are incorporated into the amplified product of an amplification reaction, such that the amplified product contains both a donor and acceptor moiety of a MET pair. When the amplified product is double-stranded, the MET pair incorporated into the amplified product may be on the same strand or, when the amplification is triamplification, on opposite strands. In certain instances wherein the polymerase used in amplification has 5'-3' exonuclease activity, one of the MET pair moieties may be cleaved from at least some of the population of amplified product by this exonuclease activity. Such exonuclease - to -activity is not detrimental to the amplification methods of the invention.
The invention also relates to methods for detecting the products of nucleic acid amplification using these labeled oligonucleotides of the invention. It further relates to a rapid, sensitive, and reliable method for detecting amplification products that greatly decreases the possibility of carryover contamination with amplification products and that is adaptable to many methods for amplification of nucleic acid sequences, including polymerase chain reaction (PCR), triamplification, and other amplification systems.
The nucleic acid amplification oligonucleotides of the invention utilize the principle of molecular energy transfer (MET) between a donor moiety and an acceptor moiety.
In a preferred embodiment, the MET is fluorescence resonance energy transfer (FRET), in which the oligonucleotides are labeled with donor and acceptor moieties, wherein the donor moiety is a fluorophore and the acceptor moiety may be a fluorophore, such that fluorescent energy emitted by the donor moiety is absorbed by the acceptor moiety. In one embodiment of the present invention, the acceptor moiety is a fluorophore that releases the energy absorbed from the donor at a different wavelength; the emissions of the acceptor may then be measured to assess the progress of the amplification reaction. In another embodiment, the acceptor moiety is a quencher.
In a preferred embodiment, the amplification primer is a hairpin primer that contains both donor and acceptor moieties, and is configured such that the acceptor moiety quenches the fluorescence of the donor. When the primer is incorporated into the amplification product its configuration changes, quenching is eliminated, and the fluorescence of the donor moiety may be detected.
In one embodiment, the present invention provides nucleic acid amplification primers that form a hairpin structure in which MET will occur when the primer is not WO 98!02449 , PCTIUS97l12315 incorporated into the amplification product. In a preferred embodiment, a primer forms a hairpin structure in which the energy of a donor fluorophore is quenched by a non-fluorescing fluorophore when the primer is not incorporated into the amplification product.
In another embodiment, the present invention provides oligonucleotides that are linear (non-duplex) and that are separately labeled with donor and acceptor moieties, such that MET will occur when the oligonucleotides are incorporated into the amplification product. For example, the blocking oligonucleotide and the reverse primer complementary to the blocking oligonucleotide can be so labeled in a triamplification reaction.
In yet another embodiment, the donor moiety and acceptor moiety are on a single, linear oligonucleotide used in an amplification reaction.
The present invention also provides a method of directly detecting amplification products. This improved technique meets two major requirements. First, it permits detection of the amplification product without prior separation of unincorporated oligonucleotides. Second, it allows detection of the amplification product directly, by incorporating the labeled oligonucleotide into the product.
The present invention provides a method of directly detecting amplification products through the incorporation of labeled oligonucleotide(s) (e. g., primers, blocking oligonucleotides) wherein instead of separating unincorporated oligonucleotides from amplification product, as in prior art approaches, signal from the remaining free oligonucleotide(s) is eliminated in one (or more) of the following ways:
a) by treatment with a 3'-5' exonuclease;
b) by heating the amplification product to a temperature such that the primer-oligonucleotide duplex dissociates and, as a result, will not generate any signal; or c) by using a primer labeled with both donor and acceptor moieties and that can form a hairpin structure, in WO 98!02449 PCTILTS97/12315 which the energy transfer from donor to acceptor will occur only when the primer is not incorporated into the amplification product.
In a further embodiment, the present invention provides a method for the direct detection of amplification products in which the detection may be performed without opening the reaction tube. This embodiment, the "closed-tube" format, reduces greatly the possibility of carryover contamination with amplification products that has slowed the acceptance of PCR in many applications. The closed-tube method also provides for high throughput of samples and may be totally automated. The present invention also relates to kits for the detection or measurement of nucleic acid amplification products. Such kits may be diagnostic kits where the presence of the nucleic acid being amplified is correlated with the presence or absence of a disease or disorder.
3.1. DEFINITIONS
As used herein, the following terms shall have the abbreviations indicated.
ARMS, amplification refractory mutation system ASP, allele-specific polymerase chain reaction bp, base pairs CRCA, cascade rolling circle amplification DAB or DABCYL, 4-(4'-dimethylaminophenylazo) benzoic acid EDANS, 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acid FAM or Flu, 5-carboxyfluorescein FRET, fluorescence resonance energy transfer JOE, 2'7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein HPLC, high-performance liquid chromatography MET, molecular energy transfer NASBA, nucleic acid sequence-based amplification PSA, prostate specific antigen W0~98102449 . PCT/US97/12~15 Rhod, rhodamine ROX, 6-carboxy-X-rhodamine R6G, 6-carboxyrhodamine SDA, strand displacement amplification TAMRA, N,N,N',N'-tetramethyl-6-carboxyrhodamine TRAP, telomeric repeat amplification protocol 4. DESCRIPTION OF THE FIGURES
The present invention may be understood more fully by reference to the following detailed description of the invention, examples of specific embodiments of the invention and the appended figures described below:
Figures 1A-B illustrate schematically the structure of the hairpin primers of the invention in the (A) closed (quenched) and (B) open (emitting signal) states. o, donor fluorophore; ~, quencher fluorophore.
Figure 2 illustrates schematically the use of hairpin primers to directly measure the amplification products from a PCR in which the employed DNA polymerase lacks 5'-3' exonuclease activity. An energy transfer signal is generated upon the incorporation of the hairpin primer into the double-stranded PCR product. (a) and (b), complementary~strands of the target sequence to be amplified;
o donor fluorophore; ~, quencher; F, forward primer; R, reverse primer.
Figure 3 (Steps A-D) illustrates the amplification products from a PCR in which the employed DNA polymerase has 5'-3' exonuclease activity. (a) and (b), complementary strands of the target sequence to be amplified; o ~3onor fluorophore; ~, quencher; F, forward primer; R, reverse primer.
Figure 4 gives a schematic example of a selected target sequence (SEQ ID N0:1) ligated to a universal hairpin (SEQ ID N0:2). (d) is the selected primer sequence of 8-40 nucleotides, preferably --15 nucleotides, that is complementary to the target nucleic acid sequence to be amplified. (d~) is the 5' cohesive end of the selected WO 98/02449 , PCT/US97I12315 primer sequence. The cohesive end is 1-10 nucleotides, preferably 3-4 nucleotides, and complementary to the 5' cohesive end (a') of the universal hairpin. (b) is a loop on the universal hairpin that is long enough provide a distance of 15-25 nucleotides, preferably 20 nucleotides, between the donor (F, FAM) and the quencher (D, DABCYL) when the hairpin is in the "open" configuration. (a) and (c) are the two strands of the stem of the universal hairpin. When the selected primer sequence is ligated to the universal hairpin, the quencher (DABCYL) will be located on a nucleotide that is internal to the 3' end. The donor (FAM) may be located on a nucleotide either at the 5' end (as shown) or internal to the 5' end. The only requirement is that the donor and quencher are close enough to enable quenching when the hairpin is in the "closed" ("silent") conformation.
Figure 5 illustrates schematically the use of a FRET donor-acceptor-labeled hairpin primer in PCR. See Section 5.2.1 for a detailed description of Cycles 1-4.
Figure 6 illustrates schematically the use of a FRET donor-acceptor-labeled hairpin primer in triamplification. In this embodiment of triamplification, unlike in PCR, a third oligonucleotide ("blocker") is ligated to the extended hairpin primer. The fluorescent signal is generated as a result of replication, however, as occurs in PCR.
Figure 7 illustrates schematically triamplification using two linear primers, each labeled with a FRET moiety.
BL, blocker; R, reverse primer; F, forward primer; ~, a commercially available 3' modifying group able to protect the oligonucleotide from extension by DNA polymerase or hydrolysis by 3'-5' exonuclease on the 3' end of the blocker;
X, 2'-O-methyl-modification in reverse primer; D, donor fluorophore; Ao, acceptor fluorophore.
. Figures 8A-B illustrate the effect of (A) 3'-5' exonuclease and (B) elevated temperature on unincorporated FRET-labeled primers during triamplification. BL, blocker;
R, reverse primer; F, forward primer; P, 5' phosphate; ~, WO 98/02449 , PCTIUS97112315 protection group on 3'-end of blocker; X, 2'-O-methyl-modification in reverse primer; D, donor fluorophore; Ao, acceptor fluorophore.
Figure 9 illustrates schematically the use of hairpin primers in nucleic acid sequence-based amplification (NASBA). NASBA depends on continuous cycling of the reverse transcription and RNA transcription reactions at one temperature. See Section 5.2.3 for a detailed description of Steps 1-9.
Figure 10 illustrates schematically the use of hairpin primers in strand displacement amplification (SDA) of a double-stranded DNA target. Primers 1 and 2 differ, being forward and reverse primers, respectively. SDA depends on continuous cycling of the nicking and the polymerization /
displacement steps at one temperature. See Section 5.2.4 for a detailed description of Steps 1-4. pol, polymerase;
restrictase, restriction endonuclease.
Figures 11A-B illustrate a two-chamber amplification tube in "closed-tube" format. The tube can be inverted (Figure 11B) and used to mix 3'-5' exonuclease with amplification product only when desired, without opening the tube after amplification takes place (see Section 12, Example 6) .
Figure 12 illustrates portions of the two strands (upper strand: SEQ ID N0:3 and SEQ ID N0:4; lower strand:
SEQ ID N0:8 and SEQ ID N0:9) of the template, and the oligonucleotides, PSA-I (SEQ ID N0:5), PSA-P (SEQ ID N0:6), and PSA-B (SEQ ID N0:7), used in the amplification of human prostate specific antigen (PSA) DNA as described in all the 3o examples except those employing hairpin primers, the sequences of which are provided in Section 12.
Figures 13A-C. Figure 13A illustrates schematically the PCR amplification procedure used in the experiment described in Section 7 (Example 1). The left portion of Figure 13A illustrates a PCR amplification using a rhodamine-modified reverse primer. The right portion of Figure I3A illustrates a PCR amplification using a non-modified reverse primer. The results are shown on the accompanying denaturing 6% polyacrylamide gel (Figure 13B) and agarose gel (Figure 13C). Figure 13B compares the sizes of the DNA strands that were amplified with [32P]-labeled forward primer when non-modified reverse primer (Lane 1) or rhodamine-modified reverse primer (Lane 2) was used. Figure 13C compares the amounts of double-stranded PCR amplification product obtained with non-modified reverse primer (Lane 1) and rhodamine-modified reverse primer (Lane 2).
Figures 14A-B. Figure 14A illustrates schematically the experimental procedure used in Section 8 (Example 2). The results are shown in the accompanying denaturing 6% polyacrylamide gel (Figure 14B). Lane 1 of the gel represents a strand of amplified DNA with incorporated [32P]-and rhodamine-labeled reverse primer, while Lane 2 represents a strand of amplified DNA with incorporated [3zP]-labeled forward (F) primer.
Figures 15A-B. Figure 15A illustrates schematically the experimental procedure used in Section 9 (Example 3). The results are shown on the accompanying denaturing 15% polyacrylamide gel (Figure 15B). Lane 1 of the gel represents [32P]- and rhodamine-labeled reverse primer, Lanes 2-4 represent [32P]- and rhodamine-labeled reverse primer after incubation with T4 DNA polymerase that has 3'-5' exonuclease activity for 2 minutes (Lane 2), 5 minutes (Lane 3), and 15 minutes (Lane 4).
Figure 16 illustrates the detection of amplification product by FRET after nuclease treatment (Section 10, Example 4). Emission spectrum 1 was obtained after triamplification with DNA template and exonuclease treatment. Spectrum 2 was obtained after triamplification without DNA template and exonuclease treatment (no DNA
control).
Figures 17A-B illustrates the effect of elevated temperatures (75° C) on FRET following triamplification (A) without and (B) with DNA template (Section 11, Example 5).

WO 98102449 . PCTIUS97112315 Figures 18A-B. Figure 18A depicts the structure of the PSA cDNA upstream hairpin primer (SEQ ID NO:10). The portion of the sequence complementary to the target DNA is shown in bold. Figure 18B shows an emission spectrum of the fluorescein-labeled hairpin primer in the absence (1) and presence (2) of a DABCYL moiety. The spectra obtained from 0.5 ml of a 40 nM sample of oligonucleotide were measured as described in Section 6.4 using a 488 nm excitation wavelength.
Figure 19 shows the efficiency of amplification with the hairpin primers. Products of amplification were separated on an MDE'"" gel (FMC Bioproducts, Rockland ME). An ethidium-bromide stained gel is shown. Lanes 1-3 show the products of amplification of 10-9 M PSA cDNA with unlabeled control linear primer (Lane 1), FAM-hairpin primer (Lane 2), and FAM/DABCYL-hairpin primer (Lane 3). Lanes 4-6 show the products of amplification of 10-1' M PSA cDNA with control primer (Lane 4), FAM-hairpin primer (Lane 5), and FAM/DABCYL-hairpin primer (Lane 6). Lane M contains a 100 by marker (Gibco BRL).
Figures 20A-B illustrates schematically and shows the results, respectively, of a PCR amplification in the presence of hairpin primers. PCR amplification of PSA cDNA
was performed with two primers: an upstream hairpin primer labeled with FAM and DABCYL, and a downstream primer labeled with 32P on its 5' end (Figure 20A). An upstream primer without the hairpin structure was used as a control. The structure of the hairpin primer is presented in Figure 18A
and the sequences of the regular primers are presented in Section 12.3. Figure 20B is an autoradiogram that shows the size of the PCR product synthesized. [32P)-labeled strands of the PCR products were synthesized in the presence of the unlabeled control linear primer (Lane 1) or FAM/DABCYL -labeled hairpin primer (Lane 2) and analyzed on a 6%
denaturing polyacrylamide gel.
Figures 21A-B. Figure 21A shows the fluorescence spectra of the amplification reactions performed with the WO 98/02449 . PCTIUS97112315 hairpin primers labeled with FAM/DABCYL. The structure of the FAM/DABCYL labeled hairpin primer is presented in Figure 18A and the sequence of the regular downstream primer is presented in Section 12.3. Spectra 1-6 show the fluorescence intensity of the amplified PSA cDNA after 0 (1), 20 (2), 25 (3), 30 (4), 35 (5) or 40 (6) cycles. Figure 21B shows the fluorescence intensity of the amplification reaction mixtures and the fraction of the [32P]-labeled primers incorporated into the PCR products plotted against the number of cycles.
The incorporation of the [32P)-labeled primers into the PCR
products was determined by electrophoresis on a 6% denaturing gel and quantitated using the PhosphorImager.
Figure 22 shows the sensitivity of PCR with hairpin primers. Spectra 1-6 show the results of the amplification i5 when o (1) , to (2) , 1o2 (3) , 103 (4) , l04 (5) , 105 (6) or l06
(7) molecules of cloned PSA cDNA per reaction were used as template DNA for the 40 cycles of PCR. The structure of the FAM/DABCYL labeled hairpin primer is presented in Figure 18A
and the sequence of the regular downstream primer is presented in Section 12.3.
Figure 23 shows the visible fluorescence of PCR
products synthesized with hairpin primers. 106 (Tube 1), l0' (Tube 2), 103 (Tube 3) and 0 (Tube 4) molecules of the cloned PSA cDNA template were used as template DNA for the 40 cycles of PCR with FAM/DABCYL labeled hairpin primers. DNA
fluorescence was visualized in 0.2 ml thin-walled PCR tubes using an UV transilluminator image analysis system.
Figures 24A-G show the fluorescence intensity of PSA cDNA amplified with different FAM/DABCYL-labeled 1-:airpin primers (Figures 24A-G correspond to SEQ ID NOS:13-18, and 25, respectively). All primers had at least an 18-nucleotide sequence complementary to the target, which consisted of a 3~
single-stranded priming sequence, a 3' stem sequence and part ~ of the loop. Sequences complementary to the target DNA are shown in shadowed bold italics. f, FAM; d, DABCYL; nucl, nucleotide number; rel. (%), percent intensity of fluorescence relative to DNA amplified with Primer A.

Figure 25 illustrates schematically the use of linear primers to directly measure the amplification products from a PCR. An energy transfer signal is generated upon the incorporation of the primer into the double-stranded PCR
product. After amplification, the signal from unincorporated primer is eliminated by 3'-5' exonuclease hydrolysis. D, donor moiety; A, acceptor moiety; F, forward primer; R, reverse primer.
Figure 26 illustrates the three sets of PCR primers used in the experiments in Section 13, Example 7. Uup (SEQ
ID N0:19) and Ud (SEQ ID N0:20), are the upstream and downstream primers, respectively, for sequences of bisulfite-treated unmethylated DNA. Mup (SEQ ID N0:21) and Md (SEQ ID
N0:22), are the upstream and downstream primers, respectively, for sequences of bisulfite-treated methylated DNA. Wup (SEQ ID N0:23) and Wd (SEQ ID N0:24), are the upstream and downstream primers, respectively, for DNA not treated with bisulfite. One of the two primers in each set has a hairpin structure at its 5' end, labeled with a FAM/DAB
(DABCYL.) FRET pair at the positions illustrated.
Figure 27 shows an example of the structure of a hairpin primer, BSK38, (SEQ ID N0:26) that can be used in the in situ PCR of a gag viral sequence, described in Section 17, Example 11.
Figures 28A-B show the visual fluorescence of PCR
products synthesized with a universal hairpin primer described in Section 14, Example 8. Cloned PSA cDNA (A;
upper row) and Chlamydia genomic DNA (B; lower row) were used as a target. Column (1), complete reaction mixture. Column (2), Control 1, reaction mixture without tailed primer.
Column (3), Control 2, reaction mixture without DNA template.
Figures 29A-B show a TRAP.(telomeric repeat amplification protocol) assay that utilizes PCR and assays for telomerase activity cells or tissues of interest. In Figure 29A (Step 1)., telomerase adds a number of telomeric repeats (GGTTAG) (longest repeat shown in lower line being SEQ ID N0:27) on the 3' end of a substrate oligonucleotide (SEQ ID N0:28) (TS, telomerase substrate).
In Figure 29B (Step 2), the extended products are amplified by PCR using the TS and a reverse primer (RP), generating a ladder of products with 6 base increments starting at 50 nucleotides: 50, 56, 62, 68, etc.
Figure 30A shows the sequence of the hairpin primer (SEQ ID N0:37) that was used in the TRAP assay described in Example 9, Section 15.
Figure 30B shows the results from a TRAP assay performed using TS primer and a hairpin RP primer of the sequence shown in Figure 30A. Assays were run on cell extracts equivalent to 10,000, 1,000, 100 or 10 cells. Three negative controls were also run. No Taq, no Taq polymerase was added in the reaction (negative control 1). CHAPS, CHAPS
lysis buffer was used instead of cell extract in the reaction (negative control 2). +H, cell extract from 10,000 cells was heat-treated prior to the.-assay (negative control 3). 10, TRAP assay with cell extract from l0 cells. 100, TRAP assay with cell extract from 100 cells. 1,000, TRAP. assay with cell extract from 1,000 cells. 10,000, TRAP assay with cell extract from 10,000 cells.
Figure 31 depicts diagrammatically Cascade Rolling Circle Amplification (CRCA), which is described in Section 5.2.6. Q, quencher; F,.fluorophore.
Figure 32 shows rolling circle (forward) hairpin primers 1 and 2 (SEQ ID NOS:46 and 4~, respectively), reverse hairpin primers 1 and 2 (SEQ ID NOS:4~ and 49, respectively), non-hairpin forward (rolling circle) primer (SEQ ID N0:5C), non-hairpin reverse primer (SEQ ID N0:51), as described in Section 19, Example 13. The hairpin primer sequences complementary to the probe or rolling circle products are underlined. Non-hairpin (i.e., linear) forward primer (SEQ
ID N0:5C) had a sequence corresponding to the underlined portion of the forward (rolling circle) hairpin primer sequences 1 and 2. Non-hairpin reverse primer (SEQ ID N0:51) had a sequence corresponding to the underlined portion of the reverse hairpin primer sequences 1 and 2. Spacer sequences are shown in bold. The nucleotides to which the two moieties of a MET pair are attached are marked with asterisks (*).
Also depicted in Figure 32Bis~a diagram of a circularized probe for CRCA, which comprises a target specific sequence (5'-TGTAGCCGT.AGTTAGGCCACCACTTCAAGAACTCT-3') (SEQ ID N0:52) for pUCl9 and a apacer (generic) sequence that includes a ligation junction as described in Section 19, Example 13. A target specific :sequence for ras (5'-GTTGGAGCTGGTGGCG'rAG-3') (SEc2 ID N0:53) is also depicted.
The ras-specific sequence was u:~ed as a target specific sequence in an additional experiment. described in Section 19, Example 13. nucl, nucleotide number. bp, base pairs. T*, T
nucleotide with DABC':fL moiety at=tached. A*, A nucleotide with FAM moiety attached.
Figr~re 33 ;shows the results of a series of Cascade Rolling Circle Ampli~°ications (<:RCAs) with hairpin primers, as described in Sect_Lon 19, Example 13. The number of template circles, i.s=. circularized probe made using pUCl9 as target, used in each reaction i~; indicated on the X-axis.
MET signals, as measured in fluorescence units (Y-axis}, were detected by fluoromet:ric analysis of signal levels in CRCAs (plus ligase) relative to background levels in control reactions (minus ligase). -~-, minus ligase; -o-, plus ligase.
Figure 34 ~;hows gag positive cells in lymph node tissue from a patient: with early HIV-1 infection, after performing in situ PCR using a linear primer and a FRET-labeled hairpin primer of the invention, as described in Section 18, Example 12.
Figure 35 shows the same view of the tissue sample as in Figure 34, at a higher magnification. The gag positive cells show a strong signal and there is low background in the preparation.
Figure 36 shows a tissue sample that served as a negative control, in which Taq polymerase was omitted from WO 98/02449 PCT/US97I12~15 the amplification cocktail as described in Section 18, Example 12.
Figure 37 shows lymph node tissue from an HIV-1 infected patient, after performing in situ PCR using a linear primer and a FRET-labeled hairpin primer, as described in Section 18, Example 12. However the signal-to-background ratio is less than in Figures 34 and 35; there is signal in some cells but cytoplasmic background in others due to an inadequate post-PCR wash.
Figure 38 shows an HIV-1 positive neuron in the cerebrum of a patient who died of AIDS dementia, after performing in situ PCR using a linear primer and a FRET-labeled hairpin primer, as described in Section 18, Example 12. Note the good signal-to-background ratio.
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to oligonucleotides for amplification of nucleic acids that are detestably labeled with molecular energy transfer (MET) labels. One or more oligonucleotides of the invention containing a donor and/or acceptor moiety of a MET pair are incorporated into the amplified product of an amplification reaction, such that the amplified- product contains both a donor and acceptor moiety of a MET pair. When the amplified product is double-stranded, the MET pair incorporated into the amplified product may be on the same strand or, when the amplification is triamplification, on opposite strands. In certain instances wherein the polymerase used in amplification has 5'-3~ exonuclease activity, one of the MET pair moiet_es may be cleaved from at least some of the population of amplified product by this exonuclease activity. Such exonuclease activity is not detrimental to the amplification methods of the invention.
~ The invention also relates to methods for detecting the products of nucleic acid amplification using these labeled oligonucleotides of the invention. It further relates to a rapid, sensitive, and reliable method for WO 98/02449 . PCTIUS97112~15 detecting amplification products that greatly decreases the possibility of carryover contamination with amplification products and that is adaptable to many methods for amplification of nucleic acid sequences, including polymerase chain reaction (PCR), triamplification, and other amplification systems.
The nucleic acid amplification oligonucleotides of the invention utilize the principle of MET between a donor moiety and an acceptor moiety. In a preferred embodiment, the MET is fluorescence resonance energy transfer (FRET), in which the oligonucleotides are labeled with donor and acceptor moieties, wherein the donor moiety is a fluorophore and the acceptor moiety may be a fluorophore, such that fluorescent energy emitted by the donor moiety is absorbed by the acceptor moiety. In one embodiment of the present invention, the acceptor moiety is a fluorophore that releases the energy absorbed from the donor at a different wavelength;
the emissions of the acceptor may then be measured to assess the progress of the amplification reaction.
In a preferred embodiment, the amplification primer is a hairpin primer that contains both donor and acceptor moieties and is configured such that the acceptor moiety quenches the fluorescence of the donor. When the primer is incorporated into the amplification product its configuration changes, quenching is eliminated, and the fluorescence of the donor moiety may be detected.
In one embodiment, the present invention provides nucleic acid amplification primers that form a hairpin structure in which MET gill occur when the primer is not incorporated into the amplification product. In a preferred embodiment, a primer forms a hairpin structure in which the energy of a donor fluorophore is quenched by a non-fluorescing fluorophore when the primer is not incorporated into the amplification product.
In another embodiment, the present invention provides oligonucleotides that are linear (non-duplex) and that are separately labeled with donor and acceptor moieties, such that MET will occur when the oligonucleotides are incorporated into the amplification product. For example, the blocking oligonucleotide and the primer complementary to the blocking oligonucleotide can be so labeled in a triamplification reaction.
In yet another embodiment, using a pair of linear primers, the donor moiety and acceptor moiety are on a single linear primer used in the amplification reaction. Where the amplification reaction is triamplification, the oligonucleotide labeled with both the donor and acceptor moieties is not the blocking oligonucleotide.
The invention provides a method for detecting or measuring a product of a nucleic acid amplification reaction comprising: (a) contacting a sample comprising nucleic acids with at least two oligonucleotides, a first one of said oligonucleotides comprising a sequence complementary to a preselected target sequence that may be present in said sample, and said first one and a second of said oligonucleotides being a pair of primers adapted for use in said amplification reaction such that said primers are incorporated into an amplified product of said amplification reaction when said target sequence is present in the sample;
at least one of said primers being labeled with a first moiety selected from the group consisting of a donor moiety and an acceptor moiety of a molecular energy transfer pair;
and wherein the same or a different oligonucleotide is labeled with a second moiety selected from the group consisting of said donor moiety and said acceptor moiety, said second moiety being the member of said group that is not said first moiety, wherein said primer labeled with said first moiety and said oligonucleotide labeled with said second moiety are configured so as to be incorporated into said amplified product, wherein the donor moiety emits energy - of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavelengths emitted by the donor moiety; (b) conducting the amplification reaction; (c) stimulating light emission from said donor moiety; and (d) detecting or measuring energy emitted by said donor moiety or acceptor moiety.
The nucleic acids in the sample may be purified or unpurified.
In a specific embodiment, the oligonucleotides of the invention are used in in situ amplification reactions, performed on samples of fresh or preserved tissues or cells.
In in situ reactions, it is advantageous to use methods that allow for the accurate and sensitive detection of the target directly after the amplification step. In contrast, conventional in situ PCR requires, in paraffin embedded tissue, detection by a hybridization step, as the DNA repair mechanism invariably present in tissue samples from, e.g., CNS, lymph nodes, and spleen, precludes detection by direct incorporation of a reporter nucleotide during the PCR step.
Typically, when conventional linear primers labelled with biotin or digoxigenin moieties are employed in in situ PCR, little or no detectable label is incorporated during amplification, which comprises annealing and extension steps.
Moreover, when amplification reaction conditions are modified to enhance incorporation of nucleotides labeled with such moieties, unacceptably high background and false positive results are obtained. This can be attributed to the activity of endogenous DNA repair enzymes, which incorporate the labeled nucleotides into nicked DNA in the sample. Others have attempted to use other types of singly labeled PCR
primers (Nuovo, 1997, PCR In Situ Hybridization: Protocols and Applications, Third Edition, Lippincott-Raven Press, New York), but have not been able to achieve adequate sensitivity, which can lead to false negative results. The requirements for a hybridization step, followed by a washing step, add additional time and expense to conventional in situ PCR protocols. It is therefore advantageous to use methods that allow for the accurate and sensitive detection of the target directly after the amplification step. Such methods are afforded by the present invention.

WO 98/02449 PCT/US97112~15 In a specific embodiment, the energy emitted by the donor moiety (e. g., when a quencher is the acceptor moiety) or by the acceptor moiety ( e.g., when a fluorophore or chromophore is the acceptor moiety), that is detected and measured after conducting an amplification reaction of the invention correlates with the amount of the preselected ' target sequence originally present in the sample, thereby allowing determination of the amount of the preselected target sequence present in the original sample. Thus, the methods of the invention can be used quantitatively to determine the number of chromosomes, or amount of DNA or RNA, containing the preselected target sequence.
A pair of primers, consisting of a forward primer and a reverse primer, for use in PCR or strand displacement amplification, consists of primers that are each complementary with a different strand of two complementary nucleic acid strands, such that when an extension product of one primer in the direction of the other primer is generated by a nucleic acid polymerase, that extension product can serve as a template for the synthesis of the extension product of the other primer. A pair of primers, consisting of a forward primer and a reverse primer, for use in triamplification, consists of primers that are each complementary with a different strand of two complementary nucleic acid strands, such that when an extension-ligation product of one primer in the direction of the other primer is generated by a nucleic acid polymerase and a nucleic acid ligase, that extension-ligation product can serve as a template for the synthesis of the extension-ligation product of the other primer. The amplified product in these instances is that content of a nucleic acid in the sample between and including the primer sequences.
As referred to herein, nucleic acids that are "complementary" can be perfectly or imperfectly complementary, as long as the desired property resulting from the complementarity is not lost, e.g., ability to hybridize.

In a specific embodiment, the invention provides a method for detecting or measuring a product of a nucleic acid amplification reaction comprising (a) contacting a sample comprising nucleic acids with at least two oligonucleotide primers, said oligonucleotide primers being adapted for use in said amplification reaction such that said primers are incorporated into an amplified product of said amplification reaction when a preselected target sequence is present in the sample; at least one of said oligonucleotide primers being a hairpin primer of the invention labeled with a donor moiety and an acceptor moiety; (b) conducting the amplification reaction; (c) stimulating energy emission from said donor moiety; and (d) detecting or measuring energy emitted by said donor moiety.
The present invention also provides a method of directly detecting amplification products. This improved technique meets two major requirements. First, it permits detection of the amplification product without prior separation of unincorporated oligonucleotides. Second, it allows detection of the amplification product directly, by incorporating the labeled oligonucleotide(s) into the product.
The present invention provides a method of directly detecting amplification products through the incorporation of labeled oligonucleotide(s) (e. g., primers, blocking oligonucleotides) wherein instead of separating unreacted oligonucleotides from amplification product, as in prior art approaches, signal from the remaining free oligonucleotide(s) is eliminated in one (or more) of the following ways:
a) by treatment with a 3'-5' exonuclease;
b) by heating the amplification product to a temperature such that the primer-oligonucleotide duplex dissociates and, as a result, will not generate any signal; or c) by using a primer labeled with both donor and acceptor moieties and that can form a hairpin structure, in which the energy transfer from donor to acceptor will occur only when the primer is not incorporated into the amplification product.
In a further embodiment, the present invention provides a method for the direct detection of amplification products in which the detection may be performed without opening the reaction tube. This embodiment, the "closed-tube" format, reduces greatly the possibility of carryover contamination with amplification products that has slowed the acceptance of PCR in many applications. The closed-tube method also provides for high throughput of samples and may be totally automated. The present invention also relates to kits for the detection or measurement of nucleic acid amplification products. Such kits may be diagnostic kits where the presence of the nucleic acid being amplified is correlated with the presence or absence of a disease or disorder.
For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections set forth below.
5.1. OLIGONUCLEOTIDES
The present invention provides oligonucleotides for nucleic acid amplification that are incorporated into the amplified product and that utilize the principle of molecular energy transfer (MET) and, preferably, fluorescence resonance energy transfer (FRET). The oligonucleotides of the invention are labeled with a donor and/or an acceptor moiety, i.e., a "MET pair." The acceptor moiety may simply quench the emission of the donor moiety, or it may itself emit energy upon excitation by emission from the donor moiety. In a preferred embodiment, the donor moiety is a fluorophore and the acceptor moiety may or may not be a fluorophore, such that fluorescent energy emitted by the donor moiety is . absorbed by the acceptor moiety. The labeled oligonucleotides are forward and/or reverse primers, and/or, in the case of triamplification, a blocking oligonucleotide.
The oligonucleotides used in the amplification reaction are WO 98102449 . PCTlUS97/12315 labeled such that at least one MET pair is incorporated into the amplified product (although 5'-3' exonuclease activity, if present, may subsequently remove a moiety from at least some of the amplified product population).
In one embodiment of the present invention, the acceptor moiety is a fluorophore that releases the energy absorbed from the donor at a different wavelength; use of the emissions of the donor and/or acceptor may then be measured to assess the progress of the amplification reaction, depending on whether the donor and acceptor moieties are incorporated into the amplification product close enough for MET to occur. In another embodiment, the acceptor moiety is a quencher that quenches the fluorescence of the donor when the donor and acceptor moieties are incorporated into the amplification product close enough for MET to occur.
In a further specific embodiment (see Section 5.1.1 infra), an oligonucleotide primer is used that forms a hairpin structure in which FRET will occur, when the primer is not incorporated into the amplification product. In a preferred embodiment, the hairpin primer is labeled with a donor-quencher FRET pair. When the hairpin primer is incorporated into the amplification product, its configuration changes (i.e., it is linearized), quenching is eliminated, and the fluorescence of the donor may be detected.
In yet another embodiment (see Section 5.1.2 infra), the labeled oligonucleotide, that can be a primer or, in the case of triamplification, a blocking oligonucleotide, is a linear molecule that does not form a hairpin configuration. In one embodiment, the donor-acceptor FRET
pair is located on the same, single-stranded oligonucleotide primer. In another embodiment, the donor moiety is located on a first oligonucleotide and the acceptor is located on a second oligonucleotide. In a specific embodiment, one of the two FRET-labeled oligonucleotides is a primer for triamplification, and the other FRET-labeled oligonucleotide is a blocker for triamplification (see Section 5.4.2).

The oligonucleotides for use in the amplification reactions of the invention can be any suitable size, and are preferably in the range of 10-100 or 10-80 nucleotides, more _ preferably 20-40 nucleotides.
The oligonucleotide can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, so long as it is still capable of priming the desired amplification reaction, or, in the case of a blocking oligonucleotide, functioning as a blocking oligonucleotide. In addition to being labeled with a MET moiety, the oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, and may include other appending groups or labels, so long as it is still capable of priming the desired amplification reaction, or functioning as a blocking oligonucleotide, as the case may be.
For example, the oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-~nethoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,5-diaminopurine.
In another embodiment, the oligonucleotide comprises at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.
In yet another embodiment, the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.
Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.
The oligonucleotides of the present invention may be derived by standard methods known in the art, e.g., by de novo chemical synthesis of polynucleotides using an automated DNA synthesizer (such as is commercially available from Biosearch, Applied Biosystems, etc.) and standard phosphoramidite chemistry; or by cleavage of a larger nucleic acid fragment using non-specific nucleic acid cleaving chemicals or enzymes or site-specific restriction endonucleases.
A preferable method for synthesizing oligonucleotides is conducted using an automated DNA
synthesizer by methods known in the art. As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 15:3209-3221), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc. Once the desired oligonucleotide is synthesized, it is cleaved from the solid support on which it was synthesized and treated, by WO 98!02449 PCT/US97112315 methods known in the art, to remove any protecting groups present. The oligonucleotide may then be purified by any method known in the art, including extraction and gel purification. The concentration and purity of the oligonucleotide may be determined by examining oligonucleotide that has been separated on an acrylamide gel, or by measuring the optical density at 260 nm in a spectrophotometer.
Oligonucleotides of the invention may be labeled with donor and acceptor moieties during chemical synthesis or the label may be attached after synthesis by methods known in the art. In a specific embodiment, the following donor and acceptor MET pairs are used: a luminescent lanthanide chelate, e.g., terbium chelate or lanthanide chelate, is used as the donor, and an organic dye such as fluorescein, rhodamine or CY-5, is used as the acceptor. Preferably, terbium is used as a donor and fluorescein or rhodamine as an acceptor, or europium is used as a donor and CY-5 as an acceptor. In another specific embodiment, the donor is fluorescent, e.g. fluorescein, rhodamine or CY-5, and the acceptor is luminescent, e.g. a lanthanide chelate. In yet another embodiment, the energy donor is luminescent, e.g., a lanthanide chelate, and the energy acceptor may be non-fluorescent. Energy transfer results in a decrease in the emission of the donor.
In another specific embodiment, the donor moiety is a fluorophore. In another specific embodiment, both donor and acceptor moieties are fluorophores. Suitable moieties that can be selected as donor or acceptors in FRET pairs are set forth in Table 1.

Table 1. Suitable moieties that can be selected as donor or acceptors in FRET pairs 4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid acridine and derivatives:
acridine acridine isothiocyanate 5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS) 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS) N-(4-anilino-1-naphthyl)maleimide anthranilamide Brilliant Yellow coumarin and derivatives:
coumarin 7-amino-4-methylcoumarin (AMC, Coumarin 120) 7-amino-4-trifluoromethylcoumarin (Coumarin 151) cyanosine 4',6-diaminidino-2-phenylindole (DAPI) 5',5 " -dibromopyrogallol-sulfonephthalein (Bromopyrogallol Red) 7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin diethylenetriamine pentaacetate 4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansyl chloride) 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL) 4-dimethylaminophenylazophenyl-4'-isothiocyanate (DABITC) eosin and derivatives:
eosin eosin isothiocyanate erythrosin and derivatives:
erythrosin B
erythrosin isothiocyanate ethidium fluorescein and derivatives:
5-carboxyfluorescein (FAM) 5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF) 2'7'-dimethoxy--4'S'-dichlc>ro-6-carboxyfluorescein (JOE) fluorescein fluorescein isothiocyanats:
QFITC (XRITC) f luorescamine Malachite Green isot:hiocyanate 4 -methylumbel l if erone ortho cresolphthalep.n nitrotyrosine pararosaniline Phenol Red B-phycoerythrin o-phthaldialdehyde pyrene and derivatives:
pyrene pyrene butyrate succinimidyl 1-~pyrene butyrate Reactive Red 4 (Cibacron~ Brilliant Red 3B-A) rhodamine and derivatives:
6-carboxy-X-rhodamine (ROx:) 6-carboxyrhodamine (R6G) lissamine rhoda~mine B sulfonyl chloride rhodamine (Rhocl) rhodamine B
rhodamine.123 rhodamine X isothiocyanate sulforhodamine B
sulforhodamine 101 sulfonyl chloride derivative of sulforhodamine 101 (Texas Red)' N,N,N',N'-tetra.methyl-6-carboxyrhodamine (TAMRA) tetramethyl rhodamine *Trade-Mark tetramethyl rho<iamine isotriiocyanate (TRITC) riboflavin rosolic acid terbium chelate derivatives One of ord:inary skill in the art can easily determine, using art--known techniques of spectrophotometry, which fluorophores wall make suitable donor-acceptor FRET
pairs. For example, FAM (which has an emission maximum of 525 nm) is a suitable donor for TAMRA, ROX, and R6G (all of which have an excitat::ion maximum of 514 nm) in a FRET pair.
Primers are preferab:Ly modified during synthesis, such that a modified T-base is introduced into a designated position by the use of Amino-Mod:iffier C6 dT (Glen Research), and a primary amino group :is incorporated on the modified T-base, as described by Ju ei: al. (1995, Proc. Natl. Acad. Sci. USA
92:4347-4351). Theses modifications may be used for subsequent incorporai:ion of fluorescent dyes into designated positions of the oligonucleotidsa.
The optimal distance between the donor and acceptor moieties will be that. distance wherein the emissions of the donor moiety are absorbed by the: acceptor moiety. This optimal distance varies with ths: specific moieties used, and may be easily determ:Lned by one of ordinary skill in the art using techniques knoom in the art. For energy'transfer in which it is desired that the acceptor moiety be a fluorophore that emits energy to be detected, the donor and acceptor fluorophores are prel:erably separated by a distance of up to 30 nucleotides, more preferably from 3-20 nucleotides, and still more preferably from 6-12 nucleotides. For energy transfer wherein it is desired that the acceptor moiety quench the emissions of the donor, the donor and acceptor moieties are preferably separated by a distance of less than 35~one nucleotide (e. g., on the opposite strand, complementary nucleotides of a dup7Lex structure), although a 5 nucleotide distance (one helica7L turn) is also advantageous for use.
*Trade-Mark In yet another embodiment, the oligonucleotides may be further labeled with any other art-known detectable marker, including radioactive labels such as 32P, 3sS, 3H, and the like, or with enzymatic markers that produce detectable signals when a particular chemical reaction is conducted, such as alkaline phosphatase or horseradish peroxidase. Such enzymatic markers are preferably heat stable, so as to survive the denaturing steps of the amplification process.
Oligonucleotides may also be indirectly labeled by incorporating a nucleotide linked covalently to a hapten or to a molecule such as biotin, to which a labeled avidin molecule may be bound, or digoxygenin, to which a labeled anti-digoxygenin antibody may be bound. Oligonucleotides may be supplementally labeled during chemical synthesis or the supplemental label may be attached after synthesis by methods known in the art.
The oligonucleotides of the invention have use in nucleic acid amplification reactions, as primers, or, in the case of triamplification, blocking oligonucleotides, to detect or measure a nucleic acid product of the amplification, thereby detecting or measuring a target nucleic acid in a sample that is complementary to a 3' primer sequence. Accordingly, the oligonucleotides of the invention can be used in methods of diagnosis, wherein a 3' primer sequence is complementary to a sequence (e.g., genomic) of an infectious disease agent, e.g. of human disease including but not limited to viruses, bacteria, parasites, and fungi, thereby diagnosing the presence of the infectious agent in a sample of nucleic acid from a patient. The target nucleic acid can be genomic or cDNA or mRNA or synthetic, human or animal, or of a microorganism, etc. In another embodiment that can be used in the diagnosis or prognosis of a disease or disorder, the target sequence is a wild type human genomic or RNA or cDNA sequence, mutation of which is implicated in the presence of a human disease or disorder, or alternatively, can be the mutated sequence. In such an embodiment, optionally, the amplification reaction can be repeated for the same sample with different sets of primers that amplify, respectively, the wild type sequence or the mutated version. By way of example, the mutation can be an insertion, substitution, and/or deletion of one or more nucleotides, or a translocation.
5.1.1. HAIRPIN PRIMERS
The present invention provides oligonucleotide primers that form a hairpin structure in which MET will occur when the primer is not incorporated into the amplification product.
Accordingly, in a specific embodiment, the invention provides a hairpin primer that is an oligonucleotide comprising, or alternatively consisting of, the following contiguous sequences in 5' to 3' order: (a) a first nucleotide sequence of fi-30 nucleotides, wherein a nucleotide within said first nucleotide sequence is labeled with a first moiety selected from the group consisting of a donor moiety and an acceptor moiety of a molecular energy transfer pair, wherein the donor moiety emits energy of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavelengths emitted by the donor moiety; (b) a second, single-stranded nucleotide sequence of 3-20 nucleotides; (c) a third nucleotide sequence of 6-30 nucleotides, wherein a nucleotide within said third nucleotide sequence is labeled with a second moiety selected from the group consisting of said donor moiety and said acceptor moiety, and said second moiety is the member of said group not labeling said first nucleotide sequence, wherein said third nucleotide sequence is sufficiently complementary in reverse order to said first nucleotide sequence for a duplex to form between said first nucleotide sequence and said third nucleotide sequence such that said first moiety and second moiety are in sufficient proximity such that, when the donor moiety is excited and emits energy, the acceptor moiety absorbs energy emitted by the donor moiety; and (d) at the 3' end of said WO 98/02449 PCTlUS97/12315 oligonucleotide, a fourth, single-stranded nucleotide sequence of 8-40 nucleotides that comprises at its 3~ end a sequence sufficiently complementary to a preselected target sequence so as to be able to prime synthesis by a nucleic acid polymerase of a nucleotide sequence complementary to a nucleic acid strand comprising said target sequence; wherein when said duplex is not formed, said first moiety and said second moiety are separated by a distance that prevents molecular energy transfer between said ffirst and second to moiety.
In a specific embodiment wherein the donor and acceptor moieties are a FRET pair, separation of the first and second moiety by a distance that prevents FRET is observed by the failure of the second moiety to quench the fluorescence of the first moiety (when the second moiety is a quencher), or the failure of the second moiety to absorb the fluorescence of the first moiety and then itself to fluoresce (when the second moiety is a fluorophore).
In a specific embodiment, the second nucleotide sequence (the loop structure) and/or the first nucleotide sequence (of the duplex) and/or third nucleotide sequence (of the duplex) do not contain a sequence complementary to the target sequence. Alternatively, the second nucleotide sequence and/or the first nucleotide sequence and/or the third nucleotide sequence or any portion of the foregoing sequences may also contain a sequence complementary to the target sequence.
In a preferred embodiment, a primer forms a hairpin structure in which the energy of a donor fluorophore is quenched by a non-fluorescing acceptor moiety when the primer is not incorporated into the amplification product. One of ordinary skill in the art can easily determine, from the known structures and hydrophobicities of a given FRET pair, the steric arrangement that will bring the pair into closest proximity for MET.
In a specific embodiment, the hairpin primer comprises four parts (Figure 1): Part (d) is a 3' terminal WO 98!02449 . PCT/US97/12~15 sequence and comprises a sequence complementary to the target sequence; it is a primer for DNA polymerase. Part (c) is a first stem sequence on the 5' end of the primer sequence.
Part (b) forms a single-stranded loop of nucleotides. Part (a) is a second stem sequence, which is complementary to the first stem sequence. Parts (a), (b), and (c) or portions thereof may or may not be complementary to the target DNA to be amplified. Part (d) is preferably 8-30 nucleotides long;
Part (c) is preferably 6-30 nucleotides long; Part (b) is preferably 3-20 nucleotides long, and most preferably, 4-6 nucleotides long.
The first stem sequence, Part (c), contains the donor fluorophore and the second stem sequence, Part (a), contains the acceptor (e.g., quencher), or it can be opposite. In a non-incorporated hairpin primer, the emission of the donor will be transferred to the acceptor, since the two moieties will be in close proximity to each other when two stem sequences are in duplex.
The donor and acceptor moieties can be located on either terminal nucleotides of the hairpin stem (duplex region), or internally located. Thus, in one embodiment of the invention, the donor and acceptor (or quencher) moieties are respectively located on the 5' end of the hairpin primer sequence that is complementary to the target and located on the complementary nucleotide residue on the hairpin stem (Figure 1), or vice versa. Each moiety may alternatively be located on a nucleotide internal within a complementary stem sequence. Alternatively, one of the moieties may be located on an internal nucleotide and the other on the terminal nucleotide at the 5' end. One or both of the moieties may alternatively be located at the other end of the duplex region.
Preferably, donor and acceptor moieties are attached to the complementary strands of the stem, one moiety on the 5' end and the other moiety 5 by apart on the complementary strand. For example, the two moieties can be offset by a 5 by (180°) turn of the double helix formed by the two complementary strands of the stem, and will therefore be in closest proximity sterically, and the emission of the donor will be transferred to (and, e.g., quenched by) the acceptor.
Alternatively, the two moieties can be on . complementary strands of the stem separated by a distance of less than 1 nucleotide (3.4A) when the hairpin is in the closed configuration. Most preferably, the two moieties are on complementary nucleotides on the stem, directly opposite from one another when the hairpin is in the closed configuration.
When a hairpin primer is linearized, the donor moiety must be separated from the acceptor (e. g., quencher) moiety by an intervening sequence that is long enough to substantially prevent MET. Where a FRET pair that consists of donor and acceptor fluorophores is used, the two FRET
moieties are separated by an intervening sequence, comprising (a) at least a portion of the first stem sequence, (b) the loop, and (c) at least a portion of the second stem sequence;
the intervening sequence being preferably 15-25 nucleotides in length, and more preferably, 20 nucleotides in length.
In one embodiment, the acceptor moiety is a fluorophore that will re-emit the energy provided by the donor at a different wavelength; that is, when the primer is in the closed state, emissions from the acceptor, but not from the donor, will be detected. In a preferred embodiment, the acceptor moiety is a quencher and absorbs the energy emitted by the donor without fluorescing. In either case, the fluorescence of donor may be detected only when the primer is in the linearized, open state i.e., is incorporated into a double-stranded amplification product. Energy transfer in this state will be minimal and the strong emission signal from the donor will be detected.
A critical aspect of the invention is that the transition from the closed to the open state occurs only during amplification. Figures 2 and 3 schematically illustrate the use of the hairpin primers of the present WO 98/02449 PCTlUS97l12315 invention in PCR. In Figure 2, the DNA polymerase used in PCR
lacks 5'-3' exonuclease activity, whereas in Figure 3, it has 5'-3'activity. For PCR, either one or both PCR primers can be a hairpin primer.
In Figures 2 and 3, (a) and (b) are two complementary strands of the target sequence to be amplified and "R" and "F" are the reverse and forward primers, respectively, for PCR amplification. By way of example and not limitation, the reverse hairpin primer is designed such that there is a donor fluorophore and quencher incorporated into it. Reverse hairpin primer that is not incorporated into the PCR product will have fluorophore and quencher in close proximity; thus the fluorescence from the free reverse primer will be quenched. See Section 5.2.1 infra for methods of use of hairpin primers in PCR.
5.1.1.1. UNIVERSAL HAIRPINS AND HAIRPIN PRIMERS
In one embodiment, the oligonucleotide of the invention is a "universal" hairpin that can be ligated, either chemically (e.g., using cyanogen bromide) or enzymatically (e. g., using ligase) to any selected primer sequence and used to amplify a target nucleic acid sequence that contains the complement of the primer sequence. The invention provides a "universal" hairpin that is an oligonucleotide, the nucleotide sequence of which consists of the following contiguous sequences in 5' to 3' order: (a) a first single-stranded nucleotide sequence of 1 to 10 nucleotides; (b) a second nucleotide sequence of 2-30 nucleotides, wherein a nucleotide within said first nucleotide sequence or said second nucleotide sequence is labeled with a first moiety selected from the group consisting of a donor moiety and an acceptor moiety of a molecular energy transfer pair, wherein the donor moiety emits energy of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavelengths emitted by the donor moiety; (c) a third, single-stranded nucleotide sequence of 3-20 WO 98/02449 . PCTlUS97/12315 nucleotides; (d) a fourth nucleotide sequence of 2-30 nucleotides, wherein a nucleotide within said fourth nucleotide sequence is labeled with a second moiety selected from the group consisting of said donor moiety and said acceptor moiety, and said second moiety is the member of said group not labeling said first or second nucleotide sequence, wherein said fourth nucleotide sequence is sufficiently complementary in reverse order to said second nucleotide sequence for a duplex to form between said second nucleotide sequence and said fourth nucleotide sequence such that said first moiety and second moiety are in sufficient proximity such that, when the donor moiety is excited and emits energy, the acceptor moiety absorbs energy emitted by the donor moiety.
An example of a universal hairpin is shown in Figure 4. The universal hairpin of the invention comprises a first stem sequence on the 3' end (2-30 nucleotides long, preferably 4-6 nucleotides long), a loop (3-20 nucleotides long, preferably 4-6 nucleotides long), a second stem sequence essentially complementary to the first stem sequence (2-30 nucleotides long, preferably 4-6 nucleotides long), and a 5' single-stranded cohesive ("sticky") end sequence (e. g., 1-10 nucleotides long, preferably 3-4 nucleotides long). In a specific embodiment, the "sticky" end sequence is 5'GGC-3'.
Selected primer sequences that are complementary to a target DNA sequence and that are suitable for ligation to the universal hairpin may be derived by standard methods known in the art, e.g., by de novo chemical synthesis of polynucleotides using an automated DNA synthesizer and standard phosphoramidite chemistry; or by cleavage of a larger nucleic acid fragment using non-specific nucleic acid cleaving chemicals or enzymes or site-specific restriction endonucleases.
w In order to join a universal hairpin to the selected primer sequence, the selected primer sequence should contain a cohesive sequence on the 5' end essentially complementary to the cohesive sequence of the universal WO 98/02449 . PCTIUS97/12315 hairpin (Figure 4). In one embodiment, the 5' cohesive end on the selected primer sequence is chemically synthesized to complement the 5' cohesive end on the universal hairpin. In another embodiment, the 5' cohesive end on the selected primer sequence is produced by the staggered cut of a restriction endonuclease.
A labeling moiety on the universal hairpin must not be situated so as to substantially interfere with subsequent ligation at its 3~ end to the selected primer sequence.
Thus, preferably, a labeling moiety is not located on the 3' terminal nucleotide of the universal hairpin (Figure 4). At the 5' end of the hairpin, a labeling moiety may be located either on the terminal nucleotide at the 5' end (as shown in Figure 4) or on a nucleotide internal to the 5' end.
The donor (fluorescent) and acceptor (quencher) moieties of a universal hairpin such as shown in Figure 4 must be separated by a distance such that the emissions of the donor moiety are quenched by the acceptor moiety.
Preferably, the donor and acceptor moieties are separated by a distance of less than 1 nucleotide (3.4A) when the hairpin is in the closed configuration.
In one embodiment, the two FRET moieties are separated by an intervening sequence, comprising a portion of the first stem sequence, the loop, and a portion of the second stem sequence, that is preferably 15-25 nucleotides in length. More preferably, the loop on the universal hairpin is long enough provide a distance of 20 nucleotides between a donor (e.g., FAM) and a quencher (e.g., DABCYL) when the hairpin is in the "open" configuration.
Figure 4 gives a schematic example of a selected target sequence (8-40 nucleotides, preferably ~15 nucleotides) and a universal hairpin prior to their ligation to each other.
In another embodiment, a universal hairpin primer of the invention is used, that contains a 3' sequence that, instead of being complementary to a preselected target nucleic acid sequence to be amplified, is identical to the 5' single stranded sequence of another primer used in the amplification reaction. The 3' sequence of the other primer is complementary to the target nucleic acid sequence, while its 5' identical sequence is not complementary to the target nucleic acid sequence (see by way of example, Figure 5 and Section 5.2.1).
5.1.2. LINEAR OLIGONUCLEOTIDES
In another embodiment, the oligonucleotide primers are both linear molecules that cannot form a hairpin configuration. In a specific embodiment, a donor-acceptor FRET pair are both fluorophores located on the same, single-stranded oligonucleotide primer, within distance of each other so that FRET can occur. In this embodiment, the double-labeling with a FRET pair increases the separation between the excitation and the emission frequencies of a label. This increased separation decreases background fluorescence that can interfere with accurate quantitation of the emission signal.
For example, in a specific embodiment, fluorescein may serve as the donor moiety and rhodamine as the acceptor moiety. Fluorescein exhibits peak excitation at 488 nm, but the excitation spectrum is broad and it exhibits some excitation at its emission frequency at 520 nm. This contributes to an emission artifact at 520 nm that decreases the accuracy and sensitivity of quantitative spectrophotometry when using fluorescein as a single label.
If a fluorescein moiety is used as a donor and a rhodamine moiety as an acceptor (rhodamine has peak excitation at 520 nm and peak emission at 605 nm), however, excitation will - occur at 488 nm and emission will occur at 605 nm, greatly decreasing background artifact.
In another specific embodiment, the donor moiety is located on a first oligonucleotide primer and the acceptor is located on a second,, complementary oligonucleotide. In a preferred aspect of this embodiment, one of the two FRET-labeled primers is a primer for triamplification, and the other FRET-labeled oligonucleot:ide is a blocking oligonucleotide (blacker) for t:riamplification.
5.2. METHODS FOR DETECTION OF AMPLIFICATION
PRODtJCTS USING FLAIRPIN PRIMERS
In a specific embodiment of a hairpin primer of the invention, the acceptor moiety is a fluorophore or quencher that absorbs the ensargy transmitted by the donor moiety. In a preferred embodims:nt, the acceptor moiety is a quencher;
the primer is configured such that the acceptor moiety on free primer quenchers the fluorescence from the donor. When the primer is incorporated into the amplification product, its configuration crianges, quenching is eliminated, and the fluorescence of the donor moiety is detected.
The detection method of the present invention may be applied to any amplification. system in which an °ligonucleotide is incorporated into an amplification product e.g., polymerase chain reaction (PCR) systems (U. S. Patent No. 4,683,195 and 4,683,,202), triamplification systems (TriAmp'", Oncor Inc. ; U. S . Patent No. 5, 593, 840;
PCZ' International Publication No. WO 9417206 A1, dated August 4, 1994; PCT International Publication No.
WO 9417210 A1, datedi. August 4, 1994), nucleic acid sequence-based amplification (NASBA) systems (U.S. Patent No.
5,409,818; Compton, 1991, Nature 350:91-92), and strand-displacement amplification (SDA) systems (Walker et al., 1992, Nucl. Acids Re.s. 20:1691-1696). As a result of amplification, the hairpin primers are incorporated into the double-stranded polynucleotide amplification products.
In a specif is embodiment, the hairpin primers are 35wsed to prime an amplification in sztu, on samples of preserved or fresh cells or tissues (see, e.g., Nuovo, 1997, - 4!i -PCR In Situ Hybridization: Protocols and Applications, Third Edition, Lippincott-Raven Press, New York).
Although various specific embodiments involving a FRET pair are described hereinbelow as involving a preferred FRET pair consisting of a donor fluorophore moiety and a quencher acceptor moiety, it will be understood that such embodiments could also have been described in terms of the acceptor moiety being a fluorophore rather than a quencher.
5.2.1. METHODS OF USE OF HAIRPIN PRIMERS
IN POLYMERASE CHAIN REACTION (PCR) In one embodiment, the hairpin primers of the invention are used to prime a polymerise chain reaction (PCR), thereby becoming incorporated into the amplification product (examples being illustrated in Figures 2 and 3A-D).
The PCR primers contain hairpin structures on their 5' ends with FRET donor and acceptor moieties located in close proximity (30 nucleotides or less) on the hairpin stem.
The primers are designed in such a way that a fluorescent signal from the donor moiety is generated only when the primers are incorporated into an amplification product. The modified hairpin primers do not interfere with the activity of DNA polymerise, and in a preferred aspect, thermostable Pfu polymerise or Taq polymerise can be used. The forward and/or reverse primers can be hairpin primers.
In the example shown in Figure 3, the hairpin primer has a quencher on its 5' terminal nucleotide, and contains a donor fluorophore on the opposite strand of its duplex, the fluorophore and quencher being a FRET pair. In the first cycle of PCR (Figure 3B), both primers will hybridize to the respective target strands and will be ~ extended by DNA polymerise. In the second cycle (Figure 3C) the extended product from the reverse primer will become a . template for the forward primer and extended product from the forward primer will become a template for the reverse primer.
When the forward primer is extended to the 5' end of the hairpin structure, either of two things can happen, depending WO 98/02449 PCTIUS97/123~5 on the DNA polymerase used: either the 5'-3' exonuclease activity of the DNA polymerase will hydrolyze the 5' nucleotides with quencher, and/or DNA polymerase will displace the 5'-end of the hairpin and copy the template. In both cases, the quencher and the fluorophore will be separated from each other and a signal will be generated (Figure 3D).
Hairpin primers may be employed in any amplification method in which the hairpin primer is not complementary to any other oligonucleotide used in the reaction mixture, and in which the hairpin primer is incorporated into a double-stranded DNA amplification product, e.g., PCR, triamplification, nucleic acid sequence-based amplification (NASBA), and strand displacement amplification (SDA) (see infra). Thus, for example, in triamplification involving the use of a hairpin primer, the other, non-hairpin primer is complementary to the blocking oligonucleotide.
In another specific embodiment (Figure 5), a universal hairpin primer is used, along with two selected linear primers, Primer 1 and Primer 2, to prime a PCR. In this case, the universal hairpin primer is incorporated into the amplification product and is not ligated to one of the two linear primer sequences. In this embodiment, the 3' sequence of the universal hairpin primer is identical to the 5' sequence of one of the pair of linear forward and reverse primers used in the amplification, and this 5' sequence (sequence "A" on Primer 2 in Figure 5) must not be complementary to the target sequence.
During the first cycle of PCR, Primer 1, which is complementary to a target DNA (+) strand is extended. Primer 2 has a 3' portion that has a sequence complementary to the target (-) strand and a 5' portion, designated "A" in Figure 5, that has a sequence that is not complementary to the target. Sequence A is preferably 10-25 nucleotides, and more preferably, 12-15 nucleotides in length.

During the second cycle, the product of the extension of Primer 2 (shown by the arrow) becomes a template for Primer 1. Primer 1 is extended and the amplification product now includes a sequence, designated "A',"
complementary to sequence A.
During the third cycle, the A sequence of the hairpin primer anneals to the A' sequence of the amplification product from the previous cycle.
During the fourth cycle, the extended hairpin primer becomes a template for Primer 1. During the extension of Primer 1, the hairpin unfolds, the quencher and fluorophore are separated, and a fluorescent signal is emitted from the amplification product. In a similar way, the method can be applied to triamplification. In this case, the hairpin primer is the primer not complementary to the blocker.
5.2.1.1. METHODS OF USE OF HAIRPIN PRIMERS
IN ALLELE-SPECIFIC PCR (ASP) In another embodiment, primers of the invention are used to prime an allele-specific PCR (ASP). In this embodiment, one or both amplification primers may be hairpin primers. In ASP, a target DNA is preferentially amplified if it is completely complementary to the 3' end of a PCR
amplification primer. The 3' end of the hairpin primer should terminate at or within one or 2 bases of a known mutation site in a gene (target DNA) to which it has a complementary sequence. Under the appropriate reaction conditions, the target DNA is not amplified if there is a base mismatch (e.g., a nucleotide substitution caused by a mutation) or a small deletion or insertion, at the 3' end of the primer (Okayama et al, 1989, J. Lab. Clin. Med. 114:105-113; Sommer et al., 1992, BioTechniques 12:82-87). Thus, ASP
can be used to detect the presence or absence of at least a single mismatch between the hairpin sequence that is complementary to the preselected target sequence and a WO 98/02449 . PCTIUS97/12315 nucleic acid in the sample; amplification indicates the absence of such a single mismatch.
5.2.2. METHODS OF USE OF HAIRPIN PRIMERS IN TRIAMPLIFICATION
5.2.2.1. GENERAL STEPS IN TRIAMPLIFICATION REACTIONS
Both hairpin primers and linear primers (see Sections 5.2 and 5.4) can be used in triamplification reactions.
A triamplification reaction is based on three oligonucleotides: two primers and a blocking oligonucleotide (blocker). An example is shown in Figure 6. The two primers, a forward and a reverse "extending" primers, are complementary to the two strands of a selected target (template) DNA. A third oligonucleotide, a blocker, is partially complementary to one of the two extending primers.
Triamplification utilizes two thermostable enzymes: DNA
polymerase and DNA ligase. During the repeated steps of polymerization and ligation, one of the extended primers is ligated to the blocker.
In one version of triamplification (the "gap"
version), the forward oligonucleotide is a primer substantially complementary to a first segment at a first end of the target sequence to be amplified. The reverse oligonucleotide is a primer substantially complementary to a second segment at a second end of the target nucleic acid sequence on a different strand of the target nucleic acid.
The third oligonucleotide (the "blocker" or "blocking oligonucleotide") is substantially complementary to at least a portion of the forward or reverse primer.
A schematic illustration of gap triamplification, which consists of repeated elongation and ligation of the amplification product, is shown in Figure 7. Blocker may be used at the same or higher concentration than the concentration of forward and reverse primers. Preferably, Mocker is used at a 1.2 to 2-fold higher concentration than the concentration of forward and reverse primers. The primer complementary to the blocker preferably is modified to prevent strand displacement during amplification; in a preferred embodiment, this primer contains 2'-O-methyl at the position complementary to the 5' end of the blocker in order to prevent strand displacement.
In the case where linear primers of the invention are used (Section 5.4), the blocker is preferably modified in order to protect it from exonuclease hydrolysis (which is used with amplification methods using linear, but not hairpin primers) and from undesirable extension during amplification.
In a preferred embodiment, the blocker has biotin on its 3' end in order to protect it from exonuclease hydrolysis and from undesirable extension during amplification.
An alternate version of triamplification, the "non-gap version," is substantially similar to the gap version described above, with the difference that the 5' end of the forward primer is adjacent to the 3' end of the reverse primer.
5.2.2.2. USE OF HAIRPIN PRIMERS IN
TRIAMPLIFICATION REACTIONS
In one embodiment of the invention, hairpin primers are used to prime a triamplification reaction, thereby becoming incorporated into the amplification product. When using hairpin primers in triamplification, the hairpin structure is part of whichever primer, either the forward or the reverse primer, that is not complementary to the blocker (Figure 6). It cannot be used on the primer complementary to the blocker, because, in this case, the blocker will Interfere with the formation of the hairpin on the primer that is not incorporated into the amplification product.
The hairpin primer is preferably labeled with a FRET donor-acceptor pair on its stem. During the first cycle of triamplification, the hairpin primer will be extended and ligated to the blocker. During the second cycle, the extended hairpin primer will become a template for the second primer. In the course of extension of the second primer, the WO X8/02449 PCTlUS97/12315 hairpin will open, the quencher will be separated from the fluorophore and the donor will emit a fluorescence signal.
5.2.3, METHODS OF USE OF HAIRPIN PRIMERS
IN NUCLEIC ACID SEQUENCE-BASED
AMPLIFICATION (NASBA) The primers of the invention may be used to prime nucleic acid sequence-based amplification (NASBA), an example of which is shown in Figure 9. NASBA uses continuous cycling of reverse transcription and RNA transcription reactions and is conducted at one temperature. It uses three enzymes (reverse transcriptase, RNase H, and T7 RNA polymerase). In one embodiment, the method uses two primers, one of which is a hairpin primer of the invention that is labeled with FRET
donor and acceptor (e.g., quencher) moieties. In an alternative embodiment, both primers are hairpin primers of the invention.
Primer 1 has preferably about 20 bases on its 3' end that are complementary to a target RNA and a promoter Sequence 5' to the target-complementary sequence that is recognized by T7 RNA polymerase. Primer 2 is a hairpin primer of the invention that is complementary to the RNA (-) sequence and has a hairpin structure on its 5' end that is labeled with energy transfer moieties such as is illustrated by way of example in Figure 9.
The non-cycling NASBA phase proceeds as follows (Figure 9). In Step 1, Primer 1 anneals to the RNA target sequence. Reverse transcriptase uses dNTPs to extend the 3' end of the Primer 1, forming a RNA/DNA hybrid. In Step 2, base H hydrolyzes the RNA strand of the hybrid. In Step 3, hairpin Primer 2 anneals to the single DNA strand remaining from the hybrid. Reverse transcriptase synthesizes the second DNA strand, rendering the promoter region double-stranded. In Step 4, the third enzyme in the mixture, T7 RNA
polymerase, binds to the promoter sequence and generates up to 100 RNA copies from each template molecule.

The cycling NASBA phase then proceeds as follows.
In Step 5, hairpin Primer 2 binds to the RNA template through its 3' end priming sequence, and reverse transcriptase extends it and generates a RNA/DNA hybrid. The 5' end of the hairpin is displaced and copied as a result of replication.
The quencher and the fluorophore are now spaced far enough apart that the fluorophore is no longer quenched and its fluorescence will be detectable. In Step 6, RNase H
hydrolyzes the RNA strand. The resulting single-stranded DNA
is now "silent" (fluorescence is quenched) because the hairpin structure is formed again. In Step 7, Primer 1 binds to the single-stranded DNA. Reverse transcriptase binds to the 3' ends of both the primer and the DNA template. In Step
8, the 3' end of the single-stranded DNA is extended, yielding a double-stranded, transcriptionally active promoter. Simultaneously, the 3' end of Primer 1 is extended. The 5' end of the hairpin is displaced and copied as a result of replication. The quencher and the fluorophore are now spaced far enough apart that the fluorophore is no longer quenched and its fluorescence will be detectable. In Step 9, T7 RNA polymerase generates multiple RNA copies from each template molecule.
Hence in this embodiment, the amplification products of steps 5 and 8 will have incorporated the FRET-labeled hairpin primer and will give a fluorescent signal during the cyclic phase.
In the above example, a hairpin primer is employed in the NASBA process as described by Compton (1991, Nature 350:91-92). However, if polymerase-specific 5'-3' exonuclease activity is present in addition to reverse transcriptase, T7 RNA polymerase and RNase H, the 5' end of ' the hairpin-primer will be hydrolyzed during replication. A
fluorescence signal will be generated not only at steps 5 and 8, but also at steps 6 and 7, since there will be no quencher attached to the DNA template.
9 PCT/US97112315 5.2.4. METHODS OF USE OF HAIRPIN PRIMERS
IN STRAND DISPLACEMENT AMPLIFICATION (SDA) The hairpin primers of the invention may be used in strand displacement amplification (SDA) of a double-stranded DNA target. The forward and/or reverse primers can be hairpin primers. SDA depends on the continuous cycling of nicking and polymerization/displacement steps and is conducted at one temperature.
In a specific embodiment (Figure 10), Primer 1 and Primer 2 are both hairpin primers of the invention. Each has a single-stranded priming sequence on the 3' end, a recognition site for the restriction endonuclease, and a FRET-labeled hairpin structure on the 5' end.
SDA proceeds as follows. In Step 1, the target DNA
is denatured and Primer 1 and Primer 2 anneal through their 3' sequences. In Step 2: The 3' ends of the primers are extended using dNTPs, one of which is a 5'-[a-thio)triphosphate. A double stranded restriction site is formed with one modified strand (the thio-modified strand is resistant to endonuclease hydrolysis). At the same time, the 5' end of the hairpin primer is displaced and copied as a result of replication. The quencher and the fluorophore are now spaced far enough apart that the fluorophore is no longer quenched and its fluorescence will be detectable. In Step 3, the non-modified strand of the double-stranded DNA is nicked by the restriction endonuclease. In Step 4, DNA polymerase that lacks 5'-3' exonuclease activity, preferably Bst DNA
polymerase Large Fragment ("Bst LF polymerase"), extends the 3' end of the nick, displacing the single-stranded DNA
target, which will go through the same cycle again.
Hence in this embodiment, the amplification products of Steps 2, 3 and 4 will have incorporated the FRET-labeled hairpin primer and will give a fluorescent signal.
5.2.5. METHODS OF USE OF HAIRPIN PRIMERS
IN TELOMERiC REPEAT AMPLIFICATION PROTOCOLS (TRAPs) Telomeres are specific structures found at the ends of chromosomes in eukaryotes. In human chromosomes, the telomeres consist of thousands of copies of 6 base repeats (TTAGGG)(Blackburn and Szostak, 1984, Ann. Rev. Biochem.
53:163); Blackburn, 1991, Nature 350: 569; Zakitan, 1989, Ann. Rev. Genet. 23:579). Telomeres stabilize chromosome ends. Broken chromosomes lacking telomeres undergo fusion, rearrangement, and translocation (Blackburn, 1991, Nature 350:569). In somatic cells, telomere length is progressively shortened with each cell division both in vivo and in vitro (Harley, et al., Nature 345:458; Hastie, et al., 1990, Nature 346:866, Lindsey, et al., 1991, Mutat. Res. 256:45; Counter, et al., EMBO J. 11:1921) due to the inability of the DNA
polymerase complex to replicate the very 5' end of the lagging strand.
Telomerase is a riboprotein that synthesizes and directs the telomeric repeats onto the 3' end of existing telomeres using its RNA component as a template. Telomerase activity has been shown to be specifically expressed in immortal cells, cancer and germ cells (Kim, et al., 1994, Science 266:2011; Shay and Wright, 1996, Current Opinion in Cancer 8:66-71), where it compensates for telomere shortening during DNA replication and thus stabilizes telomere length.
These observations have led to a hypothesis that telomere length may function as a "mitotic clock" to sense cell aging and eventually signal replicative senescence or programmed cell death (Shay and Wright, 1996, Current Opinion in Cancer 8:66-71; Harley, 1991, Mutat. Res 256:271; Greider, 1990, BioEssays 12:363; Piatyszek, et al., Methods in Cell Science 17:1) .
The TRAP (telomeric repeat amplification protocol) assay is a highly sensitive in vitro system that utilizes PCR
and is used for the detection of telomerase activity.
Telomerase-positive cells may be detected by employing the hairpin primers of the invention with a TRAP assay, e.g., a TRAP-ezeT"" (Oncor, Inc., Gaithersburg, MD) assay.

A TRAP assay is preferably carried out following the instructions provided with 'the TRAP-eze"' kit (Oncor, Inc. , Gaithersburg, MD) . The TI.ZAP-eze"' assay is a one buffer, two enzyme system utili;~ing PCR. As will be apparent, however, telomerase a:~says can also be carried out using amplification :methods oth~:r than PCR, although described in terms below of PCR. In the first step of a TRAP-eze~" reaction, telomerase adds a number of telomeric repeats (GGTTAG) on the 3' end of a substrate oligonucleotide (TS, telomerase substrate) ( Fig~.~re 2 9 ) .
A specific sequence, Ea.g., AGAGTT or TTAGGG, at the 3' end of an oligome:r is critical in order for the oligomer to serve as a TS (see Morin, 19~~1, Nature 353:454-456).
Preferably, the sequence is 5-6 nucleotides long, although shorter sequences, ~s.g., 4 nucleotides, may also be employed.
In the second step, the extended products are amplified by PCR usi:ng the TS and a reverse primer (RP) which comprises a sequence complementary to the telomeric repeats' sequence of the TS-telomerase e:ctension product, generating a ladder of products with 6 base :increments starting at 50 nucleotides: 50, 56, 62, 68, etc. Thus PCR amplification of these ladder bands takes place only when telomerase is present in the samples, since the reaction products~of active telomerase serve as templates for the PCR amplification. The level of telomerase activity is assessed by measuring the amount of PCR producits.
In a preferred aspect,. the RP is a hairpin primer of the invention. In one specific embodiment, a 17 bp-long nucleotide, labelled with a MET pair, 5'-ACGCAATGTATGCGT*GG
3' (SEQ ID N0:29), i:~ added to t:he 5' end of a linear RP
primer, forming a ha:irpin primer of the invention for use as an RP (See Example 1!5, Figure 30A). By way of example, a donor moiety can be attached to the 5' end of the oligomer, 35~and an acceptor moiei:y attached to the T residue.
By optimiz:Lng the reacaion conditions, a very low level of telomerase activity can be detected; the sensitivity of the assay is comparable to those of conventional assays that utilize polyacrylamide gel electrophoresis of PR
products (Figure 30B).
In another embodiment, the stem-loop hairpin structure may be attached to the 5' end of the TS primer. The modified TS oligomer therefore serves not only as a primer for PCR amplification but also as a substrate for the telomerase. It does so because the substrate specificity of the telomerase appears to be determined by the nucleotide sequences at the 3' end of the TS oligomer.
In yet another embodiment, telomerase-positive cells can be detected in tissue sections by using TRAP in situ in tissue sections, and by using a hairpin primer of the invention, e.g., the primer shown in Figure 30A, as a primer for the TRAP. The method described herein can be used for the detection of single cells with telomerase activity. Such a sensitive level of detection is difficult to obtain by conventional in-tube TRAP assays of tissue samples.
While the PCR-based TRAP assay is sensitive enough to detect small amounts of telomerase activity in cell/tissue extract (i.e., telomerase activity present in 1% of the cell population will be detected) it is impossible to identify individual telomerase-positive cells in the heterogeneous population, and to correlate cell/tissue morphology with telomerase expression. In contrast, identification of telomerase-positive cells using conventional fluorescence microscopy in an in situ TRAP assay permits the study of both the telomerase expression and the pathophysiological co:~dition of a single cell.
Like an in-tube TRAP assay, an in situ TRAP assay (see Section 15.1, Experiment 2) requires enzymatically active telomerase. The in situ TRAP assay detects telomerase activity by means of amplifying the telomerase-extended products, which serve as the DNA templates for the amplification reaction, preferably PCR.
To detect PCR products in a standard in-tube TRAP
assay, several procedures are possible. For example, in one WO 98/02449 . PCT/US97/12315 embodiment, labeled probe for a gene target of interest can be hybridized to the PCR products, followed by antibody detection of the bound probe. Alternatively, incorporation of a label into the PCR product may be detected by an antibody.
In contrast, utilization of the hairpin primers of the invention for in situ TRAP assay eliminates the detection step described above. As in an in-tube TRAP assay, an in situ TRAP assay can use a hairpin primer for either the TS or RP primer. Since only hairpin primers that are incorporated into the resulting PCR products fluoresce, after amplification, the slides can be viewed directly under a fluorescence microscope without detection/washing steps after PCR amplification. Cells will only fluoresce if the gene target of interest is amplified.
The utilization of hairpin primers in in situ TRAP
assays has great advantages over other methods. First, it eliminates the detection step. One of the technical problems of in situ PCR methodology is the diffusion of the PCR
products, making the identification of the native site of the amplified products extremely difficult. Elimination of the detection step minimizes this problem. Further, elimination of both the detection and washing steps allows the morphology of the tissues to be maintained.
Second, an internal control can be incorporated.
Heterogeneity of the slide preparations and possible presence of PCR amplification inhibitors may lead to false-negative results. Incorporation of an internal positive control for PCR amplification will obviate the problem. The internal control consists of a pair of primers and a DNA template, and is added into the TRAP reaction mixture. One of the two primers of the internal control is a MET pair-labeled hairpin primer of the invention, e.g., a rhodamine/DABCYL labeled hairpin primer that performs FRET. Utilization of this second fluorescent label (e. g., rhodamine) with an emission profile that is distinct from the fluorescent label on the non-control hairpin primer allows simultaneous identification WO 98/02449 PCT/ITS971123~15 of two different amplification products: e.g., the telomerase product labeled with FAM and the internal control labeled with rhodamine. By viewing the sample in a fluorescence microscope through separate filters appropriate for FAM and for rhodamine, respectively, one can assess whether amplification of the control has occurred.
The amplification of the internal control is independent of the presence or absence of telomerase activity in the specimen. The presence of PCR inhibition can be assessed by the failure or marked decrease of the amplification of the internal control on the sample slides.
Therefore, when a sample shows no telomerase products but does show amplification of the internal control, the result can be interpreted as indicating that the sample is truly telomerase-negative, and that it is not a false-negative result caused by PCR inhibition. Thus, the reliability of the methodology is greatly enhanced.
Finally, one of the biggest obstacles in setting up TRAP assays in a clinical laboratory setting is that the assay is extremely prone to PCR carry-over contamination. The closed-tube format of the TRAP assay described above, which uses the hairpin primers of the invention rather than conventional PCR primers, will have great utility in clinical laboratories.
5.2.6. METHODS OF USE OF HAIRPIN PRIMERS
IN CASCADE ROLLING CIRCLE AMPLIFICATION (CRCA1 Hairpin primers of the invention may be used in Cascade Rolling Circle Amplification (CRCA) (Lizardi and Caplan, PCT International Publication No. WO 97/19193, published May 29, 1997) (Figure 31). As in PCR, CRCA is driven by two primers. In an embodiment of the invention using CRCA, one or both of the primers is a hairpin primer labeled with a MET pair, and preferably, only one hairpin primer is labeled with a MET pair. The hairpin primer will only generate a MET signal when it is incorporated into the cascade reaction products. However, unlike PCR, the reaction does not require repeated cycle's of heat denaturation, and thus is isothermal. In this process, a first, forward primer hybridizes to a circularized probe template, and is extended by a DNA polymerase, e.g., Bst DNA polymerase Large Fragment ("Bst LF polymerase"), around tree circle and eventually displaces the primer end to form a long 5~ tail. A second, reverse primer initiates strand displacement synthesis on the tail that is displacead from the first-primer synthesis.
A CRCA results, wherein both primers are continually cycled to initiate :synthesis on the displaced strand from the previous round of synthesis. The use of a hairpin primer of then invention, either as the forward or the reverse primer, makes possible direct detection of CRCA
products in a closed system. Wren it is coupled with an initial, highly discriminatory 7.igation reaction (see below) to circularize a divalent linear probe at a target site, a CRCA reaction using i=he hairpin primers of the invention can serve as an extremely sensitive and simple system for detection of infectious agents, allotyping, and rare event detection such as in cancer diagnostics.
In order for CRCA to begin, ligation of a linear probe (preferably approximately 90 bases in length) to a target sequence must take place. This is catalyzed by a thermophilic ligase, e.g., AmpligasF (Epicentre Technologies, Madison, WI). The forward primer is added and anneals to the circularized probe. CRCA is initiated upon addition of a polymerase with strong strand-displacement activity, preferably Bst DNA polymerase, barge Fragment (8 units).
This thermophilic enzyme generates a tailed product several kilobases in length and produce:c many tandem repeats of the target sequence, and hence, many binding sites for the reverse primer.
Both the forward and reverse primers, one or both of which can be a hairpin primer labeled with a MET pair, but preferably only one :Labeled with a MET pair, are preferably present in excess (1 ~cM) to ensure rapid. binding to template *Trade-Mark DNA. As each primer is extended., the polymerase displaces the growing strand ahead of it, creating a new set of single-stranded tails with binding sitea fo:r the other primer (Figure 31).
This process continues. through many cycles and can generate, from a few hundred copies of the original circle, several micrograms o7: double-stranded amplification product containing incorporai:ed hairpin primers. Upon lowering the temperature for measurement of a MET emission, any unincorporated hairpin primers will return to a hairpin configuration. When the MET pair is a donor-quencher FRET
pair, this return to hairpin configuration will quench the fluorescent signal. Thus, when used with hairpin primers labeled with donor-quencher FRET pairs, no signal above background shauld be obtained in samples in which no ligation or cascade reaction occurred.
Since CRCA takes place at one temperature, generally around 60-~65°C, the primers need to be long enough (18 mers or longer) to bind effectively at these temperatures. Hairpin primers <~re preferably chosen that can form a strong hairpin at ambient: temperatures yet be relatively unstable .at 60-65°C such that the hairpin does not inhibit strand displacement syni:.hesi.s (Figure 32). The hairpin can partially overlap the primer binding sequences, which will further destabilize the hairpin during synthesis, or may be separated by a spacer region from the primer binding site.
In a preferred embodiment of a CRCA using the hairpin primers of the invention, other reaction components include 200 ~,M dNTPs, 2 mM MgSO," 20 mM Tris-HC1, pH 8.8, 10 mM KC1, 10 mM (NH,) 2S~04, and 0.1-l; Triton X-100. The ligation and cascade reactions can take ;place in the same tube and at the same temperature, with the ligase being added first in the presence of NAD+ (0.5 mM) a:nd incubated for 10 minutes 35~before addition of the polymerase.
5.3. METHODS OF DETECTION OF AMPLIFICATION
*Trade-Mark - 6:L -WO 98/02449 _ PCTIUS97/12315 PRODUCTS USING 3'-5' EXONUCLEASE
AND,IOR ELEVATED TEMPERATURE
The methods of the invention described in the subsections below may be also combined with those methods described in Section 5.4 (employing linear primers) for use during nucleic acid amplification reactions including PCR, triamplification, NASBA and SDA. Since the use of 3~-5' exonuclease or elevated temperature allows detection of amplified product without the need for separation of unincorporated primers (thus allowing a "closed tube"
format), such procedures are preferred for use with linear primers. Since the use of hairpin primers allows one to distinguish between amplified produce and unincorporated primers based on type of signal detected, exonuclease treatment or heat is not necessary for use in procedures employing the hairpin primers of the invention.
5.3.1. USE OF 3'-5' EXONUCLEASE IN AMPLIFICATION REACTIONS
As described in certain of the embodiments in Section 5.4 relating to PCR and triamplification, and also for use with NASBA and SDA, after an amplification reaction is complete, 3'-5' exonuclease can be introduced into the reaction vessel to cleave all free primer. Then, the donor label is stimulated with light of the appropriate wavelength.
When the acceptor moiety is a fluorophore, the only acceptor label that will emit is that which remains on uncleaved primer that has been incorporated into the amplified product, thus giving an indication of the extent of amplification.
The further amplification has proceeded, the greater the signal will be. When the acceptor moiety does not fluoresce and dissipates transfer energy as heat (i.e., quenches), the progress of the amplification reaction may be measured as a decrease in the emissions of the donor.
In one embodiment, wherein triamplification is employed (Section 5.4.2), single-strand-specific 3'-5' exonuclease is added to the amplification vessel after the amplification is complete. As shown in Figure 8, 3'-5' exonuclease treatment hydrolyzes the non-base-paired end of the reverse primer. The 3'-end of the blocker is protected and remains intact.
The interaction of the FRET fluorophores inside the amplified product will not be affected by this treatment for two reasons. First, the 3'-end of the amplified product will be base-paired and thus will not be a good substrate for the exonuclease. Second, the primer that is incorporated into the amplification product is extended on its 3' end and its labeled nucleotide residue will be relatively far from the unprotected 3'-hydroxyl. Therefore, it will take much longer for the nuclease to reach the modified residue. As a result, the only detectable FRET signal will come from the amplified product and will be free of background. Preferably the donor should be on the forward primer, and the acceptor on the blocker, but the converse is also possible.
The use of 3'-5' exonuclease in nucleic acid amplifications using linear primers eliminates the necessity of separating the amplification product from the non-incorporated oligonucleotides after the reaction. In a preferred embodiment, the method of the present invention may be carried out in the vessel in which the amplification reaction proceeds, without opening the vessel in order to allow for separation of amplification product. Polymerase and exonuclease may be mechanically separated during amplification, for example, in a two-chamber reaction tube as shown in Figure 11A. After amplification, the reaction tube is inverted, as in Figure 11B, allowing exonuclease to mix with the amplification mixture, resulting in hydrolysis of unreacted labeled primer. This provides for a greatly decreased chance of carryover contamination, and consequently, fewer false positive results in clinical studies. This "closed-tube" format is also readily amenable to automation.
In another embodiment, triamplification or PCR
amplification can be performed as described in Sections 5.4.1, 5.4.2 and 6, with the exception that thermostable DNA

WO 98!02449 . PCTIUS97112315 polymerase is present as a combination of two enzymes, with and without 3'-5' exonuclease activity. The ratio of polymerase to exonuclease can be adjusted such that polymerization predominates during the amplification cycles.
After amplification, when the cycling is over, single-stranded template will no longer be generated to which primers can bind. Hence there will be no template/primer complex for DNA polymerase to bind for dNTP incorporation.
Therefore, the DNA polymerase will have a chance to bind and digest the unreacted primers using its 3'-5' exonuclease activity.
5.3.2. USE OF TEMPERATURE ELEVATION
IN AMPLIFICATION REACTIONS
Background fluorescence of an amplification reaction such as a triamplification reaction can be decreased greatly by increasing the temperature of the amplification vessel, as an alternative to using exonuclease. During detection, the temperature in the vessel is raised sufficiently high enough to cause the short duplex formed between the unused blocker and the reverse primer to dissociate, preventing FRET. At the same time, the much longer amplification product remains double-stranded and generates a FRET signal (see, e.g., Example 5). In this embodiment, detection will preferably be carried out using a thermostable-cuvette or plate-reader fluorimeter. This embodiment also has the advantage that separation of the amplification product from unused primer is not required.
Thus, as in the previous embodiment that uses exonuclease treatment, amplification products may be detected directly, without opening the reaction vessel.
5.4. METHODS FOR DETECTION OF AMPLIFICATION
PRODUCTS USING LINEAR PRIMERS
Linear primers of the invention can be employed, for example, in PCR, NASBA, strand displacement, and triamplification in vitro or in situ. When using linear primers in closed-tube format amplification reactions, 3'-5' exonuclease treatment and/or temperature elevation (Section 5.3) is preferably used to distinguish the primers from the amplification product.
5.4.1. METHODS OF USE OF LINEAR PRIMERS
IN POLYMERASE CHAIN REACTION (PCR) In one embodiment, the primers of the invention are used to prime a polymerase chain reaction (PCR) (an example of which is shown in Figure 25), thereby becoming incorporated into the amplification product. A donor fluorophore moiety is attached to the primer, and an acceptor moiety that is either a fluorophore or a quencher is attached a short distance away from the donor (30 nucleotides or less) on the same primer.
After the PCR amplification is complete, 3'-5' exonuclease is introduced into the reaction vessel. The exonuclease cleaves all free primer in the reaction vessel.
The reaction mixture is then exposed to light of the appropriate wavelength to excite the donor moiety.
When the acceptor moiety is a fluorophore, the only acceptor label that will emit light is that which remains on uncleaved primer that has been incorporated into the amplified product, thus giving an indication of the extent of amplification. The further amplification has proceeded, the greater the signal from the acceptor moiety will be. When the acceptor moiety does not fluoresce and dissipates transfer energy as heat (i.e., it quenches), the progress of the reaction may be measured as a decrease in the emissions of the donor.
5.4.1.1. METHODS OF USE OF LINEAR PRIMERS
IN ALLELE-SPECIFIC PCR (ASP) In another embodiment, linear primers of the invention are used to prime an allele-specific PCR (ASP) as _ is described in Section 5.2.1.1 supra. In this embodiment, one or both amplification primers can be linear primers.

WO 98/02449 , PCTlUS97/12315 5.4.2. METHODS OF USE OF LINEAR
OLIGONUCLEOTIDES IN TRIAMPLIFICATION
In one embodiment, a pair of linear primers of the invention is used in triamplification (the general steps for which are described in Section 5.2.2.1).
As applied to the gap version of triamplification, and in an embodiment wherein the donor and acceptor moieties, respectively, of a MET pair are situated on separate linear oligonucleotides, either the forward or the reverse extending primer, and the third or blocking oligonucleotide are labeled. However, one of the pair of MET donor-acceptor labels should be on the blocker, and the other should be on a single-stranded 3~ end of the primer that is complementary to the blocker (see, e.g., Figures 7 and 8). In such a specific embodiment employing a FRET pair consisting of donor and acceptor fluorophores, the primer and blocking oligonucleotide are labeled with the donor and acceptor fluorophores, respectively, such that when both oligonucleotides are in close proximity (hybridized to each other) and the donor label is stimulated, FRET occurs and a fluorescence signal is produced at the emission wavelength of the acceptor fluorophore. (Alternatively, the acceptor moiety may be a quencher.) In a specific embodiment, the primer that is not complementary to the blocker is unlabeled with either the donor or acceptor moieties of the FRET pair, or alternatively, is labeled with both moieties (see paragraph below). After triamplification, exonuclease treatment and/or temperature elevation are preferably used to allow detection of amplified product without the need for separation of unincorporated primers (see Sections 5.3.1 and 5.3.2).
In another embodiment using triamplification wherein it is desired to use linear oligonucleotide(s) doubly labeled with both acceptor and donor moieties of a MET pair, and wherein exonuclease treatment (but not temperature elevation) is to be used after the triamplification reaction so as to avoid the need for separation of unincorporated WO 98102449 . PCTIUS97112315 labeled oligonucleotides, the forward and/or the reverse primer can each be labeled with both the donor and acceptor moieties of the FRET pair (within FRET distance of each ' other) if one of the moieties is on a 3' single stranded extension.
5.5. METHODS OF USE OF HAIRPIN OR
LINEAR PRIMERS IN MULTIPLEX ASSAYS
Through the use of several specific sets of primers, amplification of several nucleic acid targets can be performed in the same reaction mixture. In a preferred embodiment, one or both primers for each target can be hairpin primers labeled with a fluorescent moiety and a quenching moiety that can perform FRET. Amplification of several nucleic acid targets requires that a different fluorescent acceptor moiety, with a different emission wavelength, be used to label each set of primers.
During detection and analysis after an amplification, the reaction mixture is illuminated and read at each of the specific wavelengths characteristic for each of the sets of primers used in the reaction. It can thus be determined which specific target DNAs in the mixture were amplified and labeled. In a specific embodiment, two or more primer pairs for amplification of different respective target sequences are used.
5.6. ASSAYING THE METHYLATION STATUS OF
DNA USING AMPLIFICATION REACTIONS
OF THE INVENTION
Methylation of cytosine located 5' to guanosine is known to have profound effects on the expression of several eukaryotic genes (Bird, 1992, Cell 70: 5-8). In normal cells, methylation occurs predominantly in CG-poor regions, while CG-rich areas, called "CpG-islands," remain ' unmethylated. The exception is extensive methylation of CpG
islands associated with transcriptional inactivation of regulatory regions of imprinted genes (Li et al., 1993, WO 98/02449 PCTlUS97/12315 Nature 366: 362-365) and with entire genes on the inactive X-chromosome of females (Pfeifer et al., 1989, Science 246:
810-813).
Aberrant methylation of normally unmethylated CpG
islands has been documented as a relatively frequent event in immortalized and transformed cells (Antequera et al., 1990, Cell 62: 503-514], and has been associated with transcriptional inactivation of defined tumor suppressor genes in human cancers (Herman et al., 1996, Proc.Natl. Acad.
Sci., USA 93: 9821-9826). Sensitive detection of CpG island methylation has the potential to define tumor suppressor gene function and provides a new strategy for early tumor detection.
Methylation specific PCR is a sensitive detection method for abnormal gene methylation in small DNA samples (Herman et al., 1996, Proc. Natl. Acad. Sci., USA 93:
9821-9826). Methylation specific PCR employs an initial bisulfate reaction to modify DNA. All unmethylated cytosines are dominated in a bisulfate reaction and converted to uracils. Methylated cytosines are unaffected by the bisulfate reaction. Consequently, a sequence of DNA that is methylated will differ in sequence, after bisulfate treatment, from an identical sequence that is unmethylated.
Hence, different sets of primers may be designed to specifically amplify each of those sequences (e.g, a pair of primers to amplify unmethylated, bisulfate treated DNA will have one or more G residues replaced by an A residue (to be complementary to nucleotides that were formerly unmethylated cytosines), and one or more C residues replaced by a T
residue, respectively, for the two primers of the pair, relative to the primer pair for the methylated or untreated DNA).
As in any other PCR-based technique, this method is very sensitive. Any carry-over contamination from sources external to the PCR will cause false positive results. The use of the MET-labeled hairpin primers of the present invention eliminates the risk of carry-over contamination, WO 9$/02449 PCTILJS97/12315 since the reaction may be performed and monitored (in real time, if necessary) in a closed-tube format.
The use of bisulfate treatment in the methods of the invention is not limited to those methods employing PCR;
other amplification methods may alternatively be employed.
The invention thus provides a method of assaying the methylation status of DNA using an amplification reaction of the invention, with hairpin or linear primers. The method comprises: prior to conducting an amplification reaction, contacting a sample containing purified nucleic acids with an amount of bisulfate sufficient to convert unmethylated cytosines in the sample to uracil; and conducting the amplification reaction in the presence of a primer pair specific for preselected target sequences, e.g., Fragile X
gene, Prader-Willi syndrome region, Angelman syndrome region, p15 gene, p16 gene, E-cadherin gene, von Hippel-Landau syndrome gene. Pairs of primers, used in separate reaction vessels, are preferably specific for bisulfate-treated methylated, bisulfate-treated unmethylated, and nonbisulfite-treated (wild type) nucleic acids, respectively. Conclusions about the methylation status of the nucleic acids in the sample can be drawn depending on which primer pairs) give amplification product. In a preferred embodiment, the amplification reaction is PCR using one or more hairpin primers.
Kits as well as methods for determining the methylation status of DNA are also provided. In specific embodiments, such kits comprise in one or more containers one or more oligonucleotides of the invention for conducting the amplifications, and sodium bisulfate (optionally in combination with hydroquinone powder). Optionally, such kits further comprise in separate containers one or more of the following: mineral oil, DNA binding matrix, NaI solution, glycogen, amplification buffer, unmethylated control DNA, and methylated control DNA.

WO 98102449 . PCTIUS97I12315 5.7. KITS FOR THE AMPLIFICATION AND DETECTION
OF SELECTED TARGET DNA SEQUENCES
An additional aspect of the present invention relates to kits for the detection or measurement of nucleic acid amplification products. In specif is embodiments, the kits comprise one or more primer oligonucleotides of the invention, such as a hairpin primer, including but not limited to a universal hairpin primer, and/or linear primers, in one or more containers. The kit can further comprise additional components for carrying out the amplification reactions of the invention. Where the target nucleic acid sequence being amplified is one implicated in disease or disorder, the kits can be used for diagnosis or prognosis.
In a specific embodiment, a kit is provided that comprises, in one or more containers, forward and reverse primers of the invention for carrying out amplification, and optionally, a DNA polymerase or two DNA polymerases respectively with and without exonuclease activity. A kit for triamplification can further comprise, in one or more containers, a blocking oligonucleotide, and optionally DNA ligase.
Oligonucleotides in containers can be in any form, e.g., lyophilized, or in solution (e.g., a distilled water or buffered solution), etc. Oligonucleotides ready for use in the same amplification reaction can be combined in a single container or can be in separate containers. Multiplex kits are also provided, containing more than one pair of amplification (forward and reverse) primers, wherein the signal being detected from each amplified product is of a different wavelength, e.g., wherein the donor moiety of each primer pair fluoresces at a different wavelength. Such multiplex kits contain at least two such pairs of primers.
In a specific embodiment, a kit comprises, in one or more containers, a pair of primers preferably in the range of 10-100 or 10-80 nucleotides, and more preferably, in the range of 20-40 nucleotides, that are capable of priming amplification [e. g., by polymerase chain reaction (see e.g., Innis et al., 1990, PCR Protocols, Academic Press, Inc., San WO 98/02449 PCT/US97112~15 Diego, CA), for example, competitive PCR and competitive reverse-transcriptase PCR (Clementi et al., 1994, Genet.
Anal. Tech. Appl. 11(1):1-6; Siebert et al., 1992, Nature ' 359:557-558); triamplification, NASBA, strand displacement, S or other methods known in the art, under appropriate reaction conditions, of at least a portion of a selected target nucleic acid.
In another embodiment, a kit for the detection of a selected target DNA target sequence comprises in one or more containers (a) PCR primers, one or both of which are hairpin primers labeled with fluorescent and quenching moieties that can perform MET; and optionally: (b) a control DNA target sequence; (c) an optimized buffer for amplification; (d) appropriate enzymes for the method of amplification contemplated, e.g., a DNA polymerase for PCR or triamplification or SDA, a reverse transcriptase for NASBA;
(d) a set of directions for carrying out amplification, e.g., describing the optimal conditions, e.g., temperature, number of cycles for amplification. Optionally, the kit provides (e) means for stimulating and detecting fluorescent light emissions, e.g., a fluorescence plate reader or a combination thermocycler-plate-reader to perform the analysis.
In yet another embodiment, a kit for triamplification is provided. The kit comprises forward and reverse extending primers, and a blocking oligonucleotide.
Either the forward or reverse primer is labeled with one moiety of a pair of MET moieties, and the blocking oligonucleotide is labeled with the other MET moiety of the pair. One embodiment of such a kit comprises, in one or more containers: (a) a first oligonucleotide; (b) a second oligonucleotide, wherein said first and second oligonucleotides are linear primers for use in a triamplification reaction; (c) a third oligonucleotide that is a blocking oligonucleotide that comprises a sequence complementary and hybridizable to a sequence of said first oligonucleotide, said first and third oligonucleotides being labeled with a first and second moiety, respectively, that are members of a molecular energy transfer pair consisting of a donor moiety and an acceptor moiety, such that when said first and third oligonucleotides are hybridized to each other and the donor moiety is excited and emits energy, the acceptor moiety absorbs energy emitted by the donor moiety;
and (d} in a separate container, a nucleic acid lipase.
Another embodiment of a kit comprises in a container a universal hairpin optionally also comprising a second container containing cyanogen bromide or a nucleic acid lipase (e. g., DNA lipase, for example, T4 DNA lipase).
A kit for carrying out a reaction such as that shown in Figure 5 comprises in one or more containers: (a) a first oligonucleotide primer; (b) a second oligonucleotide primer, wherein the first and second oligonucleotide primers are forward and reverse primers for DNA synthesis in an amplification reaction to amplify a nucleic acid sequence, and wherein said second oligonucleotide primer comprises (i) a 5' sequence that is not complementary to a preselected target sequence in said nucleic acid sequence, and (ii) a 3' sequence that is complementary to said preselected target sequence; and (c) a third oligonucleotide primer that comprises in 5' to 3' order (i) a first nucleotide sequence of 6-30 nucleotides, wherein a nucleotide within said first nucleotide sequence is labeled with a first moiety selected from the group consisting of a donor moiety and an acceptor moiety of a molecular energy transfer pair, wherein the donor moiety emits energy of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavele:zgths emitted by the donor moiety;
(ii) a second, single-stranded nucleotide sequence of 3-20 nucleotides; (iii) a third nucleotide sequence of 6-30 nucleotides, wherein a nucleotide within said third nucleotide sequence is labeled with a second moiety selected from the group consisting of said donor moiety and said acceptor moiety, and said second moiety is the member of said group not labeling said first nucleotide sequence, wherein said third nucleotide sequence is sufficiently complementary WO 98102449 . PCTIUS97112~315 in reverse order to said first nucleotide sequence for a duplex to form between said first nucleotide sequence and said third nucleotide sequence such that said first moiety ' and second moiety are in sufficient proximity such that, when the donor moiety is excited and emits energy, the acceptor moiety absorbs energy emitted by the donor moiety; (iv) at the 3' end of said third oligonucleotide primer, a fourth nucleotide sequence of 10 - 25 nucleotides that comprises at its 3~ end a sequence identical to said 5' sequence of said second oligonucleotide primer. Where such kit is used for triamplification, a blocking oligonucleotide can also provided.
Another kit of the invention comprises in one or more containers: (a) a first oligonucleotide; (b) a second oligonucleotide, said first and second oligonucleotide being hybridizable to each other; said first oligonucleotide being labeled with a donor moiety said second oligonucleotide being labeled with an acceptor moiety, said donor and acceptor moieties being a molecular energy transfer pair, wherein the donor moiety emits energy of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavelengths emitted by the donor moiety; and (c) in a separate container, a nucleic acid ligase.
6. EXAMPLES: GENERAL EXPERIMENTAL METHODS
The following experimental methods were used for all of the experiments detailed below in the Examples, Sections 7-13, except as otherwise noted. In all of the Examples, the experiments were carried out using either triamplification or PCR.
6.1. OLIGONUCLEOTIDE SEQUENCES: SYNTHESIS AND MODIFICATION
' Three oligodeoxynucleotides complementary to segments of human prostate specific antigen (PSA) DNA were ' synthesized (Figure 12). Reverse primer contained a 2'-0-methyl moiety at a position complementary to the 5'-end of the blocker. This modification was essential for prevention of strand displacement during the amplification process (see Section 5.2.2.1) The blocker had biotin on its 3' end, in order to protect it from 3'-5'exonuclease hydrolysis and from undesirable extension during amplification. During the synthesis of blocker and forward primer, the primary amino group was incorporated on the modified T-base (Amino-Modifier C6 dT) as described by Ju et al. (1995, Proc. Natl. Acad.
Sci. USA 92:4347-4351). These modifications were used for subsequent incorporation of fluorescent dyes into designated positions of the oligonucleotides. Synthesized oligonucleotides were desalted and FAM (as a donor) and rhodamine (as an acceptor) were attached to a modified thymidine residue of the reverse primer and blocker, respectively, by the method published by Ju et al. (1995, Proc. Natl. Acad. Sci. USA 92:4347-4351). Labeled oligonucleotides were purified on a 15% denaturing polyacrylamide gel.
The absorption spectra of the primers were measured on a Hewlett Packard 8452A diode array spectrophotometer and fluorescence emission spectra were taken on a Shimadzu RF-5000 spectrofluorophotometer (Columbia, MD).
6.2. AMPLIFICATION OF PROSTATE SPECIFIC
ANTIGEN fPSA) TARGET DNA
Triamplification was performed in 120 ~,1 of 20 mM
Tris-HC1 (pH 8.5), 10 mM (NH4)ZS04, 0.1 mg/ml BSA, 2 mM NAD
0.1% Triton X100, 2 mM MgCl2, 200 ~,M each dNTP, 10-1' M
template, 250 nM forward primer, 250 nM reverse primer labeled with FAM, 500 nM blocker labeled with Rhod, 6 units of Pfu-exo- DNA polymerase (polymerase without 3'-5' exonuclease activity; Stratagene) and 30 units of AmpligaseT""
DNA ligase (Epicentre Technologies, Madison, WI). PCR
amplification was performed using the same conditions, except that blocker and ligase omitted from the PCR reaction mixture.

WO 98!02449 PCT/US97112315 Thermal cycling was performed using denaturation for 5 min at 94°C, followed by 35 cycles of 30 sec at 95°C
and 2 min 60°C. The PCR was completed with a final 6 min ' extension at 60°C.
As a first control, a similar triamplification reaction was performed in the absence of DNA template. As a second control, the reaction mixture was not incubated in the thermocycler.
6.3. 3'-5' EXONUCLEASE TREATMENT
Four units of T4 DNA polymerase that had 3'-5' exonuclease activity were added to the amplified DNA or control probe in 120 ~,1 of the amplification buffer and incubated at 37°C for 15 min, unless otherwise indicated.
6.4. ENERGY TRANSFER MEASUREMENTS
Energy transfer measurements were made on a Shimadzu RF-5000 spectrofluorophotometer. The excitation wavelength was 488 nm and the emission spectra were taken between 500 and 650 nm.
7. EXAMPLE l: DNA POLYMERASE COPIES A DNA
TEMPLATE WITH RHODAMINE MODIFICATION
This experiment (Figure 13A) was conducted to determine the effects of modification of a DNA template with rhodamine on the activity of DNA polymerase. If rhodamine labeling of the reverse primer were to block the incorporation of dNTP, elongation of the forward primer would stop at the base opposite the modification. In this case, the two strands of amplified product would be of different sizes: the one with incorporated forward primer would be shorter.
A PCR amplification (Figure 13A) was performed using the conditions for triamplification described in Section 6, but without using blocker. As illustrated in Figure 13B, the strands synthesized in the presence of modified and unmodified reverse primer were of the same size, indicating that rhodamine-labeling did not interfere with amplification.
The effects of rhodamine labeling on the yield of the amplification reaction were also estimated. PCR
amplification was performed and as a control, unmodified reverse primer was used. As shown on the agarose gel of Figure 13C, the amount of product was similar when rhodamine-reverse primer or non-modified reverse primer was present.
These results lead to the conclusion that the modifications in the DNA template do not affect the elongation reaction catalyzed by DNA polymerase.
8. EXAMPLE 2: MODIFICATION OF A REVERSE
PRIMER DOES NOT AFFECT THE REACTION
CATALYZED BY DNA LIGASE
Since triamplification uses thermostable DNA-ligase for amplification, it was important to determine whether the modification of primers affects ligation efficiency.
Triamplification was performed as described in Section 6 with rhodamine-labeled reverse primer. As shown in Figure 14A, the blocker had four nucleotides plus biotin on its 3~-end that extended it beyond the reverse primer sequence.
In cases in which the extended forward primer was ligated to the blocker, the resulting strand would be expected to be approximately 4 nucleotides longer than the opposite strand, which would have incorporated the extended reverse primer. If no ligation took place and instead the blocker was displaced, then both strands would be expected to be of the same length. By using [32P]-labeled forward or reverse primer in parallel experiments, the efficiency of ligation was estimated.
As shown in Figure 14B, most of the product with labeled forward primer was longer than the strand with labeled reverse primer, indicating that there was no significant effect of modification on the ligation reaction.
9. EXAMPLE 3: EXONUCLEASE CAN REMOVE A
NUCLEOTIDE RESIDUE LABELED WITH RHODAMINE

Exonuclease hydrolysis of a [32P)-labeled reverse primer labeled with rhodamine (Figure 15A) was performed in an amplification reaction mixture in a PCR amplification - using the methods described in Section 6. T4 DNA polymerase with 3'-5' exonuclease activity was used. Products of hydrolysis were analyzed on a 15o denaturing polyacrylamide gel. The results presented in Figure 15B demonstrate nearly quantitative hydrolysis of the modified oligonucleotide after 5 minutes. Similar results were obtained when a [32P)-labeled reverse primer labeled with rhodamine was in complex with blocker.
10. EXAMPLE 4: DETECTION OF AMPLIFICATION
PRODUCT BY ENERGY TRANSFER AFTER
NUCLEASE TREATMENT
To detect the triamplification product by FRET
between the reverse primer labeled with FAM and the blocker labeled with rhodamine, the triamplification and the subsequent exonuclease treatment were performed as described in Section 6. As a control, the triamplification reaction was also performed in the absence of DNA template.
Emission spectra are presented in Figure 16. The FRET signal at 605 nm was emitted by the double-stranded amplification product (Figure 16, Spectrum 1) whereas no FRET
signal was emitted from the control reaction run without DNA
template (Figure 16, Spectrum 2).
11. EXAMPLE 5: DETECTION OF AMPLIFICATION
PRODUCT BASED ON DIFFERENT
THERMOSTABILITY OF AMPLIFIED PRODUCT
AND HLOCRER/REVERSE PRIMER COMPLEX
The goal of this experiment was to determine whether a specific temperature could be found at which free blocker and reverse primer were no longer in duplex, so that no energy transfer could occur between them. At this temperature, however, the double-stranded triamplification product would still remain in duplex, so that the primers ~ incorporated into it would generate a FRET signal.
_ 77 _ WO 98/02449 . PCTIUS97l12315 Triamplification was performed as described in Section 6. A control reaction was run in the absence of DNA
template. After amplification, reaction mixtures were heated to 75°C and emission spectra were taken. The results indicate that at this temperature, there was no signal from non-amplified primers (Figures 17A-B). However, emission of rhodamine at 605 nm (i.e., a FRET signal) from the amplified product could be clearly detected.
12. EXAMPLE 6: CLOSED-TUBE FORMAT USING
HAIRPIN PRIMERS FOR AMPLIFICATION
AND DETECTION OF DNA BASED ON ENERGY TRANBFER
12.1. SUMMARY
A new method for the direct detection of PCR-amplified DNA in a closed system is described. The method is based on the incorporation of fluorescence resonance energy transfer-labeled primers into the amplification product. The PCR primers contain hairpin structures on their 5' ends with donor and acceptor moieties located in close proximity on the hairpin stem. The primers are designed in such a way that a fluorescent signal is generated only when the primers are incorporated into an amplification product. A signal to background ratio of 35:2 was obtained using the hairpin primers labeled with FAM as a donor and DABCYL as a quencher.
The modified hairpin primers do not interfere with the activity of DNA polymerase, and both thermostable Pfu and Taq polymerase can be used. This method was applied to the detection of cDNA for prostate specific antigen. The results demonstrate that the fluorescent intensity of the amplified product correlates with the amount of incorporated primers, and as little as ten molecules of the initial template can be detected. This technology eliminates the risk of carry-over contamination, simplifies the amplification assay, and opens up new possibilities for the real-time quantification of the amplified DNA over an extremely wide dynamic range.
12.2. INTRODUCTION
_ 78 -WO 98/02449 P(:T/US97/12315 Polymerase chain reaction (PCR) and other nucleic acid amplification techniques provide a tool for the geometric amplification of minute amounts of initial target ~ sequences (reviewed in Mullis and Faloona, 1987, Methods in Enzymology 155: 335-350; Landegren, 1993, Trends Genet. 9:
199-204). The extreme sensitivity of DNA/RNA amplification methods has encouraged the development of diagnostics for the early detection of cancer and infectious agents. However, drawbacks to the clinical use of nucleic acid amplification include the possibility of false-positive results due to carry-over contamination, and false-negative results caused by unsuccessful reactions and/or nonstandardized reaction conditions (Orrego, 1990, in Innis et al. (eds.), PCR
Protocols, A guide to methods and applications, Academic Press, San Diego, CA, pp. 447-454).
A major source of carry-over contamination are amplification products from previous amplification reactions.
Due to the extreme sensitivity of PCR, even minimal contamination can generate a false positive result, and accordingly, several approaches have been devised to deal with this problem. These include incorporation of dUTP with subsequent treatment with uracil N-glycosylase (Longo et al., 1990, Gene 93: 125-128), incorporation of ribonucleotides into the PCR primers followed by base treatment (Walder et al., 1993, Nucleic Acids Res. 21: 4339-4343) or the use of isopsoralen derivatives which undergo a cycloaddition reaction with thymidine residues upon exposure to W light (Cimino et al., 1991, Nucleic Acids Res. 19: 88-107).
However, a simpler and more certain solution to the problem would be a closed system, where both the amplification reaction and the detection step take place in the same ' vessel, so that the reaction tube is never opened after amplification. In addition, the "closed tube" format _ significantly simplifies the detection process, eliminating the need for post-amplification analysis by such methods as gel electrophoresis or dot blot analysis.

WO 98!02449 PCTIUS97/12315 The method described infra is designed to measure directly amplified DNA by incorporation of labeled oligonucleotide primers into the reaction product. The conformational transitions that the primers undergo serve as switches for energy transfer between two labels. In this method, the donor and acceptor (quencher) moieties are both attached to a hairpin structure on the 5' end of the amplification primer. The primers are designed in such a way that the fluorescent signal is generated only when the labeled oligonucleotides are incorporated into the double-stranded amplification product. This highly sensitive method may be used to obtain quantitative or qualitative results.
Applications for this system to the detection of a specific DNA sequence include, in addition to PCR, triamplification, nucleic acid sequence-based amplification (NASBA), and strand displacement amplification.
12.3. MATERIALS AND METHODS
Oligonualeotide primers The following oligodeoxynucleotides complementary to the 172 by segment of human prostate specific antigen (PSA) cDNA were chemically synthesized: 5'-CCCTCAGAAGGTGACCAAGTTCAT (SEQ ID N0:11), as an upstream primer, and 5'-GGTGTACAGGGAAGGCCTTTCGGGAC (SEQ ID N0:12), as a downstream primer. The structures of the upstream hairpin primers with energy transfer labels are shown in Figures 24A-G. FAM was incorporated into the 5' end of hairpin primers by using FAM phosphoramidite in the last step of the chemical synthesis. A modified T-base was introduced into a designated position by the use of Amino-Modifier C6 dT (Glen Research), and the DABCYL was attached to the primary amino group as described by Ju et al. (1995, Proc. Nat!. Acad. Sci.
USA 92: 4347-4351). Labeled oligonucleotides were purified by HPLC.
Preparation of PSA cDNA

The human PSA-expres;sing LNCaP cell line (American Type Culture Collection) was u:~ed i.n the experiments. LNCaP
pells were diluted with lymphocytes isolated from whole blood at ratios ranging from 1 LNCaP cell. to 10z lymphocytes to 1 LNCaP cell to 106 lymphocytes. Messenger RNA was isolated using the Dynal purification k.it. cDNA was synthesized from the isolated mRNA using revers.. transcriptase (Appligene) and oligodTl2_18 primers (Pharmacia).accarding to the recommended protocol.
PCR conditions Amplification of the PSA cDNA was performed in 100 ~1 of 20 mM Tris-HC1 (pH 8.5), 50 mM KC1, 2 mM MgCl2, 200 ~M
each dNTP, 500 nM each of the 'upstream and the downstream primers, and 5 units of the Pfue"°- DNA polymerase (which lacks 3'-5' exonuclease activity; St:ratagene). Thermal cycling was performed with a 5 :min denaturation at 94°C, followed by 20-40 cycles of 30 sec at 95°C, 45 sec at 60°C and 1.5 min at 72°C, and completed with a final 5 min extension at 72°C.
The PCR product wa's ;purified using QIAquick~Spin PCR Purification Kit (Qiagen) and cloned into pUCl9 plasmid.
MDE"' gels (FMC BioProducts) were used for the gel-based detection of the PCR products. Electrophoresis in a 6%
polyacrylamide gel with__7M urea, and subsequent quantification on a PhosphorImager~-SP (Molecular Dynamics) was used to estimate the amount of primer incorporated into the amplification product.
Fluorescence detection A Shimadzu RF-5000 spectrofluorophotometer was used to measure the fluorescence spectra of the individual samples. The 100 ~cl reaction mixture was diluted to 500 ~1 with 20 mM Tris-HC1, pH 8.5, 50 mM NaCl, and 2 mM MgCll, and placed into a 10 x 3 cuvette (NSG Precision Cells, Inc.) at room-temperature. For the FAM / DABCYL (4-(4'-dimethylaminophenylazo) benzoic acid) FRET pair, a 488 nm excitation wavelength was used and a spectrum was taken *Trade-Mark - ~Bl -between 500 and 650 nm. The fluorescent PCR product was also visualized by placing the tube directly against a UV
transilluminator image analysis system (Appligene), and photographed with a mounted camera using a D540/40 filter (Chroma Technology).
12.4. RESULTS
Experimental design of PCR with hairpin primers In this method, a hairpin structure is present on the 5' end of one (or both) of the PCR primers (Figure 1).
The sequence of the hairpin stem and loop may be partially complementary to the target DNA sequence, but this is not necessary. There are two moieties attached to the stem sequence of the hairpin: a quencher on the 5' end of the hairpin and a fluorophore on the opposite side of the hairpin stem. The positions of the fluorophore and the quencher may be switched, depending on the availability of the commercial precursors of these moieties. DABCYL is a nonfluorescent chromophore whose absorption spectrum overlaps with the emission spectrum of FAM. When stimulated by light of peak wavelength of 488 nm, FAM emits fluorescence of peak wavelength 516 nm. However, when DABCYL is located sufficiently close to the donor fluorophore, the energy can be transferred to DABCYL and dissipated as heat. Therefore, when the modified primer is in a "closed" configuration (hairpin), the FAM and DABCYL are in close proximity, and the emission of the fluorescein is quenched by DABCYL.
During the first cycle of PCR (Figure 2), the primers are extended and become templates during the second cycle. Since the hairpin structures are very stable (Varani, 1995, Annu. Rev. Biophys. Biomol. Struct. 24: 379-404), the stems are unlikely to be melted during the annealing step of the PCR on every target molecule. In this case, when the DNA
polymerase lacking 5'-3' exonuclease activity reaches the 5' end of the hairpin stem, it will displace it and copy the sequence. Thus, the hairpin primer will be linearized by incorporation into the double-stranded helical structure during PCR, the donor and acceptor will be about 20 nucleotides (-70 A) apart, resulting in no significant energy transfer between them (Selvin, 1995, Methods Enzymol. 246:
300-334), and the fluorescence from the FAM will be markedly enhanced.
' Sequence and spectroscopic properties of the hairpin primer The structure of the hairpin primer for the amplification of cDNA for prostate specific antigen (PSA) is shown in Figure 18A (SEQ ID NO:10). The primer consists of a 12 nucleotide long single-stranded priming sequence, a 7 by stem, and a 6 nucleotide loop. The fluorescent moiety (FAM) is located on the 5' end of the primer and a quencher (DABCYL) is across from FAM on the opposite strand of the stem sequence. Figure 18B presents the emission spectra of the FAM labeled hairpin primer before and after the incorporation of DABCYL. With no quencher present, FAM that is excited at a wavelength of 488 nm emits a peak wavelength of 516 nm. When the same oligonucleotide is also labeled with DABCYL, the fluorescence energy is transferred to the quencher and a much lower peak is detected at 516 nm. The residual fluorescence of the FAM/DABCYL-labeled oligonucleotide is partially caused by the presence of small quantities of oligonucleotides labeled with FAM alone.
Therefore an extensive HPLC purification of the labeled oligonucleotides was very important for the low background in subsequent experiments.
Similar results were obtained with rhodamine as a quencher (data not presented). As a quencher, r:owever, DABCYL has an advantage of being a non-fluorescent chromophore: it absorbs the energy of the fluorescein without - emitting light itself. As a result, the emission of the fluorescein may be detected more precisely, without interference from the emission of the acceptor.
Use of hairpin-oligonucleotides as PCR primers WO 98102449 . PCT/US97/12315 PCR of the fragment of PSA cDNA was performed using thermostable Pfue"~- DNA polymerise. Total cDNA from human PSA-expressing LNCaP cells mixed with lymphocytes was used for amplification. The preliminary experiments using ethidium bromide-stained gels for the assay showed that one PSA cell per 105 lymphocytes could be detected. For quantification purposes, the PCR product was cloned and used to compare the efficiency of amplification in the presence of the hairpin primer with that for the control primer, which lacks the hairpin structure and modifications. Figure 19 shows that the amount of amplified product was similar for the control primer, the hairpin primer containing FAM alone and the hairpin primer labeled with the FAM/DABCYL FRET
pair.
A crucial requirement for the method is the linearization of the hairpin primer during amplification.
Therefore DNA polymerise must be able to synthesize the strand complementary to the hairpin primer all the way through the hairpin to its 5' end. The following experiment 2o was conducted to determine whether modifications of the structure of the hairpin primer affect the subsequent synthesis of the full-length PCR product. PCR amplification of PSA cDNA was performed with two primers: an upstream FAM/DABCYL-labeled hairpin primer and a downstream primer labeled with 32P on its 5' end (Figure 20A). An upstream primer without the hairpin structure was used as a control.
If the structure and/or the modifications of the hairpin primer creates an obstacle for DNA polymerise, this primer will not be copied all the way to its 5' end, ar_d the [32P]-labeled strand will be shorter than the corresponding strand synthesized in the presence of the control primer.
To estimate the length of the individual strands, denaturing gel electrophoresis was performed. As illustrated by the results in Figure 20B, the [32P]-labeled strand that was synthesized in the presence of the hairpin primer was longer than the corresponding strand made with the control primer, indicating that DNA polymerise was able to read through the hairpin structure and synthesize a full-length product.
Another important aspect of this method is the thermostability of the hairpin primer. If the oligonucleotide phosphodiester bonds or the linker arms through which donor and/or acceptor are tethered to the oligonucleotide are cleaved as a result of high temperature, the quencher will be separated from the fluorophore and the background will increase. Indeed, when 50 pmoles of the hairpin primer was incubated in a 100 ~,1 reaction for 40 cycles, the background signal increased from 3.8 units to 12 units of fluorescence intensity. However, the observed background was still very low: it comprised only 6% of the fluorescence emitted by 50 pmoles of fluorescein-labeled oligonucleotides (200 units), which was the amount used in the assays.
Monitoring of PCR with hairpin primers To demonstrate that the fluorescence of the PCR
product could be used to monitor the reaction, total cDNA
from the mixture of 1 human PSA-expressing LNCaP cell per 104 lymphocytes was amplified with the FAM/DABCYL-labeled hairpin primer. After different numbers of cycles, the fluorescence intensity of the amplified product was determined using a spectrofluorophotometer (Figure 21A). The results show that after only 20 cycles, the fluorescence intensity increased five times compared to the non-amplified reaction mixture, and a thirty-five-fold increase was detected after 40 cycles of amplification. The same samples were also analyzed by denaturing gel electrophoresis with subsequent quantification on the PhosphorImager to determine the fraction of [32P]-labeled primers incorporated into the product. The results in Figure 21B demonstrate that the fluorescence intensity of the reaction mixture correlates with the amount of primers incorporated into the product.
In another experiment, the sensitivity of this method was explored. For quantification purposes, cloned PSA

cDNA was used as a template. 40 cycles of PCR were performed with 0, 10, 102, 103, 104, 105, or 106 molecules of cloned PSA
cDNA per reaction. The results in Figure 22 demonstrate that the method is sensitive enough to detect 10 molecules of the initial DNA template with a spectrofluorophotometer. The fluorescent PCR product was also visualized by placing the tube directly on a W transilluminator equipped with a mounted camera and D540/40 filter. This filter permits the detection of the emission in a narrow wavelength window:
between 515 and 560 nm. As shown in Figure 23, the fluorescence of the PCR reaction performed with 104, 105 and 106 molecules of the initial template could easily be detected by visual inspection of the tubes.
Effect of the structure of labeled hairpin primer on the amplification and detection Several hairpin primers with varying sizes of stem, loop and 3' single-stranded sequences were synthesized to estimate how these parameters might affect the efficiency of the PCR and the signal-to-background ratio. The structures and the relative fluorescent intensities are presented in Figures 24A-G. All primers tested had at least an 18-nucleotide sequence complementary to the target, which comprised a 3' single-stranded priming sequence, a 3' stem sequence and part of the loop (highlighted in bold in Figures 24A-G).
The length of the 3' single-stranded priming sequence was found to be very important for the efficiency of the ?hairpin primers in the PCR reaction. Almost no product was detected when the length of the priming sequence was decreased from twelve nucleotides in Structure A to six nucleotides in Structure G (Figure 24). A possible explanation for this result is that the hairpin structure is the preferred conformation of this oligonucleotide, even at the 60°C annealing temperature, and that the nucleotides in the stem and loop of the hairpin are not available for hybridization to the target DNA. In this case, the only part of the molecule not involved in the secondary structure is the 3' single-stranded sequence; however, the six nucleotide sequence on the 3' end of Structure G is not long enough to - be an efficient PCR primer.
Only minor variations in the amount of product generated were found when the sizes of stem and loop were changed slightly. The PCR was slightly less efficient when the length of the stem was greater than 7 bp. Stabilization of the stem by replacement of an AT-base pair at the 3' end with GC increased the signal-to-background ratio by 10%.
12.5. DISCUSSION
The method for detection of amplification products in a "closed tube" format is an important step towards a PCR-based automated diagnostic system, since it not only reduces the complexity of the reaction, but also eliminates the chances of carry-over contamination and, consequently minimizes the chances of false-positive results. The amplification primer contains a hairpin structure with two labels on its stem that can undergo fluorescence resonance energy transfer. One label is a fluorophore donor and another is a quencher that can absorb energy emitted by the fluorophore. A thirty-five-fold quenching of the fluorescence was observed when the oligonucleotide primers were in the hairpin conformation, so that less than 3% of maximum fluorescence is detected when the primers are not incorporated into the product. The switch from the hairpin to linearized conformation occurs as a result of replication:
the 5' end of the stem is displaced by DNA polymerase, a complementary strand is synthesized and the hairpin can no longer be formed. In the incorporated primers, the distance between the fluorophore and the quencher is around 20 base pairs, which is close to 70 A, the distance at which energy transfer is negligible (Selvin, 1995, Methods Enzymol. 246:
300-334) and so the quantitative emission of the fluorophore can be detected.
_ 87 _ WO 98102449 , PCTIUS97112315 The main advantage of this method is the generation of the fluorescent signal by the product itself, rather than by the hybridized probe, as in previous methods (Holland, et al., 1991, Proc. Natl. Acad. Sci. USA 88: 7276-7280; Lee et al., 1993, Nucleic Acids Res. 21: 3761-3766; Tyagi and Kramer, 1996, Nature Biotechnol. 14: 303-309). This keeps background low and allows the real-time quantification of the amplified DNA over an extremely wide dynamic range. In addition, the detection does not require special buffer or temperature conditions that are necessary for methods involving hybridization. The discrimination between a long double-stranded DNA product and the short hairpin primer is so efficient that the signal-to-background ratio will be the same over a wide temperature range under a variety of reaction conditions.
This method can be applied to many amplification systems in which a single-stranded oligonucleotide is incorporated into the double-stranded product, and is compatible with any thermostable DNA polymerase. The present example used Pfue"~- DNA polymerase, an enzyme without 5'-3' and 3'-5' exonuclease activity. Similar results were obtained with Taq polymerase, which has 5'-3' exonuclease activity (data not shown). 5'-3' exonuclease activity is a part of the excision-repair function of some DNA polymerases, and it will not attack a free primer. However, if the extended hairpin primer still maintains its hairpin conformation when annealed to the template DNA, then DNA
polymerase will hydrolyze the 5' end of the hairpin stem, and the 5' nucleotide with the tethered donor or acceptor will be released into the solution. In either case, replication or hydrolysis, the donor fluorophore will be separated from the acceptor, quenching will be eliminated, and the fluorescence signal from the amplification product will be detected, allowing any thermostable DNA polymerase to be used for the proposed amplification/detection method.
The thirty-five-fold signal-to-background ratio presented in this example can probably be increased even _ 88 _ further. Published data suggest that when the fluorophore and the quencher are covalently linked to each other, 200-fold quenching may be achieved (Wang et al., 1990, - Tetrahedron Lett. 31: 6493-6496). This implies that placing FRET labels in closer proximity to one another on the stem structure will increase the efficiency of quenching. This ' goal may be achieved by several approaches, such as variation of the linker arms, changing the positions of the labels, or using FRET pairs in which the donor and acceptor have some affinity to each other. Another way to improve the system is to increase the thermostability of the FRET-labeled oligonucleotides to prevent an increase in the background during amplification due to the spontaneous release of the labels into the solution.
The method described presented in this example can be applied to any diagnostic procedure in which the presence of the target nucleic acid is to be detected either qualitatively or quantitatively. It may be applied to the detection of infectious disease agents and microorganism contamination of food or water, as well as to the detection of some forms of cancer. An important step in the development of any application of this method is optimization of the structure of the primers and cycling conditions, since any side product can give a signal. However, optimization is facilitated by the fact that the size and purity of the product can be confirmed by gel electrophoresis, since the DNA amplified with the labeled hairpin primers can be analyzed by any of the traditional methods.
The present example demonstrates the utility of this method for the detection of cDNA of prostate specific antigen. The results show that the specificity and the ' sensitivity of detection are comparable to that of other amplification-based methods: as few as ten molecules of the _ initial target can be detected. This method can also be used for a "multiplex" analysis in which several targets are amplified in the same reaction. For this purpose, hairpin primers labeled with different fluorophores can be used. For _ 89 _ clinical applications, in which a large number of samples are to be tested, a fluorescence plate reader could be used to read the assay results, either separately or coupled with the PCR machine.
13. EXAMPLE 7: ASSAY FOR THE METHYLATION
STATUE OF CpG ISLANDS USING PCR WITH
HAIRPIN PRIMERS
13.1. MATERIALS AND METHODS
Genomic DNA was obtained from OH3 (unmethylated P16 DNA) and HN 12 (methylated P16 DNA) cell lines (acquired from Drs. S. B. Baylin and D. Sidransky, The Johns Hopkins Medical Institutions) and treated with bisulfite (Herman et al., 1996, Proc. Natl. Acad. Sci. USA, 93: 9821-9826).
Three sets of PCR primers (Figure 26) that amplify respectively bisulfite-treated unmethylated DNA (Uup and Ud (SEQ ID NOS:19 and 20, respectively)), bisulfite-treated methylated DNA (Mup and Md) (SEQ ID NOS:21 and 22, respectively), and the DNA not treated with bisulfite (wild type, WT) (Wup and Wd) (SEQ ID NOS:23 and 24, respectively) were chemically synthesized. One of the two primers in each set had a hairpin structure at its 5' end, labeled with FAM/DABCYL.
PCR was performed in 40 ~1 of 10 mM Tris-HC1 (pH
8.3), 50 mM KCl, 2 mM MgCl2, 0.25 mM each dNTP, 0.5 ~,M each primer, 100 ng of the corresponding DNA template and 1 unit of AmpliTaq GoldT"' polymerase (Perkin Elmer). Thermal cycling was performed using denaturation for 12 min at 94° C (these conditions were also required for the activation of the AmpliTaq GoldT"" polymerase), followed by 35 cycles of 45 sec at 95° C, 45 sec at 65° C and 1 min at 72° C. The PCR was completed with a final 5 min extension at 72° C.
13.2. RESULTS
The reaction products were analyzed as described in Section 6. After PCR amplification, the fluorescence intensities of the reaction mixtures were measured. The fluorescence intensity of the reaction mixture amplified in the presence of DNA template (+) differed significantly from the fluorescence intensity of the reaction mixture amplified in the absence of DNA template (-) (Table 2). For example, - 5 when a U-primer set (for amplification of a sequence of U
(bisulfate-treated unmethylated) DNA, see Table 2) was used with U DNA, it was amplified and the intensity of signal differed significantly from the intensity of the reaction mixture with no template. Similarly, use of an M-primer set led to amplification of M (bisulfate-treated methylated) DNA, and use of a W-primer set led to amplification of W (wild-type chemically unmodified) DNA.
Table 2. The fluorescence intensity (expressed as fluorescence units) in 20 ~cl of the reaction mixture after PCR in the presence (+) and in the absence (-) of DNA
template. U, unmethylated genomic DNA that underwent chemical modification with bisulfate; M, methylated genomic DNA that underwent chemical modification with bisulfate; W, clenomic DNA that did not undergo chemical modification.
U DNA M DNA W DNA
+ - + - + -13.3. CONCLUSION
The results show that MET-labeled hairpin primers may be used in an amplification reaction to detect, reliably and sensitively, methylated or unmethylated DNA.
14. EXAMPLE 8: PCR AMPLIFICATION USING
A UNIVERSAL HAIRPIN PRIMER
- 14.1. INTRODUCTION
This example presents experiments in which a universal hairpin primer was used, along with two selected linear primers, Primer 1 and "tailed" Primer 2, to prime a PCR amplification (see Section 5.2.1). The universal hairpin primer was incorporated into the amplification product and was not ligated to one of the two linear primer sequences.
The 3' sequence of the universal hairpin primer was identical to the 5' sequence of one of the pair of linear forward and reverse primers used in the amplification, and this 5' sequence (sequence "A" on Primer 2 in Figure 5) and was not complementary to the target sequence.
During the first cycle of PCR, Primer 1 (Figure 5), which was complementary to a target DNA (+) strand was extended. Primer 2 (Figure 5) had a 3' portion that has a sequence complementary to the target sequence (-) strand and a 5' portion, designated "A" in Figure 5, that had a sequence that was not complementary to the target sequence.
(Sequences for Primer 1 and Primer 2 appear below in Section 14.2.) Sequence A was 15 nucleotides in length.
During the second cycle, the product of the extension of Primer 2 (shown by the arrow in Figure 5) became a template for Primer 1. Primer 1 was extended and the amplification product acquired a sequence, designated "A',"
complementary to sequence A.
During the third cycle, the A sequence of the universal hairpin primer annealed to the A~ sequence of the amplification product from the previous cycle. The 3'-end of the template was extended, the universal hairpin primer unfolded and was copied, the quencher and fluorophore were separated, and a fluorescent signal was emitted from the amplification product.
During the fourth cycle, the extended universal hairpin primer became a template for Primer 1. During the extension of Primer 1, the hairpin unfolded and was copied, the quencher and fluorophore were separated, and a fluorescent signal was emitted from the amplification product.
Conditions of the reaction and the concentrations of the primers were optimized, so that > 80% of the PCR
product contained incorporated universal primer and was detectable by fluorescence detection.

WO 98!02449 PCT/US971I2~15 14.2. MATERIALS AND METHODS
PCR conditions.
In one set of experiments (see Table 3, below), amplification of prostate specific antigen (PSA) cDNA cloned into pUC 19 plasmid, Chlamydia genomic DNA, and the P16 gene present in total human genome, was performed using PCR
amplification with a universal hairpin primer labeled with Flu/DABCYL (see "Sequence of the universal hairpin primer,"
below), and three pairs of linear Primer 1 and linear tailed Primer 2 specific for PSA, Chlamydia, and P16, respectively.
106 molecules of PSA and Chlamydia sequences, and 100 ng of human DNA were used per reaction.
Amplifications were performed in 20 ~,1 of 20 mM
Tris-HC1 (pH 8.8), 50 mM KC1, 1.5 mM MgClz, O.OOlo gelatin, 200 ~,M each dNTP, 0.5 ~M of Primer 1, 0.1 uM of Primer 2, 0.5 ACM of the universal hairpin primer labeled with Flu/DABCYL and 1 unit of Taq DNA polymerase (Takara, Shiga, Japan). For amplification of the P16 gene, however, a Hot StartT"' amplification was performed, using AmpliTaq GoldT"" DNA
polymerase (Perkin Elmer) instead of Taq. For optimum amplification conditions, the concentration of the tailed primer (Primer 2) was kept low in order to obtain a majority of PCR amplification product with incorporated universal hairpin primer.
Thermal cycling was performed with 5 min of denaturation at 94°C, followed by 20-40 cycles: 20 sec at 95°C, 30 sec at 55°C and 1 min at 72°C, and completed with a final 5 min extension at 72°C. The required number of cycles depends on the concentration of the initial target. A PCR
reaction with a universal hairpin primer usually requires 3-5 cycles more than regular PCR to obtain a comparable amount of product. Universal hairpin primer only starts to incorporate at cycle 3 (Figure 5), and there is also competition from the tailed primer throughout the amplification.
Two control reactions were run per each DNA target.
Control 1 contained no tailed primer in the reaction mixture.
No product would be expected in this case if the universal hairpin primer was specific for the sequence complementary to the tail sequence only and could not hybridize to any other sequence of the DNA target.
Control 2 contained no DNA target in the reaction mixture.
In a second set of experiments (see Table 4), a set of PCR amplifications was run using varying concentrations of the PSA cDNA target and the PSA-specific Primer 1 and tailed Primer 2, and the universal hairpin primer. Another set of (conventional) PCR amplifications was run using PSA-specific Primer 1 and untailed Primer 2.
PCR in this second set of experiments was performed in 40 ~C1 of 10 mM Tris-HC1 (pH 8.3), 50 mM KC1, 2 mM MgCl2, 0.25 mM each dNTP, 0.5 ~,M each primer, 100 ng of the corresponding DNA template and 1 unit of AmpliTaq Gold""
polymerase (Perkin Elmer). Thermal cycling was performed using denaturation for 12 min at 94° C. These conditions were also used for the activation of the AmpliTaq GoldTM
polymerase, and were followed by 35 cycles of 45 sec at 95°
C, 45 sec at 65° C and 1 min at 72° C. The PCR was completed with a final 5 min extension at 72° C.
The products of the amplification using linear unlabeled primers was visualized on ethidium bromide stained gels.
Fluorescence detection.
A Shimadzu RF-5000 spectrofluorophotometer was used to measure the fluorescence spectra of the individual samples. A 5 ~,l aliquot of the reaction mixture was diluted to 600 ~,1 with 20 mM Tris-HC1, pH 8.8, 50 mM KC1, 2 mM MgCl2 and placed into a 10 x 3 mm cuvette (NSG Precision Cells, Inc., Farmingdale, NY) at room temperature. For the fluorescein/ 4-(4'-dimethylaminophenylazo) benzoic acid (DABCYL) FRET pair, a 488 nm excitation wavelength was used and a spectrum was taken between 500 and 650 nm.
The fluorescence intensities were determined after subtracting the background. The background was defined as the fluorescence of the universal hairpin primer in the reaction mixture before the PCR amplification reaction was run.
- When the amount of the initial target was not too low (1000 molecules or more), the fluorescent PCR
amplification product was also visualized by placing the tube directly against a W transilluminator image analysis system (Appligene, Strasbourg, France), and photographed with a mounted camera using a green D540/40 filter (Chroma Technology, Brattleboro, VT).
Alternatively, to obtain quantitative results, a fluorometric plate reader can be used. In this case the reaction can be performed in a sealed 96-well PCR plate. The same plate is then transferred into the plate reader, and the fluorescence emitted from the top of the plate is measured.
The measurement can be done after the desired amount of cycles. If the signal will not be strong enough the same plate can be transferred back to the PCR machine and more cycles can be performed after the short (1-2 min) preheat step. To determine the exact amount of the initial target, the proper internal control should be included. A hairpin primer of a different color should be used for the internal control. Quantitation of the initial target can be made easier if a real-time detection PCR machine is used, e.g., an Idaho Light-cycler (Idaho Technology, Inc., Idaho Falls, ID).
Sequence of the universal hairpin primer.
DABCYL
T A
C TCCAGCTCCTGCAGGCTGAGGT-3' SEQ ID N0:30 G AGGTCGA-5' C A
Flu The boldfaced sequence is identical to the tail on the specific primers.
Sequences of specific linear primers.

WO 98102449 , PCTIUS97/12315 In each sequence, the tail sequence of Primer 2 appears in bolded lowercase letters.
PSA:
Primer 1:
5'-ggt gta cag gga agg cct ttc ggg ac SEQ ID N0:31 Primer 2:
5'-cct gca ggc tga ggt gaa ggt gac caa gtt cat SEQ ID N0:32 Chlamydia genomic DNA
Primer 1:
5'-gta cta gag gac tta cct ctt ccc SEQ ID N0:33 Primer 2:
5'-cct gca ggc tga ggt ctg taa caa caa gtc agg tt SEQ ID N0:34 Primer 1:
5'-CAG AGG GTG GGG CGG ACC GC SEQ ID N0:35 Primer 2:
5'-cct gca ggc tga ggt CCC GGG CCG CGG CCG TGG
SEQ ID N0:36 14.3. RESULTS
As shown in Table 3, a universal hairpin primer can be used in a PCR amplification reaction to specifically detect three different targets. All three genomic sequences, PSA, Chlamydia genomic DNA, and P16, were amplified, and their amplification products were detected by measuring the fluorescence spectra of the amplification reactions with a spectrofluorophotometer.

Table 3. The fluorescent intensities of the PCR reaction mixtures with universal hairpin primer on different DNA
' targets.' Target Complete reaction no tailed primer no DNA
control 1 control 2 Chlamydia 286 14 5 genomic DNA
P16 gene 140 10 9 'The fluorescence intensity was determined after subtraction of background present before the PCR amplification reaction was run.
In addition, the products of amplification of PSA
and Chlamydia were visualized by placing the tubes on a transilluminator and photographing them through a green filter. The results are presented in Figures 28A-B.
Fluorescence was significantly enhanced after amplification compared to the controls, indicating that the DNA targets had been amplified.
The sensitivity of PCR amplifications using Primer 1, tailed Primer 2, and the universal hairpin primer was compared with that of conventional PCR amplifications using Primer 1 and untailed Primer 2. As demonstrated in Table 4 (below), the sensitivity of a PCR reaction using Primer 1, tailed Primer 2, and the universal hairpin primer is comparable to that obtained in a PCR reaction using Primer 1 - and untailed Primer 2. Under optimized conditions and concentrations of the primers, as described in Section 14.2, as little as 10 molecules of the PSA target could be detected using either the universal hairpin primer or the conventional linear (untailed) sequence-specific primers. The fluorescence intensity was determined after subtraction of _ 97 _ WO 98/02449 . PCT/US97/12315 background present before the PCR amplification reaction was run.
Table 4. The fluorescence intensities of the PCR reaction in the presence of specific and universal hairpin primer and different numbers of molecules of the initial PSA DNA target."
Number of target molecules per reaction: 0 10 10z 104 106 Labeled primer Specific 4 55 165 250 320 Universal 7 42 140 220 244 *The fluorescence intensity was determined after subtraction of background present before the PCR amplification reaction was run.
14.4. DISCUSSION
The results presented in this example demonstrate that there are several distinct advantages of using universal hairpin primers, rather than conventional linear PCR primers, in a PCR amplification.
First, a universal hairpin primer can be used for an amplification with any previously optimized set of PCR
primers. Second, the use of the universal hairpin primer permits a closed tube format; amplification and detection are performed in the same tube, without ever opening it. This ensures that there will be no carry-over contamination with amplicon (amplification products from previous reactions) and consequently no false positive results. Such minimization of carry-over contamination is especially important when large numbers of clinical samples are analyzed. In the past, contamination has generally been difficult to avoid when analyzing large numbers of clinical samples and false positive results are harmful. Use of the universal hairpin primers of the invention in closed tube PCR amplifications avoids the possibility of such contamination. Using this closed tube format and the hairpin primers of the invention in a PCR-based assay, at least three different targets can be specifically detected in one assay.
Third, by using the universal hairpin primers of the invention in a.PCR amplification, quantitative results can be obtained. One can quantitate the amount of amplification product by using, e.g., a fluorimetric plate reader, provided that proper internal controls are used, e.g., a known number of molecules of a second known target sequence and the corresponding primers for that target.
Fourth, by using the universal hairpin primers of the invention in a PCR amplification, one does not need to perform a time-consuming post-amplification analysis like gel electrophoresis or dot-blot. By omitting this step, one saves 2-3 hours on each set of amplification reactions.
Finally,. the results presented here indicate that the universal hairpin primer can be used to amplify the P16 gene. Hence a universal hairpin primer is suitable for inclusion. in a kit for the detection of the methplation status of the P16 gene, which is a tumor suppressor.
15. EXAMPLE 9: OSE OF HAIRPIN PRIMERS IN A
TELOMERIC REPEAT AMPLIFICATION PROTOCOL (TRAP) ASSAY FOR THE DETECTION OF TELOMERASE-POSITIVE~CELLS
- The present example demonstrates the detection of telomerase-positive cells in which a TRAP assay is used with a hairpin primer of the invention.
15.1. METHODS AND RESULTS
Experiment 1.
A 17 bp-long nucleotide, 5'-ACGCAATGTATGCGT*GG-3' (SEQ ID N0:2Q), was added to the 5' end of a RP primer (Figure 30A). FAM was attached to the 5' end of the oligomer and DABCYL was attached to the T* residue. When the intra-chain stem-loop of the hairpin primer formed, FAM and DABCYL
residues were positioned opposite one other (Figure 30A). In this configuration, the fluorescence emission of the 5' FAM
was minimal in unincorporated oligomer due to FRET between FAM and DABCYL.
A series of TRAP assays utilizing this hairpin RP
primer demonstrated that the 5' modification of the RP does not significantly alter the efficiency of the TRAP assay (Figure 30B). TRAP assays were performed using TS primer and the RP primer sequence (SEQ ID N0:37) shown in Figure 30A, with cell extract equivalent to 10,000, 1000, 100, or to cells. Three negative controls were also run (Figure 30B):
"No Taq," in which no Taq polymerase was added in the reaction (negative control 1); "CHAPS," in which CHAPS lysis buffer was used instead of cell extract in the reaction (negative control 2); "+H," cell extract from 10,000 cells was heat-treated prior to the assay (negative control 3).
Four reaction tubes (0.05 ml per tube) were prepared for each extract or control and PCR amplification in a thermal cycler (cycle conditions: 94° C for 30 sec and 55° C for 30 sec) was performed for the number of cycles indicated in Figure 30B.
At the end of the cycles, the tubes were removed from the heating block of the thermal cycler and stored in the dark until measured for fluorescence. To perform fluorescence measurements, 0.02 ml of the reaction mix was mixed with 0.60 ml of buffer (10 mM Tris-HC1, pH 7.6, 150 mM NaCl, 2 mM MgClz) and emission at 516 nm excited by 488 nm light was measured with a Shimadzu RF5000U spectrofluorophotometer.
By optimizing the reaction conditions, a very low level of telomerase activity was detected; the sensitivity of the assay is comparable to those of conventional assays that utilize polyacrylamide gel electrophoresis of PR products (Figure 30B).
Experiment 2.
In the first step of an in situ TRAP assay, a slide is prepared of selected tissues or cells of interest.
Unfixed tissues are frozen quickly in liquid nitrogen and frozen sections are prepared by microtome sectioning. Single cell spreads are prepared by centrifugation of cell suspensions utilizing, e.g., Cyi~ospin~" (Shandon Lipshaw Inc., Pittsburgh, PA). The prepared s:Lides are then treated with a solution containing :RNase-free l~Nase in 40 mM Tris-HCL pH
7.4, 6 mM MgCl2 and 2mM CaCl2 for 5-15 hours.
A slide sealing system such as Probe-Clips (GraceBio-Labs, Pontiac, MI) is used. Probe-Clips are attached on the slides and the ;specimens are covered with the DNA solution and incubated for !5 to 15 hours. The Probe-Clips, which form a sealed chamber around the specimen without the usage of adhesives or other toxic solvents, can also be utilized in the TRAP extension amplification reaction.
The TRAP assay is run on the samples on the prepared slides following the instructions provided with the TRAP-eze"' kit. Experimental conditions for standard in-tube TRAP assays can be used with minor modification. After amplification, the_slides are viewed directly under a fluorescence microscope without detection/washing steps after PCR amplification. Cells will only fluoresce if the gene target- of interest is amplified.
16. EXAMPLE 10: USE OF HAIRPIN PRIMERS IN AN AMPLIFICATION
REFRACTORY MUTATION SYSTEM (ARMS) ASSAY
16.1. INTRODUCTION
Allele-specific PCR was run, using hairpin primers, to amplify the normal sequence and the W64R mutation of the beta-3-adrenergic receptor (B3A1R) gene. The normal product 3Q of the gene is a G-protein link~ad receptor that is expressed predominately in visceral fat. It is believed to be a regulator of resting metabolic :rate and lipolysis, and the W64R mutation has been associat~_d with obesity (Clement et al., 1995, New Engl. J. Med. 33:3: 352-354).
16 . 2 . 1'4ETHODS
The amplification refractory mutation system (ARMS) *Trade-Mark WO 98102449 . PCTIUS97/12315 assay (Newton et al., 1989, Nucl. Acids Res. 17: 2503-2516) was used for allele-specific PCR. The upstream allelic primers in the ARMS assay had a hairpin format, and used a common downstream primer. The ARMS assay is designed such that there is a mismatch at the 3' end of the primer when the primer is paired to the incorrect allele.
The sequence of the B3AR gene and the allelic primers are shown in Table 5 (below). Boldface type has been used to highlight codon 64 of the B3AR sequence, and the underlined sequences indicate the area for which the allele-specific primers were designed. Hairpin primers were modified at an internal thymine, as indicated in Table 5, using DABCYL as the quencher, and on the 5' end with FAM as the fluorophore.

TABLE 5. Sequence of the H3AR gene target and the allelic primers used for the ARMS assay W64 Allele:
(5') . . . TGC TGG TCA TCG TGG CCA TCG CCT GGA . . . (3') SEQ ID N0:38 T
G C AGTAGCA (5') A
C G TCATCGT GG TCA TCG TGG CCA TCG CCT (3') G
DABCYL
WO 98/02449 . PCTIUS97/12~J15 R64 Allele:
(5') . . . TGC TGG TCA TCG TGG CCA TCG CCC GGA . . . (3') SEQ ID N0:39 W64 Allelic Primer:
FAM
SEQ ID N0:40 R64 Allelic Primer:
T
G C AGTAGCA (5') A ~IIII~I
C G TCATCGT GG TCA TCG TGG CCA TCG CCC (3') G I
DABCYL
SEQ ID N0:41 Downstream Common Primer:
(5') CCA CTA CCC TGA GGA CCA CC (3') SEQ ID N0:42 FAM
The ARMS assay was run in 10 mM Tris-HC1, pH 8.3 buffer containing 50 mM KC1, 2 mM MgCl2, 400 ACM each dATP, dCTP, dTTP, and dGTP, and 10% dimethylsulfoxide (DMSO). The primers were used at a concentration of 1 ~,M each, and Taq polymerase (Takara, Shiga, Japan) at 1.5 U per 20 ~,L
reaction. The 20 ~,L PCR reactions were run on a PE-2400 WO 98/02449 . PCT/US97112315 thermal cycler (PE Applied Biosystems, Foster City, CA) for 4 min at 94°C, followed by 35 cycles of 30 sec at 94°C, 30 sec at 55°C and 30 sec at 72°C, followed by a 10 min incubation at 72°C and a 4°C hold.
16.3. RESULTS
Using the reaction conditions described above, cloned normal (W64) and mutant (R64) templates were tested for amplification specificity and yield. A no target negative control was also run with each reaction. After PCR, 3 ~,L of each PCR reaction was run on a gel and stained with ethidium bromide. Using the PCR system described above, the normal (W64) target only gave a visible band when the normal primer was present and the mutant target (R64) only gave a visible band when the mutant target was present. No background PCR artifacts were observed in the negative control or in the PCR reactions run with the mismatched target. Each PCR reaction was also tested for fluorescence yield by diluting 5 ~L from each reaction into 0.6 mL of 15 mM Tris-HC1, pH 8.0, 50 mM NaCl, and 2 mM MgClz buffer. The fluorescence of each reaction was measured on a Shimadzu RF-5000U spectrofluorophotometer using an excitation wavelength of 488 nm and an emission wavelength of 516 nm.
After subtracting the background fluorescence of the negative control from each sample, the PCR run with the normal (W64) allelic primer and the normal (W64) target DNA
had a relative fluorescence of 37, while fluorescence from the PCR run with the normal (W64) allelic primer and the mutant target (R64) was the same as the negative control.
The PCR run with the mutant (R64) allelic primer and the normal (W64) target DNA had a relative fluorescence of 2, and the PCR run with the mutant (R64) allelic primer and the mutant target (R64) had a relative fluorescence of 19. These results indicate good PCR product and fluorescence yield from an allele-specific PCR using hairpin primers with an ARMS
design, and the capability of distinguishing normal and mutant alleles based on fluorescence alone, without the need to run gel electrophoresis.

WO 98102449 PCT/US97I12a15 i7. EXAMPLE 11: AS8AY FOR THE gag REGION OF THE HIV-1 VIRAL GENOME USING IN SITU PCR WITH HAIRPIN PRIMERS
17.1. INTRODUCTION
- 5 HIV-1 provirus is very difficult to detect with standard in situ hybridization but can be routinely and - reliably detected after in situ PCR, but with the additional time and expense of hybridization and washing steps. The present example describes methods of the invention that allow for the accurate and sensitive detection of the target directly after the amplification step.
The following methods are used to detect an HIV-1 DNA target, and employ FRET-labeled hairpin primers in in situ PCR. These methods avoid the hybridization step and will not lead to false positive results due to DNA repair.
Another advantage of this method is that the generation of the fluorescent signal is by the product itself, rather than by the hybridized probe as in previous .in situ PCR methods.
The primary use of in situ PCR at present is the detection of viral DNA or RNA. Improvement in sensitivity, as provided by using the labeled primers of the invention, will allow for broader applications such as detection of small gene deletions or mutation detection by allele specific in situ PCR.
17.2. MATERIALS AND METHODS
Tissues that comprise a wide range of potentially HIV-1 infected cells, including those from the central nervous system, lymph nodes, and spleen, are assayed for HIV-1 DNA, using the FRET-labeled primers of the invention and standard in situ PCR methods commonly known in the art (see _ e.g., Nuovo and Bloch, U.S. Patent No. 5,538,871; Bagasra and Seshamma, 1994, Protocol: In situ amplification and hybridization, Second Ed., John Wiley and Sons, Somerset, NJ).
A pair of upstream and downstream PCR primers (SEQ
ID NOS: 43-44, see below) are chemically synthesized and used WO 98/02449 , PCTIUS97112315 to amplify a portion of a sequence from the gag region of an HIV-1 viral genome DNA. One or both oligonucleotide PCR
primers that are used can have a hairpin structure at the 3' end, labeled with a MET pair, e.g., FAM/DABCYL.
For example, a hairpin primer may be used in which the single-stranded nucleotide sequence at its 3~ end comprises the sequence of SEQ ID N0:43 or SEQ ID N0:44 so as to be able to prime synthesis by a nucleic acid polymerase of a nucleotide sequence complementary to a nucleic acid strand 1o comprising the gag target sequence.
An example of such a hairpin primer, BSK38 (SEQ ID
N0:26) is shown in Figure 27. The primer forms a hairpin structure in which MET will occur when the primer is not incorporated into the amplification product. When it is incorporated into the amplification product, its configuration changes (i.e., it is linearized), and, in the case of a FAM/DABCYL FRET pair, quenching is eliminated, and the fluorescence of the donor is detected.
Alternatively, the pair of primers may be MET-labeled linear primers that do not form a hairpin configuration (see Section 5.4).
When one or both primers are linear primers, they may have the following sequences which are complementary to the gag sequence:
Primer SK 38:
ATAATCCACCTATCCCAGTAGGAGAAAT (SEQ ID N0:43) Primer SK 39:
TTTGGTCCTTGTCTTATGTCCAGAATGC (SEQ ID N0:44) In control experiments, a conventional in situ PCR
(e.g., Nuovo, 1997, PCR In Situ Hybridization: Protocols and Applications, Third Edition, Lippincott-Raven Press, New York) is run using two linear primers complementary to the gag sequence, e.g., SK 38 (SEQ ID N0:43) and SK 39 (SEQ ID

WO 98102449 . PCT/US97II2315 N0:44). Amplification products are detected through an in situ hybridization step using the SK 19 sequence as probe.
SK 19 (hybridization probe):
ATCCTGGGATTAAATAAAATAGTAAGAATGTATAGCCCTAC (SEQ ID N0:45).
In situ PCR using the FRET-labeled primers of the invention is performed by carrying out the following steps.
First, a sample is placed on a glass microscope slide and then fixed by standard methods. Common fixatives include, e.g., ethanol, methanol, methanol: acetic acid, formaldehyde, paraformaldehyde and glutaraldehyde, or any other fixative known in the art.
The sample is optionally pretreated with a protease, e.g., proteinase K, to aid in penetration of amplification reagents. The concentration of protease and time of treatment is determined empirically for each sample.
An amplification cocktail, which consists of nucleotides, hairpin (or linear) primers of the invention, an amplification buffer, and a thermal stable DNA polymerase, e.g., Taq polymerase, is then added. A coverslip or other suitable solution containment device is attached to keep the concentration of the cocktail consistent during subsequent thermal cycling steps. (For general methods and buffer compositions for in situ PCR, see, e.g., Nuovo, 1997, PCR In Situ Hybridization: Protocols and Applications, Third Edition, Lippincott-Raven Press, New York; Nuovo, et al., U.S. Patent No. 5,538,871) In situ amplification is then performed in a thermal cycler, for e.g., 30-40 cycles, using conditions for annealing and extension previously established by solution PCR, e.g., first thermal cycle, denaturation for 3 min at 94°
C, and annealing/extension for 2 min at 55° C; the remaining - 39 cycles consist of 1 min denaturation at 94° C and 2 min annealing/extension.
Since the unincorporated hairpin primers do not produce signal post-amplification, wash steps are reduced or WO 98!02449 PCT/US97/12315 eliminated. This improves sensitivity of detection because no amplification product is lost during post-amplification wash steps.
After PCR amplification, the MET signal intensities of the reaction mixtures are measured using, e.g., a fluorescence microscope. Cells positive for the HIV gag template should show a signal, e.g., fluorescence; cells negative for gag should show no signal.
18. EXAMPLE 12: CHARACTERIZATION OF THE gag REGION OF

HAIRPIN PRIMERS
18.1. INTRODUCTION
In this example, a series of HIV-1 infected tissues from the spleen, lymph node, brain, and cervix were assayed for the gag region of the HIV-1 viral genome using in situ PCR with hairpin primers.
18.2. MATERIALS AND METHODS
A hairpin primer and a linear primer were chemically synthesized and used to amplify a portion of a sequence from the gag region of an HIV-1 viral genome DNA.
The linear primer used was SK 39 (SEQ ID N0:44).
The hairpin primer used, BSK38 (SEQ ID N0:26) is shown in Figure 27 (see also Section 17 above). The single stranded nucleotide sequence of the hairpin primer comprised, at its 3' end, a 3' portion of the sequence of SK 38 (SEQ ID
N0:43). The 5' portion of the primer comprised a hairpin labeled with a FAM/DABCYL MET pair. Since the 3' single stranded sequence was complementary to the gag sequence, it served as a primer.
The primer forms a hairpin structure in which MET
will occur when the primer is not incorporated into the amplification product. When it is incorporated into the amplification product, its configuration changes (i.e., it is linearized), and, in the case of a FAM/DABCYL FRET pair, quenching is eliminated, and the fluorescence of the donor is detected.
In control experiments, a conventional in situ PCR
(Nuovo, 1997, PCR In Situ Hybridization: Protocols and Applications, Third Edition, Lippincott-Raven Press, New York) was run using two linear primers SK 38 (SEQ ID N0:43) and SK 39 (SEQ ID N0:44) complementary to the gag sequence in the amplification cocktail (see below). Amplification products were detected through an in situ hybridization step using the SK 19 (SEQ ID N0:45) sequence as probe.
In situ PCR using the linear primer and the FRET-labeled hairpin primer of the invention was performed essentially as described in Section 17 with a few modifications. Tissue sections were affixed to silane coated glass microscope slides and fixed for one week in 10% neutral buffered formalin, then embedded in a paraffin embedding medium using standard methods known in the art. Section were deparaffinized (by incubating with xylene for 5 min, followed by 100% ethanol for 5 min). The sample was pretreated with 2 mg/ml of pepsin for 30 min. 10 - 20 ~cl per sample of an amplification cocktail were then added to the slide, which was then coverslipped with an autoclaved polypropylene coverslip and overlaid with preheated mineral oil.
The amplification cocktail consisted of the following reagents per 50 ~,1 of cocktail:
5 ~C1 PCR buffer II (Perkin-Elmer) 9 ~C1 MgCl2 ( f final concentration 4 . 5 mM) 8 ~.1 dNTP (final concentration 200 ~M each) 1.5 ~,1 2% BSA
2 ~l modified SK38 oligonucleotide (final concentration of 0.2 ~,M) ' 2 ~,1 SK39 oligonucleotide (final concentration of 0.2 ~tM) 21.5 ~,1 DEPC-treated water 1 ~1 Taq polymerase (Perkin-Elmer 5 U/~cl) In situ amplification was then performed in a thermal cycler for 35 cycles using a "hot start" protocol.
Taq polymerase was withheld from the amplification cocktail until the block reached 55° C, then the DNA sample was denatured initially by heating at 94° C for 3 min, after which cycling began, with denaturation for 1 min at 94° C, and annealing/extension for 1.5 min at 60° C.
After PCR amplification, a high stringency wash was performed (60° C in 15 mM salt and 2% BSA for 10 min after PCR). The MET signal intensities of cells in the samples were then measured using a fluorescence microscope.
18.3. RESULTS
Figure 34 shows the gag positive cells in lymph node tissue from a patient with early HIV-1 infection, after performing in situ PCR using the linear primer and the FRET-labeled hairpin primer of the invention.
Figure 35 shows the same view of the tissue sample at a higher magnification. The gag positive cells show a strong signal and there is low background in the preparation.
Figure 36 is a negative control in which Taq polymerase was omitted from the amplification cocktail. No gag positive cells were observed.
Figure 37 also shows lymph node tissue from an HIV-1 infected patient after performing in situ PCR using a linear primer and a FRET-labeled hairpin primer. gag positive cells are seen. However the signal-to-background ratio is less than in Figures 34 and 35; there is signal in some cells but cytoplasmic background in others due to an inadequate post-PCR wash.
Figure 38 shows an HIV-1 positive neuron in the cerebrum of a patient who died of AIDS dementia, after performing in situ PCR using a linear primer and a FRET-labeled hairpin primer. Note the good signal-to-background ratio.
18.4. DISCUSSION
Cells from HIV-infected patients, and thus known to be positive for the HIV gag template, showed a fluorescent signal whereas cells expected to be negative for gag showed no signal.
19. EXAMPLE 13: USE OF IiAIRPIN PRIMERS-IN A CASCADE
ROLLING CIRCLE AMPLIFICATION (CRCA) ASSAY
19.1. METHODS AND RESULTS
Cascade rolling circle amplification (CRCA) performed with one hairpin (MET) primer and one non-hairpin primer was used to amplify a "padlock" probe that was circularized by ligation with DNA ligase upon hybridization to a model target sequence (Nilsson, et al., 1994, Science 265:2085-2088), pUCl9,, and achieved high signal to background ratios and sensitivity down to -10 template~circles.~ When either rolling circle (forward) hairpin primer 1 or 2 (SEQ ID
NOS: 46-4%) or a reverse hairpin primer 1 or 2 (SEQ ID NOS:
48-49) was labeled with a FAM/DABCYL MET pair (see Figure 32), normal cascade products were observed, by agarose gel analysis, when using 8 units of Bst DNA polymerase, large fragment in the amplification-reaction:
CRCA reactions were run with the...following pairs of primers (see Figure 32): MET-labeled hairpin forward-(rolling circle) primer 1.(SEQ ID N0:46) and non-hairpin reverse primer (SEQ ID N0:51); MET-labeled hairpin forward primer 2 (SEQ ID NO:4~) and non-hairpin reverse primer (SEQ ID N0:5~);
non-hairpin forward (rolling circle) primer (SEA ID N0:5U) and MET-labeled hairpin reverse primer 1. (SEQ ID N0:48); and non-hairpin forward (rolling circle) primer (SEQ ID N0:5U) and MET-labeled hairpin reverse primer 2 (SEQ ID N0:49).
Several micrograms of double-stranded DNA product were generated, in a 25-~,1 reaction, in 1 hour at 64°C.
Strong MET signals were detected by fluorometric analysis relative to background levels in control reactions (minus ligase). Fluorescent product were also observed by direct visualization of the reaction tubes on a transilluminator.
As depicted in Figure 33, MET signals above background were clearly observed with as few as 10 template circles (+ ligase). The CRCA depicted in Figure 33 was run using unlabeled, non-hairpin forward (rolling circle) primer 1 (SEQ ID N0:46) and MET-labeled hairpin reverse primer 1 (SEQ ID N0:48). Template circles were circularized probe made using pUCl9 as target. 8 units of Bst polymerase, large fragment, were used and the CRCA reaction was run for l hour at 64°C. Signals from samples were then measured in a spectrofluorometer. Signals remained low at a.11 probe concentrations in the absence of ligase, demonstrating that circularized template is required for CRCA, and that non-specific reactions, where hairpin primers could potentially be incorporated, are suppressed.
Furthermore, the CRCA products were digested with a restriction endonuclease, HaeIII, which~cuts only at the ligation junction of the original probe. This digestion yielded double-stranded products that were the unit length size of the probe, demonstrating that the amplified products were true CRCA products.
CRCA was also performed in which the reverse primer was a hairpin primer labeled with a FAM/DABCYL MET pair (either hairpin reverse primer 1 or 2 as shown in Figure 32), while the forward primer was an unmodified hairpin primer _ (identical to either forward hairpin primer 1 or 2, as shown in Figure 32-; minus the MET moieties). Similar to the results described above using a hairpin forward primer and a non-hairpin reverse primer, MET signals above background were clearly observed, and normal, low background signals were observed. The use of two hairpin primers may improve specificity and reduce ba~~kground with other target systems by preventing non-specific interactions between target and/or genomic DNA and the primers.
CRCA using a non-hairpin forward (rolling circle) primer (SEQ ID NO: 50), a MET-labeled hairpin reverse primer 1 (SEQ
ID N0:4p) and a ras target specific sequence (SEQ ID N0:53), was performed to detect ras mutant and wild-type sequences.
Ligation reactions~.were performed in which the ligation junction contained correct or incorrect basepairs at codon 12 of the ras sequence (SEQ ID N0:53). MET signals were detected when a correctly paire~x ACT ligation reaction was diluted down to -104 input targsa molecules, while 108 molecules of a mispaired A~G reaction were required for detection, demonstrating about .a 10,000-fold discrimination between correct and incorrect basepairs.
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures.
Such modifications are intended to fall within the scope of the appended claims.
20 - 11.3 SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: ONCOR, INC.
(ii) TITLE OF INVENTION: NUCLEIC ACID AMPLIFICATION
OLIGONUCLEOTIDES WITH MOLECULAR ENERGY TRANSFER LABELS AND
METHODS BASED THEREON
(iii) NUMBER OF SEQUENCES: 53 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: SWABEY OGILVY RENAULT
(B) STREET: 1981 McGill College Avenue (C) CITY: Montreal (D) PROVINCE: Quebec (E) COUNTRY: Canada (F) ZIP: H3A 2Y3 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,260,973 (B) FILING DATE: 15-JUL-1997 (C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: PCT/US97/12315 (B) FILING DATE: 15-JUL-1997 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/837,034 (B) FILING DATE: 11-APR-1997 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/778,487 (B) FILING DATE: 03-JAN-1997 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/683,667 (B) FILING DATE: 16-JUL-1996 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: COTS, France (B) REGISTRATION NUMBER: 4166 (C) REFERENCE/DOCKET NUMBER: 7194-226 FC/ntb (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (514) 845-7126 (B) TELEFAX: (514) 288-8389 (C) TELEX:
-113a-(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

(2) INFORMATION FOR SEQ ID N0:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:2:

(2) INFORMATION FOR SEQ ID N0:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:3:

(2) INFORMATION FOR SEQ ID N0:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear -113b-(ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:

(2) INFORMATION FOR SEQ ID N0:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:5:

(2) INFORMATION FOR SEQ ID N0:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:6:

(2) INFORMATION FOR SEQ ID N0:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:7:

(2) INFORMATION FOR SEQ ID N0:8:
-113c-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:8:

(2) INFORMATION FOR SEQ ID N0:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:9:

(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
-113d-(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

(2) INFORMATION FOR SEQ ID N0:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:12:

(2) INFORMATION FOR SEQ ID N0:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:13:

(2) INFORMATION FOR SEQ ID N0:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:14:

(2) INFORMATION FOR SEQ ID N0:15:
-113e-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:15:

(2) INFORMATION FOR SEQ ID N0:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:16:

(2) INFORMATION FOR SEQ ID N0:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:17:

(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
-113f-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:18:

(2) INFORMATION FOR SEQ ID N0:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:19:

(2) INFORMATION FOR SEQ ID N0:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:20:

(2) INFORMATION FOR SEQ ID N0:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:21:

(2) INFORMATION FOR SEQ ID N0:22:
-113g-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:22:

(2) INFORMATION FOR SEQ ID N0:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:23:

(2) INFORMATION FOR SEQ ID N0:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:24:

(2) INFORMATION FOR SEQ ID N0:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
-113h-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:25:

(2) INFORMATION FOR SEQ ID N0:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:26:

(2) INFORMATION FOR SEQ ID N0:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:27:

(2) INFORMATION FOR SEQ ID N0:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:28:

(2) INFORMATION FOR SEQ ID N0:29:
-113i-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:29:

(2) INFORMATION FOR SEQ ID N0:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:30:

(2) INFORMATION FOR SEQ ID N0:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:31:

(2) INFORMATION FOR SEQ ID N0:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
-113j -(xi) SEQUENCE DESCRIPTION: SEQ ID N0:32:

(2) INFORMATION FOR SEQ ID N0:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:33:

(2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:34:

(2) INFORMATION FOR SEQ ID N0:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:35:

(2) INFORMATION FOR SEQ ID N0:36:
-113k-(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:36:

(2) INFORMATION FOR SEQ ID N0:37:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "synthetic oligonucleotide"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:37:

(2) INFORMATION FOR SEQ ID N0:38:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:38:

(2) INFORMATION FOR SEQ ID N0:39:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:39:

(2) INFORMATION FOR SEQ ID N0:40:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:40:

(2) INFORMATION FOR SEQ ID N0:41:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:41:

(2) INFORMATION FOR SEQ ID N0:42:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:42:

(2) INFORMATION FOR SEQ ID N0:43:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs -113m-(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:43:

(2) INFORMATION FOR SEQ ID N0:44:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:44:

(2) INFORMATION FOR SEQ ID N0:45:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 41 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "hybridization probe"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:45:

(2) INFORMATION FOR SEQ ID N0:46:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
-113n-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:46:

(2) INFORMATION FOR SEQ ID N0:47:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:47:

(2) INFORMATION FOR SEQ ID N0:48:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:48:

(2) INFORMATION FOR SEQ ID N0:49:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:49:

(2) INFORMATION FOR SEQ ID N0:50:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer"
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:50:

(2) INFORMATION FOR SEQ ID N0:51:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "primer' (xi) SEQUENCE DESCRIPTION: SEQ ID N0:51:

(2) INFORMATION FOR SEQ ID N0:52:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (xi) SEQUENCE DESCRIPTION: SEQ ID N0:52:

(2) INFORMATION FOR SEQ ID N0:53:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) -113p-(xi) SEQUENCE DESCRIPTION: SEQ ID N0:53:

-113q-

Claims (165)

WHAT IS CLAIMED IS:
1. An oligonucleotide for use as a primer in detecting a target nucleotide sequence, said oligonucleotide comprising:
(a) a first nucleotide sequence complementary to a sequence flanking said target sequence, (b) a second nucleotide sequence at the 5' end of said first sequence, (c) a third nucleotide sequence at the 5' end of said second sequence, (d) a fourth nucleotide sequence at the 5' end of said third sequence, said fourth sequence being complementary to said second sequence so as to form a double stranded duplex, and (e) means for emitting a detectable signal when the strands of said duplex are separated.
2. The oligonucleotide of claim 1, wherein the first nucleotide sequence is not complementary to the fourth nucleotide sequence.
3. The oligonucleotide of claim 1, wherein the first nucleotide sequence is not complementary to the second nucleotide sequence.
4. The oligonucleotide of claim 1, wherein the first nucleotide sequence is not complementary to the third nucleotide sequence.
5. The oligonucleotide of claim 1, wherein the detectable signal emitted by the oligonucleotide if the hairpin is not formed is more intense than a signal emitted by the oligonucleotide if the hairpin is formed.
6. The oligonucleotide of claim 1, wherein the oligonucleotide emits the detectable signal only if the hairpin is not formed.
7. The oligonucleotide of claim 6, wherein the detectable signal is quantifiable over background.
8. The oligonucleotide of claim 1 further containing a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the second nucleotide sequence and the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the second nucleotide sequence and the donor moiety is attached to a nucleotide of the fourth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
9. The oligonucleotide of claim 1, wherein the target nucleotide sequence is genomic DNA, cDNA, mRNA, chemically synthesized DNA, a sequence of an infectious disease agent, a wild-type human genomic sequence, a mutation of which is implicated in the presence of a human disease or disorder, an amplification product, or an amplification product containing a restriction endonuclease recognition site.
10. The oligonucleotide of claim 8, wherein the donor moiety is a fluorophore and the acceptor moiety is a quencher of light emitted by the fluorophore.
11. The oligonucleotide of claim 8, wherein the donor moiety is fluorescein, a derivative of fluorescein, 5-carboxyfluorescein, rhodamine, 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acid, anthranilamide, coumarin, a metal chelate, a terbium chelate derivative, or Reactive Red 4.
12. The oligonucleotide of claim 8, wherein the acceptor moiety is DABCYL, rhodamine, pyrene butyrate, eosine nitrotyrosine, ethidium, fluorescein, a derivative of fluorescein, Malachite green, or Texas Red*.
13. The oligonucleotide of claim 8, wherein the donor moiety is fluorescein and the acceptor moiety is DABCYL.
14. The oligonucleotide of claim 8, wherein the donor moiety is a derivative of fluorescein and the acceptor moiety is DABCYL.
15. The oligonucleotide of claim 8, wherein the nucleotide to which the donor moiety is attached is complementary to the nucleotide to which the acceptor moiety is attached.
16. The oligonucleotide of claim 8, wherein, if the hairpin is formed, then the nucleotide to which the donor moiety is attached and the complement of the nucleotide to which the acceptor moiety is attached are five nucleotides apart.
17. The oligonucleotide of claim 8, wherein the nucleotide to which the donor moiety is attached and the nucleotide to which the acceptor moiety is attached are from 15 to 25 nucleotides apart.
18. The oligonucleotide of claim 1, wherein the oligonucleotide is an oligodeoxynucleotide.
19. The oligonucleotide of claim 1, wherein the first nucleotide sequence contains a restriction endonuclease recognition site.
20. The oligonucleotide of claim 1, wherein the signal is light.
21. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:1, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:1, and DABCYL is attached to the nucleotide at position 22 of SEQ ID
NO:1.
22. The oligonucleotide of claim 21 consisting of the nucleotide sequence of SEQ ID NO:1.
23. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:13, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:13, and DABCYL is attached to the nucleotide at position 20 of SEQ ID
NO:13.
24. The oligonucleotide of claim 23 consisting of the nucleotide sequence of SEQ ID NO:13.
25. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:14, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:14, and DABCYL is attached to the nucleotide at position 24 of SEQ ID
NO:14.
26. The oligonucleotide of claim 25 consisting of the nucleotide sequence of SEQ ID NO:14.
27. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:15, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:15, and DABCYL is attached to the nucleotide at position 24 of SEQ ID
NO:15.
28. The oligonucleotide of claim 27 consisting of the nucleotide sequence of SEQ ID NO:15.
29. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:16, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:16, and DABCYL is attached to the nucleotide at position 22 of SEQ ID
NO:16.
30. The oligonucleotide of claim 29 consisting of the nucleotide sequence of SEQ ID NO:16.
31. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:17, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:17, and DABCYL is attached to the nucleotide at position 22 of SEQ ID
NO:17.
32. The oligonucleotide of claim 31 consisting of the nucleotide sequence of SEQ ID NO:17.
33. An oligonucleotide comprising the nucleotide sequence of SEQ ID NO:18, wherein fluorescein or a derivative of fluorescein is attached to the nucleotide at position 1 of SEQ ID NO:18, and DABCYL is attached to the nucleotide at position 20 of SEQ ID
NO:18.
34. The oligonucleotide of claim 33 consisting of the nucleotide sequence of SEQ ID NO:18.
35. A kit comprising:
(a) a polymerase, and (b) an oligonucleotide containing:
(i) a first nucleotide sequence, (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, (iii) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and (iv) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, wherein the oligonucleotide is capable of forming a hairpin containing nucleotides of the second and fourth nucleotide sequences, and the oligonucleotide emits a detectable signal if the hairpin is not formed.
36. The kit of claim 35, wherein the first nucleotide sequence contains the nucleotide at the 3' end of the oligonucleotide, the fourth nucleotide sequence contains the nucleotide at the 5' end of the oligonucleotide, and the first nucleotide sequence is not complementary to the fourth nucleotide sequence.
37. The kit of claim 36, wherein the first nucleotide sequence is not complementary to the second nucleotide sequence.
38. The kit of claim 36, wherein the first nucleotide sequence is not complementary to the third nucleotide sequence.
39. The kit of claim 35, wherein the detectable signal emitted by the oligonucleotide if the hairpin is not formed is more intense than a signal emitted by the oligonucleotide if the hairpin is formed.
40. The kit of claim 35, wherein the oligonucleotide emits the detectable signal only if the hairpin is not formed.
41. The kit of claim 40, wherein the detectable signal is quantifiable over background.
42. The kit of claim 37, wherein the oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the second nucleotide sequence and the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the second nucleotide sequence and the donor moiety is attached to a nucleotide of the fourth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
43. The kit of claim 35, wherein the polymerase is a DNA
polymerase.
44. The kit of claim 35, wherein the oligonucleotide is an oligodeoxynucleotide.
45. The kit of claim 35 further comprising a ligase in a container that does not contain the polymerase or the oligonucleotide.
46. A kit comprising first and second oligonucleotides, wherein the first oligonucleotide contains:
(i) a first nucleotide sequence complementary to a nucleotide sequence flanking a target nucleotide sequence, and (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, and wherein the second oligonucleotide contains:
(i) a third nucleotide sequence, (ii) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, (iii) a fifth nucleotide sequence at the 5' end of the fourth nucleotide sequence, and (iv) a sixth nucleotide sequence at the 5' end of the fifth nucleotide sequence, wherein the second oligonucleotide is capable of forming a hairpin containing nucleotides of the fourth and sixth nucleotide sequences, and the second oligonucleotide emits a detectable signal if the hairpin is not formed.
47. The kit of claim 46, wherein the third nucleotide sequence contains the nucleotide at the 3' end of the oligonucleotide, the sixth nucleotide sequence contains the nucleotide at the 5' end of the oligonucleotide, and the third nucleotide sequence is not complementary to the sixth nucleotide sequence.
48. The kit of claim 47, wherein the third nucleotide sequence is not complementary to the fourth nucleotide sequence.
49. The kit of claim 47, wherein the third nucleotide sequence is not complementary to the fifth nucleotide sequence.
50. The kit of claim 46, wherein the second oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the fourth nucleotide sequence and the acceptor moiety is attached to a nucleotide of the sixth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence and the donor moiety is attached to a nucleotide of the sixth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
51. The kit of claim 46 further comprising a polymerase.
52. The kit of claim 51, wherein the polymerase is a DNA
polymerase.
53. The kit of claim 48, wherein the first oligonucleotide is an oligodeoxynucleotide.
54. The kit of claim 46, wherein the second oligonucleotide is an oligodeoxynucleotide.
55. A kit comprising:
(a) a polymerase, (b) a first oligonucleotide, and (c) a second oligonucleotide, wherein the first oligonucleotide is capable of annealing to the second oligonucleotide, and the first or second oligonucleotide emits a detectable signal only if the first oligonucleotide is not annealed to the second oligonucleotide.
56. The kit of claim 55, wherein the detectable signal emitted by the first or second oligonucleotide if the first oligonucleotide is not annealed to the second oligonucleotide is more intense than a signal emitted by the first or second oligonucleotide if the first oligonucleotide is annealed to the second oligonucleotide.
57. The kit of claim 55, wherein the first or second oligonucleotide emits the detectable signal only if the first oligonucleotide is not annealed to the second oligonucleotide.
58. The kit of claim 57, wherein the detectable signal is quantifiable over background.
59. The kit of claim 55 further comprising a molecular energy pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the first oligonucleotide and the acceptor moiety is attached to a nucleotide of the second oligonucleotide, or the acceptor moiety is attached to a nucleotide of the first oligonucleotide and the donor moiety is attached to a nucleotide of the second oligonucleotide, and the acceptor moiety absorbs the amount of energy only if the first oligonucleotide is annealed to the second oligonucleotide.
60. A method for determining if a target nucleotide sequence is present in a sample comprising:
(a) contacting the sample with an oligonucleotide containing:
(i) a first nucleotide sequence, (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, (iii) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and (iv) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, wherein the oligonucleotide is capable of forming a hairpin containing nucleotides of the second and fourth nucleotide sequences, and the oligonucleotide emits a detectable signal if the hairpin is not formed, (b) incorporating the oligonucleotide into a double-stranded nucleic acid, and (c) determining that the target nucleotide sequence is present in the sample if the signal is detected, or determining that the target nucleotide sequence is not present in the sample if the signal is not detected.
61. The method of claim 60 comprising, in between (b) and (c), conducting an amplification reaction, thereby incorporating the oligonucleotide into an amplification product if the target nucleotide sequence is present in the sample.
62. The method of claim 60, wherein the oligonucleotide is incorporated into the double-stranded nucleic acid using a polymerase.
63. The method of claim 60, wherein the first nucleotide sequence contains the nucleotide at the 3' end of the oligonucleotide, the fourth nucleotide sequence contains the nucleotide at the 5' end of the oligonucleotide, and the first nucleotide sequence is not complementary to the fourth nucleotide sequence.
64. The method of claim 63, wherein the first nucleotide sequence is not complementary to the second nucleotide sequence.
65. The method of claim 63, wherein the first nucleotide sequence is not complementary to the third nucleotide sequence.
66. The method of claim 60, wherein the detectable signal emitted by the oligonucleotide if the hairpin is not formed is more intense than a signal emitted by the oligonucleotide if the hairpin is formed.
67. The method of claim 60, wherein the oligonucleotide emits the detectable signal only if the hairpin is not formed.
68. The method of claim 67, wherein the detectable signal is quantifiable over background.
69. The method of claim 60, wherein the oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the second nucleotide sequence and the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the second nucleotide sequence and the donor moiety is attached to a nucleotide of the fourth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
70. The method of claim 60, wherein the first nucleotide sequence is complementary to a nucleotide sequence flanking the target nucleotide sequence.
71. The method of claim 70, wherein the target nucleotide sequence is genomic DNA, cDNA, mRNA, chemically synthesized DNA, a sequence of an infectious disease agent, a wild-type human genomic sequence, a mutation of which is implicated in the presence of a human disease or disorder, an amplification product, or an amplification product containing a restriction endonuclease recognition site.
72. The method of claim 69, wherein the donor moiety is a fluorophore and the acceptor moiety is a quencher of light emitted by the fluorophore.
73. The method of claim 69, wherein the donor moiety is fluorescein, a derivative of fluorescein, 5-carboxyfluorescein, rhodamine, 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acid, anthranilamide, coumarin, a metal chelate, a terbium chelate derivative, or Reactive Red 4.
74. The method of claim 69, wherein the acceptor moiety is DABCYL, rhodamine, pyrene butyrate, eosine nitrotyrosme, ethidium, fluorescein, a derivative of fluorescein, Malachite green, or Texas Red.
75. The method of claim 69, wherein the donor moiety is fluorescein and the acceptor moiety is DABCYL.
76. The method of claim 69, wherein the donor moiety is a derivative of fluorescein and the acceptor moiety is DABCYL.
77. The method of claim 69, wherein the nucleotide to which the donor moiety is attached is complementary to the nucleotide to which the acceptor moiety is attached.
78. The method of claim 69, wherein, if the hairpin is formed, then the nucleotide to which the donor moiety is attached and the complement of the nucleotide to which the acceptor moiety is attached are five nucleotides apart.
79. The method of claim 69, wherein the nucleotide to which the donor moiety is attached and the nucleotide to which the acceptor moiety is attached are from 15 to 25 nucleotides apart.
80. The method of claim 61, wherein the amplification reaction is a polymerase chain reaction, an allele-specific polymerase chain reaction, a triamplification, a nucleic acid sequence-based amplification, a strand displacement amplification, a telomeric repeat amplification, or a cascade rolling circle amplification; is conducted using an amplification refractory mutation system; or is conducted in situ.
81. The method of claim 60 further comprising, prior to (b), contacting the sample with bisulfite to convert unmethylated cytosine residues to uracil residues.
82. The method of claim 60, wherein the oligonucleotide is an oligodeoxynucleotide.
83. The method of claim 60, wherein the first nucleotide sequence contains a restriction endonuclease recognition site.
84. The method of claim 60, wherein the signal is light.
85. A method for detecting a target nucleotide sequence comprising:
(a) annealing a first oligonucleotide to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains:
(i) a first nucleotide sequence, (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, (iii) a third nucleotide sequence at the 5' end of the second nucleotide sequence, and (iv) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, wherein the first oligonucleotide is capable of forming a hairpin containing nucleotides of the second and fourth nucleotide sequences, and the first oligonucleotide emits a detectable signal if the hairpin is not formed, (b) extending the 3' end of the first oligonucleotide using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand, (c) separating the target nucleotide sequence from the extended first strand, (d) annealing a second oligonucleotide to the extended first strand, (e) extending the 3' end of the second oligonucleotide using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand, and (f) detecting the signal to detect the target nucleotide sequence.
86. The method of claim 85, comprising, in between (e) and (f), amplifying the extended first and second strands.
87. The method of claim 85, wherein the first nucleotide sequence contains the nucleotide at the 3' end of the oligonucleotide, the fourth nucleotide sequence contains the nucleotide at the 5' end of the oligonucleotide, and the first nucleotide sequence is not complementary to the fourth nucleotide sequence.
88. The method of claim 87, wherein the first nucleotide sequence is not complementary to the second nucleotide sequence.
89. The method of claim 87, wherein the first nucleotide sequence is not complementary to the third nucleotide sequence.
90. The method of claim 85, wherein the detectable signal emitted by the first oligonucleotide if the hairpin is not formed is more intense than a signal emitted by the first oligonucleotide if the hairpin is formed.
91. The method of claim 85, wherein the first oligonucleotide emits the detectable signal only if the hairpin is not formed.
92. The method of claim 91, wherein the detectable signal is quantifiable over background.
93. The method of claim 86, wherein the amplification of the extended first and second strands comprises:
(i) separating the extended first strand from the extended second strand, (ii) annealing the first oligonucleotide to the extended second strand, and annealing the second oligonucleotide to the extended first strand, (iii) extending the 3' end of the first oligonucleotide using the extended second strand as a template to form another extended first strand, wherein the extended second strand is annealed to said another extended first strand; and extending the 3' end of the second oligonucleotide using the extended first strand as a template to form another extended second strand, wherein the extended first strand is annealed to said another extended second strand, and (iv) repeating (i), (ii), and (iii) for a finite number of times, wherein, in (i), the extended first and second strands respectively are the extended first strand and said another extended second strand of (iii), or respectively are said another extended first strand and the extended second strand of (iii).
94. The method of claim 85, wherein the first oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the second nucleotide sequence and the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the second nucleotide sequence and the donor moiety is attached to a nucleotide of the fourth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
95. A method for detecting a target nucleotide sequence comprising:
(a) annealing a first oligonucleotide to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains:
(i) a first nucleotide sequence complementary to the nucleotide sequence flanking the target nucleotide sequence, and (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, (b) extending the 3' end of the first oligonucleotide using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand, (c) separating the target nucleotide sequence from the extended first strand, (d) annealing a second oligonucleotide to the extended first strand, (e) extending the 3' end of the second oligonucleotide using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand, (f) separating the extended first strand from the extended second strand, (g) annealing a third oligonucleotide to the extended second strand, wherein the third oligonucleotide contains:
(i) a third nucleotide sequence, (ii) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, (iii) a fifth nucleotide sequence at the 5' end of the fourth nucleotide sequence, and (iv) a sixth nucleotide sequence at the 5' end of the fifth nucleotide sequence, wherein the third nucleotide sequence is complementary to the complement of the second nucleotide sequence, the third oligonucleotide is capable of forming a hairpin containing nucleotides of the fourth and sixth nucleotide sequences, and the third oligonucleotide emits a detectable signal if the hairpin is not formed, (h) extending the 3' end of the third oligonucleotide using the extended second strand as a template to form a doubly extended first strand, wherein the doubly extended first strand is annealed to the extended second strand, (i) separating the doubly extended first strand from the extended second strand, (j) annealing the second oligonucleotide to the doubly extended first strand, (k) extending the 3' end of the second oligonucleotide using the doubly extended first strand as a template to form a doubly extended second strand, wherein the doubly extended first strand is annealed to the doubly extended second strand, and (1) detecting the signal to detect the target nucleotide sequence.
96. The method of claim 95 comprising, in between (k) and (l), amplifying the doubly extended first and second strands.
97. The method of claim 95, wherein the third nucleotide sequence contains the nucleotide at the 3' end of the oligonucleotide, the sixth nucleotide sequence contains the nucleotide at the 5' end of the oligonucleotide, and the third nucleotide sequence is not complementary to the sixth nucleotide sequence.
98. The method of claim 97, wherein the third nucleotide sequence is not complementary to the fourth nucleotide sequence.
99. The method of claim 97, wherein the third nucleotide sequence is not complementary to the fifth nucleotide sequence.
100. The method of claim 95, wherein the detectable signal emitted by the third oligonucleotide if the hairpin is not formed is more intense than a signal emitted by the third oligonucleotide if the hairpin is formed.
101. The method of claim 95, wherein the third oligonucleotide emits the detectable signal only if the hairpin is not formed.
102. The method of claim 101, wherein the detectable signal is quantifiable over background.
103. The method of claim 95, further comprising, before the detection step:
(i) separating the doubly extended first strand from the doubly extended second strand, (ii) annealing the second oligonucleotide to the doubly extended first strand, and annealing the third oligonucleotide to the doubly extended second strand, (iii) extending the 3' end of the second oligonucleotide using the doubly extended first strand as a template to form another doubly extended second strand, wherein the doubly extended first strand is annealed to said another doubly extended second strand;
and extending the 3' end of the third oligonucleotide using the doubly extended second strand as a template to form another doubly extended first strand, wherein the doubly extended second strand is annealed to said another doubly extended first strand, and (iv) repeating (i), (ii), and (iii) for a finite number of times, wherein, in (i), the doubly extended first and second strands respectively are the doubly extended first strand and said another doubly extended second strand of (iii), or respectively are said another doubly extended first strand and the doubly extended second strand of (iii).
104. The method of claim 95, wherein the third oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the fourth nucleotide sequence and the acceptor moiety is attached to a nucleotide of the sixth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the fourth nucleotide sequence and the donor moiety is attached to a nucleotide of the sixth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
105. A method for detecting a target nucleotide sequence comprising:
(a) annealing a first oligonucleotide to a nucleotide sequence flanking a target nucleotide sequence, wherein the first oligonucleotide contains:
(i) a first nucleotide sequence complementary to the nucleotide sequence flanking the target nucleotide sequence, and (ii) a second nucleotide sequence at the 5' end of the first nucleotide sequence, (b) extending the 3' end of the first oligonucleotide using the target nucleotide sequence as a template to form an extended first strand, wherein the target nucleotide sequence is annealed to the extended first strand, (c) separating the target nucleotide sequence from the extended first strand, (d) annealing a second oligonucleotide to a nucleotide sequence of the extended first strand, wherein the second oligonucleotide contains:
(i) a third nucleotide sequence complementary to the sequence of the extended first strand, and (ii) a fourth nucleotide sequence at the 5' end of the third nucleotide sequence, (e) extending the 3' end of the second oligonucleotide using the extended first strand as a template to form an extended second strand, wherein the extended first strand is annealed to the extended second strand, (f) separating the extended first strand from the extended second strand, (g) annealing a third oligonucleotide to the extended second strand, wherein the third oligonucleotide contains:
(i) a fifth nucleotide sequence, (ii) a sixth nucleotide sequence at the 5' end of the fifth nucleotide sequence, (iii) a seventh nucleotide sequence at the 5' end of the sixth nucleotide sequence, and (iv) an eighth nucleotide sequence at the 5' end of the seventh nucleotide sequence, wherein the fifth nucleotide sequence is complementary to the complement of the second nucleotide sequence, the fifth nucleotide sequence is not complementary to the eighth nucleotide sequence, the third oligonucleotide is capable of forming a first hairpin containing nucleotides of the sixth and eighth nucleotide sequences, and the third oligonucleotide emits a first detectable signal if the first hairpin is not formed, (h) extending the 3' end of the third oligonucleotide using the extended second strand as a template to form a doubly extended first strand, wherein the doubly extended first strand is annealed to the extended second strand, (i) separating the doubly extended first strand from the extended second strand, (j) annealing a fourth oligonucleotide to the doubly extended first strand, wherein the fourth oligonucleotide contains:
(i) a ninth nucleotide sequence, (ii) a tenth nucleotide sequence at the 5' end of the ninth nucleotide sequence, (iii) an eleventh nucleotide sequence at the 5' end of the tenth nucleotide sequence, and (iv) a twelfth nucleotide sequence at the 5' end of the eleventh nucleotide sequence, wherein the ninth nucleotide sequence is complementary to the complement of the fourth nucleotide sequence, the ninth nucleotide sequence is not complementary to the twelfth nucleotide sequence, the fourth oligonucleotide is capable of forming a second hairpin containing nucleotides of the tenth and twelfth nucleotide sequences, and the fourth oligonucleotide emits a second detectable signal if the second hairpin is not formed, (k) extending the 3' end of the fourth oligonucleotide using the doubly extended first strand as a template to form a doubly extended second strand, and extending the 3' end of the doubly extended first strand using the fourth oligonucleotide as a template to form a triply extended first strand, wherein the doubly extended second strand is annealed to the triply extended first strand, and (l) detecting the first or second signal to detect the target nucleotide sequence.
106. The method of claim 105 comprising, in between (k) and (l), amplifying the doubly extended second strand and the triply extended first strand.
107. The method of claim 105, wherein the fifth nucleotide sequence contains the nucleotide at the 3' end of the third oligonucleotide, the eighth nucleotide sequence contains the nucleotide at the 5' end of the third oligonucleotide, and the fifth nucleotide sequence is not complementary to the eighth nucleotide sequence.
108. The method of claim 107, wherein the fifth nucleotide sequence is not complementary to the sixth nucleotide sequence.
109. The method of claim 107, wherein the fifth nucleotide sequence is not complementary to the seventh nucleotide sequence.
110. The method of claim 105, wherein the ninth nucleotide sequence contains the nucleotide at the 3' end of the fourth oligonucleotide, the twelfth nucleotide sequence contains the nucleotide at the 5' end of the fourth oligonucleotide, and the ninth nucleotide sequence is not complementary to the twelfth nucleotide sequence.
111. The method of claim 110, wherein the ninth nucleotide sequence is not complementary to the tenth nucleotide sequence.
112. The method of claim 110, wherein the ninth nucleotide sequence is not complementary to the eleventh nucleotide sequence.
113. The method of claim 105, wherein the first detectable signal emitted by the third oligonucleotide if the first hairpin is not formed is more intense than a signal emitted by the third oligonucleotide if the first hairpin is formed.
114. The method of claim 105, wherein the third oligonucleotide emits the first detectable signal only if the first hairpin is not formed.
115. The method of claim 114, wherein the first detectable signal is quantifiable over background.
116. The method of claim 105, wherein the second detectable signal emitted by the fourth oligonucleotide if the second hairpin is not formed is more intense than a signal emitted by the fourth oligonucleotide if the second hairpin is formed.
117. The method of claim 105, wherein the fourth oligonucleotide emits the second detectable signal only if the second hairpin is not formed.
118. The method of claim 117, wherein the second detectable signal is quantifiable over background.
119. The method of claim 105, wherein the complete nucleotide sequences of the third and fourth oligonucleotides are identical.
120. The method of claim 105, wherein the second and fourth nucleotide sequences are identical.
121. The method of claim 105, further comprising, before the detection step:
(i) separating the doubly extended second strand from the triply extended first strand, (ii) annealing the third oligonucleotide to the doubly extended second strand, and annealing the fourth oligonucleotide to the triply extended first strand, (iii) extending the 3' end of the third oligonucleotide using the doubly extended second strand as a template to form another triply extended first strand, wherein the doubly extended second strand is annealed to said another triply extended first strand; and extending the 3' end of the fourth oligonucleotide using the triply extended first strand as a template to form another doubly extended second strand, wherein the triply extended first strand is annealed to said another doubly extended second strand, and (iv) repeating (i), (ii), and (iii) for a finite number of times, wherein; in (i), the doubly extended second strand is the doubly extended second strand of (iii) and the triply extended first strand is said another triply extended first strand of (iii), or the doubly extended second strand is said another doubly extended second strand of (iii) and the triply extended first strand is the triply extended first strand of (iii).
122. The method of claim 105, wherein the third oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the sixth nucleotide sequence and the acceptor moiety is attached to a nucleotide of the eighth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the sixth nucleotide sequence and the donor moiety is attached to a nucleotide of the eighth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
123. The method of claim 105, wherein the fourth oligonucleotide further contains a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the tenth nucleotide sequence and the acceptor moiety is attached to a nucleotide of the twelfth nucleotide sequence, or the acceptor moiety is attached to a nucleotide of the tenth nucleotide sequence and the donor moiety is attached to a nucleotide of the twelfth nucleotide sequence; and the acceptor moiety absorbs the amount of the emitted energy only if the hairpin is formed.
124. A method for determining if a target nucleotide sequence is present in a sample comprising:
(a) contacting the sample with first and second oligonucleotides, wherein the first oligonucleotide is capable of annealing to the second oligonucleotide to form a duplex, and one of the first and second oligonucleotide emits a detectable signal if the duplex is not formed, (b) incorporating the first or second oligonucleotide into a double-stranded nucleic acid using a polymerase if the target nucleotide sequence is present in the sample, thereby preventing first and second nucleotides from forming the duplex, and (c) determining that the target nucleotide sequence is present in the sample if the signal is detected, or determining that the target nucleotide sequence is not present in the sample if the signal is not detected.
125. The method of claim 124 comprising, in between (b) and (c), conducting an amplification reaction, thereby incorporating the first or second oligonucleotide into an amplification product if the target nucleotide sequence is present in the sample.
126. The method of claim 124, wherein the detectable signal emitted by the first or second oligonucleotide if the first oligonucleotide is not annealed to the second oligonucleotide is more intense than a signal emitted by the first or second oligonucleotide if the first oligonucleotide is annealed to the second oligonucleotide.
127. The method of claim 126, wherein the first or second oligonucleotide emits the detectable signal only if the first oligonucleotide is not annealed to the second oligonucleotide.
128. The method of claim 127, wherein the detectable signal is quantifiable over background.
129. The method of claim 125, wherein the first or second oligonucleotides contain a molecular energy transfer pair including an energy donor moiety that is capable of emitting energy, and an energy acceptor moiety that is capable of absorbing an amount of the emitted energy, wherein the donor moiety is attached to a nucleotide of the first oligonucleotide and the acceptor moiety is attached to a nucleotide of the second oligonucleotide, or the acceptor moiety is attached to a nucleotide of the first oligonucleotide and the donor moiety is attached to a nucleotide of the second oligonucleotide, and the acceptor moiety absorbs the amount of energy only if the duplex is formed.
130. A method of detecting telomerase activity comprising:
(a) contacting a sample suspected of having telomerase activity with at least two oligonucleotide primers comprising a first primer and a second primer, wherein the first primer comprises the following continuous sequences in 5' to 3' order:
(i) a first nucleotide sequence of 6-30 nucleotides, wherein a nucleotide within the first nucleotide sequence is labeled with a first moiety selected from the group consisting of a donor moiety and an acceptor moiety of a molecular energy transfer pair, wherein the donor moiety emits energy of one or more particular wavelengths when excited, and the acceptor moiety absorbs energy at one or more particular wavelengths emitted by the donor moiety;
(ii) a second, single-stranded nucleotide sequence of 3-20 nucleotides;
(iii) a third nucleotide sequence of 6-30 nucleotides, wherein a nucleotide within the third nucleotide sequence is labeled with a second moiety selected from the group consisting of the donor moiety and the acceptor moiety, and the second moiety is the member of the group not labeling the first nucleotide sequence, wherein the third nucleotide sequence is sufficiently complementary in reverse order to the first nucleotide sequence for a duplex to form between the first nucleotide sequence and the third nucleotide sequence such that the first moiety and second moiety are in sufficient proximity such that, when the donor moiety is excited and emits energy, the acceptor moiety absorbs energy emitted by the donor moiety; and (iv) at the 3' end of the first primer, a fourth, single-stranded nucleotide sequence of 8-40 nucleotides that comprises at its 3' end a sequence that is a substrate for a telomerase; wherein the second primer comprises at its 3' end a sequence sufficiently complementary so as to be able to hybridize to telomeric repeats that result from the activity of the telomerase;
(b) subjecting the sample to conditions suitable for telomerase activity;
(c) conducting a nucleic acid amplification reaction under conditions suitable for the first and second primers to prime DNA
synthesis;
(d) stimulating energy emission from the donor moiety; and (e) detecting or measuring energy emitted by the donor moiety or acceptor moiety, the presence or amount of the energy indicating the presence or amount of telomerase activity in the sample.
131. The oligonucleotide of claim 1, wherein the signal-emitting means comprises an energy donor moiety and an energy acceptor moiety, each bound to the oligonucleotide and spaced such that the signal is detectable only when the strands of the duplex are separated.
132. The oligonucleotide of claim 131, wherein the energy donor moiety is a fluorophore and the energy acceptor moiety is a quencher of a fluorophore.
133. The oligonucleotide of claim 131, wherein the energy donor and acceptor moieties are spaced a distance in the range of about 15-25 nucleotides.
134. The oligonucleotide of claim 131, wherein the acceptor moiety is a fluorophore that emits fluorescent light at a wavelength different than that emitted by the donor moiety.
135. The oligonucleotide of claim 1, wherein the target nucleotide sequence is selected from the group consisting of genomic DNA, cDNA, mRNA, and chemically synthesized DNA.
136. The oligonucleotide of claim 1, wherein the target nucleotide sequence is a sequence of an infectious disease agent.
137. The oligonucleotide of claim 1, wherein the target nucleotide sequence is a wild-type human genomic sequence, a mutation of which is implicated in the presence of a human disease or disorder.
138. The oligonucleotide of claim 131, wherein the donor moiety is selected from the group consisting of fluorescein, 5-carboxyfluorescein (FAM), rhodamine, 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acid (EDANS), anthranilamide, coumarin, terbium chelate derivatives, and Reactive Red 4; and the acceptor moiety is selected from the group consisting of DABCYL, rhodamine, tetramethyl rhodamine, pyrene butyrate, eosine nitrotyrosine, ethidium, fluorescein, Malachite green, and Texas Red.
139. The oligonucleotide of claim 138, wherein the donor moiety is fluorescein or a derivative thereof, and the acceptor moiety is DABCYL.
140. The oligonucleotide of claim 1, wherein the first or third nucleotide sequence further comprises a restriction endonuclease recognition site.
141. The oligonucleotide of claim 131, wherein the energy donor moiety and the energy acceptor moiety are situated on complementary nucleotides that are opposite each other in the duplex.
142. The oligonucleotide of claim 131, wherein the energy donor moiety and the energy acceptor moiety are situated on opposite strand nucleotides that are five nucleotides apart in the duplex.
143. A kit for use in detecting a target nucleotide sequence comprising:
(a) first and second oligonucleotide primers at least one of which comprises:

(i) a 3' nucleotide sequence that is complementary to a sequence flanking a target nucleotide sequence, (ii) a 5' nucleotide sequence that is not complementary to a sequence flanking the target sequence, and (b) a third oligonucleotide primer comprising:
(i) a first sequence identical to the 5' nucleotide sequence, (ii) a second sequence at the 5' end of the first sequence, (iii) a third nucleic acid sequence at the 5' end of the second sequence, (iv) a fourth nucleotide sequence at the 5' end of the third sequence, the fourth sequence being complementary to the second sequence so as to form a double-stranded duplex, and (v) means for emitting a detectable signal when the strands of the duplex are separated.
144. A kit comprising in one or more containers:
(a) a first oligonucleotide, and (b) a second oligonucleotide, wherein the first and second oligonucleotides are primers for use in a nucleic acid amplification reaction to amplify a preselected target nucleic acid sequence, and at least one of the first and second oligonucleotides is the oligonucleotide of claim 1.
145. The kit of claim 144, wherein the amplification reaction is selected from the group consisting of the polymerase chain reaction, strand displacement, triamplification, and NASBA.
146. The kit of claim 144, wherein the first and second oligonucleotides are oligodeoxynucleotides.
147. The kit of claim 144 further comprising DNA ligase in a separate container.
148. The kit of claim 144 further comprising a blocking oligonucleotide containing a sequence complementary and hybridizable to a sequence of the first or the second oligonucleotide.
149. The kit of claim 144 further comprising in one or more containers:
(c) an optimized buffer for the amplification reaction, (d) a control nucleic acid comprising the preselected target sequence, and (e) a DNA polymerase.
150. A kit comprising in one or more containers:
(a) a first oligonucleotide, (b) a second oligonucleotide, wherein the first and second oligonucleotides are primers for use in a nucleic acid amplification reaction to amplify a first preselected target nucleic acid sequence, and at least one of the first and second oligonucleotides is the oligonucleotide of claim 132, (c) a third oligonucleotide, and (d) a fourth oligonucleotide, wherein the third and fourth oligonucleotides are primers for use in the nucleic acid amplification reaction to amplify a second preselected target sequence, and at least one of the third and fourth oligonucleotides is an oligonucleotide of claim 132, and wherein one of said first and second oligonucleotides comprises a first donor moiety and one of said third and fourth oligonucleotides comprises a second donor moiety that emits fluorescent light of a different wavelength than said first donor moiety.
151. A method for the amplification and detection of a target nucleotide sequence in a sample comprising:
(a) providing a pair of primers each complementary to a target nucleotide sequence, at least one member of the primer pair comprising the detecting oligonucleotide of claim 1, (b) separating the strands of the nucleic acid containing the target nucleotide sequence, (c) annealing the pair of primers to the opposite strands of the separated nucleic acid, (d) synthesizing new strands of nucleic acid complementary to the strands of the separated nucleic acid, (e) separating the new strands from their complementary strands, and (f) repeating (c) through (e), wherein the synthesis of new strands separates the duplex strands of the oligonucleotide, thereby causing the detectable signal to be emitted.
152. A method for detecting or measuring a product of a nucleic acid amplification reaction comprising:
(a) contacting a sample comprising nucleic acids with at least two oligonucleotide primers, the oligonucleotide primers being adapted for use in the amplification reaction such that the primers are incorporated into an amplified product of the amplification reaction when a preselected target sequence is present in the sample, at least one of the oligonucleotide primers being the oligonucleotide of claim 131, (b) conducting the amplification reaction, (c) stimulating energy emission from the donor moiety, and (d) detecting or measuring energy emitted by the acceptor moiety.
153. The method of claim 152, wherein the donor moiety is a fluorophore.
154. The method of claim 152, wherein the acceptor moiety is a quencher of light emitted by the fluorophore.
155. The method of claim 152, wherein the acceptor moiety emits fluorescent light of a wavelength different from that emitted by the donor moiety.
156. The method of claim 152, wherein the preselected target sequence is selected from the group consisting of genomic DNA, cDNA, and mRNA.
157. The method of claim 152, wherein the donor moiety is selected from the group consisting of fluorescein, 5-carboxyfluorescein (FAM), rhodamine, 5-(2'-aminoethyl) aminonapthalene-1-sulfonic acid (EDANS), anthranilamide, coumarin, terbium chelate derivatives, and Reactive Red 4; and the acceptor moiety is selected from the group consisting of DABCYL, rhodamine, tetramethyl rhodamine, pyrene butyrate; cosine nitrotyrosine, ethidium, Malachite green, fluorescein, and Texas Red.
158. The method of claim 152, wherein the donor moiety is fluorescein or a derivative thereof, and the acceptor moiety is DABCYL.
159. The method of claim 152, wherein the oligonucleotide is a oligodeoxynucleotide.
160. The method of claim 157, wherein the donor moiety and the acceptor moiety are situated on complementary nucleotides that are opposite each other in the duplex.
161. The method of claim 157, wherein the donor moiety and the acceptor moiety are situated on opposite strand nucleotides that are five nucleotides apart in the duplex.
162. The method of claim 157, wherein the oligonucleotide primers comprise a plurality of different oligonucleotides, each oligonucleotide comprising at its 3' end a the sequence complementary to different preselected target sequences whereby the different oligonucleotides are incorporated into different amplified products when each of the target sequences is present in the sample, each of the oligonucleotides being labeled with a donor moiety that emits light of a different wavelength than that emitted by the other donor moieties, and wherein (d) of the method comprises detecting or measuring light emitted by each of the donor moieties.
163. The method of claim 157, wherein the amplification reaction is selected from the group consisting of polymerase chain reaction, allele-specific polymerase chain reaction, triamplification, strand displacement, and NASBA.
164. The method of claim 152 further comprising, prior to the conducting step, contacting the nucleic acids with an amount of bisulfite sufficient to convert unmethylated cytosines in the sample to uracils.
165. The oligonucleotide of claim 1, wherein the oligonucleotide is capable of forming only one hairpin.
CA002260973A 1996-07-16 1997-07-15 Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon Expired - Lifetime CA2260973C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US68366796A 1996-07-16 1996-07-16
US08/683,667 1996-07-16
US08/778,487 1997-01-03
US08/778,487 US5866336A (en) 1996-07-16 1997-01-03 Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US08/837,034 1997-04-11
US08/837,034 US6117635A (en) 1996-07-16 1997-04-11 Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
PCT/US1997/012315 WO1998002449A1 (en) 1996-07-16 1997-07-15 Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon

Publications (2)

Publication Number Publication Date
CA2260973A1 CA2260973A1 (en) 1998-01-22
CA2260973C true CA2260973C (en) 2003-03-18

Family

ID=27418429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260973A Expired - Lifetime CA2260973C (en) 1996-07-16 1997-07-15 Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon

Country Status (9)

Country Link
US (2) US6117635A (en)
EP (1) EP0912597B1 (en)
JP (2) JP3597869B2 (en)
AT (1) ATE305476T1 (en)
AU (1) AU3728597A (en)
CA (1) CA2260973C (en)
DE (1) DE69734283T2 (en)
ES (1) ES2248852T3 (en)
WO (1) WO1998002449A1 (en)

Families Citing this family (308)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269799A9 (en) * 1994-06-22 2007-11-22 Zhang David Y Nucleic acid amplification methods
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DK0862656T3 (en) * 1995-11-21 2001-04-09 Univ Yale Unimolecular segment amplification and detection
US6130038A (en) * 1996-07-16 2000-10-10 Gen-Probe Incorporated Method for amplifying target nucleic acids using modified primers
US7070925B1 (en) 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US5928869A (en) * 1997-05-30 1999-07-27 Becton, Dickinson And Company Detection of nucleic acids by fluorescence quenching
GB9725237D0 (en) * 1997-11-29 1998-01-28 Secr Defence Amplification system
EP1036201A2 (en) * 1997-12-12 2000-09-20 Intergen Company Method for detecting apoptosis using fret labeled oligonucleotides
US6117986A (en) * 1998-06-10 2000-09-12 Intergen Company, L.P. Pyrimidines linked to a quencher
WO1999064432A2 (en) * 1998-06-12 1999-12-16 Intergen Company Multi-fluorescent hairpin energy transfer oligonucleotides
GB9812768D0 (en) * 1998-06-13 1998-08-12 Zeneca Ltd Methods
AU762728B2 (en) * 1998-07-02 2003-07-03 Gen-Probe Incorporated Molecular torches
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
DE19858588B4 (en) * 1998-08-22 2016-04-07 Qiagen Gmbh Dye-labeled oligonucleotide for labeling a nucleic acid molecule
US6551778B1 (en) 1999-01-28 2003-04-22 Gen-Probe Incorporated Nucleic acid sequences for detecting genetic markers for cancer in a biological sample
AUPP844899A0 (en) * 1999-02-01 1999-02-25 University Of Western Australia, The A method for detecting methylated nucleic acids
US6521428B1 (en) * 1999-04-21 2003-02-18 Genome Technologies, Llc Shot-gun sequencing and amplification without cloning
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6277607B1 (en) 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
FR2794755A1 (en) * 1999-06-14 2000-12-15 Inst Nat Sante Rech Med PROCESS FOR CIRCULARIZING OLIGONUCLEOTIDES AROUND A DOUBLE-STRANDED NUCLEIC ACID, THE STRUCTURES OBTAINED AND THEIR APPLICATIONS
US20020025519A1 (en) 1999-06-17 2002-02-28 David J. Wright Methods and oligonucleotides for detecting nucleic acid sequence variations
JP2003510017A (en) 1999-06-22 2003-03-18 インビトロジェン コーポレイション Improved primers and methods for nucleic acid detection and identification
US6830902B1 (en) * 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
GB9917307D0 (en) * 1999-07-23 1999-09-22 Sec Dep Of The Home Department Improvements in and relating to analysis of DNA
ATE360706T1 (en) * 1999-07-27 2007-05-15 Adnexus Therapeutics Inc PEPTIDE ACCEPTOR LIGATION PROCEDURE
GB9918237D0 (en) * 1999-08-04 1999-10-06 Secr Defence Detection system
DE59909871D1 (en) 1999-11-16 2004-08-05 Atto Tec Gmbh Dye-marked oligonucleotide for labeling a nucleic acid molecule
WO2001040516A2 (en) * 1999-12-02 2001-06-07 Molecular Staging Inc. Generation of single-strand circular dna from linear self-annealing segments
DE19959691A1 (en) * 1999-12-06 2001-08-16 Epigenomics Ag Method for the parallel detection of the methylation state of genomic DNA
GB2359625B (en) * 1999-12-10 2004-10-20 Molecular Light Tech Res Ltd Monitoring oligonucleotide binding process using chemiluminescence quenching
US7205129B1 (en) 2000-02-28 2007-04-17 Qiagen Gmbh Method for reducing artifacts in nucleic acid amplification
US7230092B2 (en) 2000-06-06 2007-06-12 Luminex Molecular Diagnostics, Inc. Capture moieties for nucleic acids and uses thereof
DE10029915B4 (en) * 2000-06-19 2005-06-16 Epigenomics Ag Method for the detection of cytosine methylations
US6531283B1 (en) 2000-06-20 2003-03-11 Molecular Staging, Inc. Protein expression profiling
ATE374835T1 (en) 2000-06-30 2007-10-15 Qiagen Gmbh SIGNAL AMPLIFICATION WITH ßLOLLIPOPß HYDRIDIZATION SAMPLES
WO2002010186A1 (en) * 2000-07-27 2002-02-07 California Institute Of Technology A rapid, quantitative method for the mass spectrometric analysis of nucleic acids for gene expression and genotyping
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002018649A1 (en) * 2000-08-25 2002-03-07 Lovelace Respiratory Research Institute Nested methylation-specific polymerase chain reaction cancer detection method
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7494817B2 (en) * 2000-09-06 2009-02-24 Transnet Yx, Inc. Methods for genotype screening using magnetic particles
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US20050266494A1 (en) * 2000-09-06 2005-12-01 Hodge Timothy A System and method for computer network ordering of biological testing
US20030082605A1 (en) * 2000-09-06 2003-05-01 Hodge Timothy A. Genomic DNA detection method and system thereof
US20030087286A1 (en) * 2000-09-06 2003-05-08 Hodge Timothy A. Isolation of eukaryotic genomic DNA using magnetically responsive solid functionalized particles
US7011943B2 (en) * 2000-09-06 2006-03-14 Transnetyx, Inc. Method for detecting a designated genetic sequence in murine genomic DNA
US20050239125A1 (en) * 2000-09-06 2005-10-27 Hodge Timothy A Methods for genotype screening
US20040166499A1 (en) 2000-10-05 2004-08-26 Yoshihide Hayashizaki Oligonucleotide linkers comprising a variable cohesive portion and method for the praparation of polynucleotide libraries by using said linkers
JP2004530410A (en) * 2000-10-24 2004-10-07 インタージェン カンパニー Detection of specific nucleotide sequences
WO2002061133A2 (en) 2000-11-09 2002-08-08 Yale University Nucleic acid detection using structured probes
US20020102557A1 (en) * 2001-01-31 2002-08-01 Gentile-Davey Maria C. Self -complementary molecular probe
NZ528348A (en) * 2001-02-27 2007-07-27 Virco Bvba Circular probe amplification (CPA) using closed circular padlock probe molecules and energy-transfer primers
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
CN1279182C (en) * 2001-04-17 2006-10-11 纽约血液中心有限公司 Universal multi-variant detection system
CA2344599C (en) * 2001-05-07 2011-07-12 Bioneer Corporation Selective polymerase chain reaction of dna of which base sequence is completely unknown
GB0112868D0 (en) 2001-05-25 2001-07-18 Secr Defence Detection system
CA2348042A1 (en) 2001-06-04 2002-12-04 Ann Huletsky Sequences for detection and identification of methicillin-resistant staphylococcus aureus
US6977163B1 (en) 2001-06-13 2005-12-20 Caliper Life Sciences, Inc. Methods and systems for performing multiple reactions by interfacial mixing
US20020197611A1 (en) * 2001-06-21 2002-12-26 Chagovetz Alexander Michael Method for real-time detection and quantification of nucleic acid sequences using fluorescent primers
US7297494B2 (en) * 2001-06-25 2007-11-20 Georgia Tech Research Corporation Activatable probes and methods for in vivo gene detection
JP4537053B2 (en) 2001-06-25 2010-09-01 ジョージア テック リサーチ コーポレーション Double resonance energy transfer nucleic acid probe
US9261460B2 (en) 2002-03-12 2016-02-16 Enzo Life Sciences, Inc. Real-time nucleic acid detection processes and compositions
AU2002367750A1 (en) * 2001-08-14 2003-11-03 Discovery, Inc. Isothermal amplification in nucleic acid analysis
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
WO2003025540A2 (en) * 2001-09-18 2003-03-27 U.S. Genomics, Inc. Differential tagging of polymers for high resolution linear analysis
WO2003027678A1 (en) * 2001-09-26 2003-04-03 Psychiatric Genomics, Inc. Fluorescence proximity assay
US6977148B2 (en) * 2001-10-15 2005-12-20 Qiagen Gmbh Multiple displacement amplification
US6617137B2 (en) * 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US7297485B2 (en) * 2001-10-15 2007-11-20 Qiagen Gmbh Method for nucleic acid amplification that results in low amplification bias
US20030165859A1 (en) * 2001-10-23 2003-09-04 Invitrogen Corporation Primers and methods for the detection and discrimination of nucleic acids
US6942972B2 (en) * 2001-10-24 2005-09-13 Beckman Coulter, Inc. Efficient synthesis of protein-oligonucleotide conjugates
US20040076994A1 (en) * 2001-10-26 2004-04-22 Hidenobu Yaku Method of detecting target nucleic acid and nucleic acid probe
DE10154318A1 (en) * 2001-10-26 2003-05-15 Epigenomics Ag Method for analyzing genomic methylation patterns
US20030148284A1 (en) * 2001-12-17 2003-08-07 Vision Todd J. Solid phase detection of nucleic acid molecules
US8323975B2 (en) * 2002-01-04 2012-12-04 The Board Of Trustees Of The Leland Stanford Junior University Telomere-encoding synthetic DNA nanocircles, and their use for the elongation of telomere repeats
EP1470147A4 (en) * 2002-01-04 2005-11-23 Univ Stanford Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
JP2003299489A (en) * 2002-02-08 2003-10-21 Mitsubishi Chemicals Corp Nucleic acid construct
US20030180776A1 (en) * 2002-02-21 2003-09-25 Ming Wu Detection by sliding template amplification
US6818420B2 (en) * 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
EP1485056B1 (en) * 2002-02-27 2011-04-06 Life Technologies Corporation Methods of using fet labeled oligonucleotides that include a'5' exonuclease resistant quencher domain and compositions for practicing the same
US9353405B2 (en) 2002-03-12 2016-05-31 Enzo Life Sciences, Inc. Optimized real time nucleic acid detection processes
AU2003267960A1 (en) * 2002-05-22 2004-01-06 Marshall University Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
US7371520B2 (en) * 2002-05-28 2008-05-13 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
US7282330B2 (en) * 2002-05-28 2007-10-16 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
JP4457001B2 (en) * 2002-05-31 2010-04-28 セクレタリー・デパートメント・オブ・アトミック・エナジー MET / FRET based method for target nucleic acid detection in which donor / acceptor moieties are on complementary strands
US9371559B2 (en) 2002-06-20 2016-06-21 The Regents Of The University Of California Compositions for detection and analysis of polynucleotides using light harvesting multichromophores
US10001475B2 (en) 2002-06-20 2018-06-19 The Regents Of The University Of California Light harvesting multichromophore compositions and methods of using the same
US7270956B2 (en) * 2002-08-26 2007-09-18 The Regents Of The University Of California Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
US8993335B2 (en) * 2003-02-13 2015-03-31 The Regents Of The University Of California Methods for detection and analysis of polynucleotide-binding protein interactions
US7144950B2 (en) 2003-09-17 2006-12-05 The Regents Of The University Of California Conformationally flexible cationic conjugated polymers
ATE476521T1 (en) * 2002-06-20 2010-08-15 Univ California METHODS AND COMPOSITIONS FOR DETECTING AND ANALYZING POLYNUCLEOTIDES USING LIGHT-TRAPPING MULTICHROMOPHORES
EP1549772B1 (en) * 2002-08-26 2013-01-02 The Regents of The University of California Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
AU2003259017A1 (en) * 2002-09-06 2004-03-29 Johns Hopkins Singapore Pte Ltd Strand specific detection and quantification
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
AU2003280603A1 (en) * 2002-10-29 2004-05-25 Kabushiki Kaisha Dnaform Method of amplifying nucleic acid
EP1567670A1 (en) * 2002-12-02 2005-08-31 Solexa Limited Recovery of original template
EP1567669B1 (en) * 2002-12-02 2010-03-24 Illumina Cambridge Limited Determination of methylation of nucleic acid sequences
US20040115643A1 (en) * 2002-12-12 2004-06-17 Lizardi Paul M. Thermodynamic equilibrium extension of primers
EP2151507B1 (en) 2002-12-20 2013-02-13 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US7955795B2 (en) * 2003-06-06 2011-06-07 Qiagen Gmbh Method of whole genome amplification with reduced artifact production
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
AU2003299867A1 (en) * 2002-12-27 2004-07-29 University Of Medicine And Dentistry Of New Jersey Method for single nucleotide polymorphism detection
WO2004068112A2 (en) * 2003-01-28 2004-08-12 Gorilla Genomics, Inc. Hairpin primer amplification
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
ES2524048T3 (en) 2003-03-31 2014-12-03 F. Hoffmann-La Roche Ag Compositions and methods for the detection of certain flaviviruses, including members of the Japanese encephalitis virus serogroup
CN1537954A (en) * 2003-04-18 2004-10-20 ������������ʽ���� Expressing genetic analysis method and probe reagent box for expressing genetic analysng
JP4336877B2 (en) * 2003-04-18 2009-09-30 アークレイ株式会社 Method for detecting β3 adrenergic receptor mutant gene and nucleic acid probe and kit therefor
AU2004235747B2 (en) * 2003-05-01 2009-05-28 Gen-Probe Incorporated Oligonucleotides comprising a molecular switch
PT1626714E (en) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diaryl ureas for diseases mediated by pdgfr
US20040248103A1 (en) * 2003-06-04 2004-12-09 Feaver William John Proximity-mediated rolling circle amplification
EP1502958A1 (en) * 2003-08-01 2005-02-02 Roche Diagnostics GmbH New detection format for hot start real time polymerase chain reaction
DE10337668A1 (en) * 2003-08-08 2005-03-03 Wessig, Pablo, Dr. Molecular probe and material for detection of an analyte and their use
DE10338308B4 (en) * 2003-08-15 2006-10-19 Epigenomics Ag Method for the detection of cytosine methylations in DNA
US20050074779A1 (en) * 2003-10-02 2005-04-07 Tuan Vo-Dinh SERS molecular probe for diagnostics and therapy
US7910296B2 (en) 2003-10-21 2011-03-22 Orion Genomics Llc Methods for quantitative determination of methylation density in a DNA locus
US7667024B2 (en) * 2003-11-19 2010-02-23 Allelogic Biosciences Corp. Oligonucleotides labeled with a plurality of fluorophores
CA2547072C (en) 2003-11-26 2015-06-23 Applera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
EP2287341B1 (en) 2003-12-01 2013-02-13 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
KR100542895B1 (en) * 2003-12-22 2006-01-11 재단법인 포항산업과학연구원 Method for controlling ballast water using effect of NaOCl produced electrolysis of natural seawater and an apparatus for the same
US20050266554A1 (en) * 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
WO2005063971A2 (en) 2003-12-23 2005-07-14 Cythera, Inc Definitive endoderm
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US8647873B2 (en) * 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
US7625753B2 (en) * 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
EP1712618B1 (en) * 2003-12-25 2014-06-04 Riken Method of amplifying nucleic acid and method of detecting mutated nucleic acid using the same
GB0406015D0 (en) * 2004-03-17 2004-04-21 Dynal Biotech Asa Improvements in magnetic polymer particles
EP1735460A1 (en) * 2004-03-24 2006-12-27 Epigenomics AG Method for analysis of cytosine methylation
US8192937B2 (en) * 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
WO2005111241A2 (en) 2004-05-07 2005-11-24 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
JP4476050B2 (en) * 2004-06-30 2010-06-09 株式会社ニデック Perimeter
AU2005280162B2 (en) 2004-08-27 2012-04-26 Gen-Probe Incorporated Single-primer nucleic acid amplification methods
DE602005025782D1 (en) * 2004-09-21 2011-02-17 Life Technologies Corp TWO-TONE REAL-TIME / END POINT QUANTIFICATION OF MICRO-RNAS (MIRNAS)
CA2584576C (en) * 2004-10-18 2015-12-08 Brandeis University Reagents and methods for improving reproducibility and reducing mispriming in pcr amplification
US20090197249A1 (en) 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
US20060105348A1 (en) * 2004-11-15 2006-05-18 Lee Jun E Compositions and methods for the detection and discrimination of nucleic acids
US20060275792A1 (en) * 2004-11-15 2006-12-07 Lee Jun E Enhancement of nucleic acid amplification using double-stranded DNA binding proteins
CA2594223C (en) * 2005-01-03 2016-03-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primer for nucleic acid detection
EP2502946B1 (en) 2005-01-10 2017-10-04 The Regents of The University of California Cationic conjugated polymers suitable for strand-specific polynucleiotide detection in homogeneous and solid state assays
US7811755B2 (en) * 2005-01-10 2010-10-12 The Regents Of The University Of California Methods and articles for strand-specific polynucleotide detection with cationic multichromophores
WO2006083932A2 (en) 2005-01-31 2006-08-10 The Regents Of The University Methods and compositions for aggregant detection
GB0502010D0 (en) * 2005-02-01 2005-03-09 Enigma Diagnostics Ltd Biochemical reagents and their uses
WO2007044057A2 (en) * 2005-02-24 2007-04-19 The Ohio State University Research Foundation Methods for quantifying microrna precursors
EP1856296A2 (en) 2005-03-11 2007-11-21 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
US8309303B2 (en) 2005-04-01 2012-11-13 Qiagen Gmbh Reverse transcription and amplification of RNA with simultaneous degradation of DNA
EP1924713B1 (en) * 2005-08-24 2011-11-09 Life Technologies Corporation A method to quantify sirnas, mirnas and polymorphic mirnas
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
ATE519863T1 (en) * 2005-10-05 2011-08-15 Hoffmann La Roche NON-FLUORESCENT ENERGY TRANSFER
US7838221B2 (en) 2005-10-11 2010-11-23 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA)
US11834720B2 (en) 2005-10-11 2023-12-05 Geneohm Sciences, Inc. Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx
EP1960542A4 (en) * 2005-12-05 2009-05-13 Temasek Life Sciences Lab Ltd Fluorescent primer system for detection of nucleic acids (q priming)
US20080057499A1 (en) * 2006-02-06 2008-03-06 Affymetrix, Inc. Methods for high specificity whole genome amplification and hybridization
GB0605584D0 (en) * 2006-03-20 2006-04-26 Olink Ab Method for analyte detection using proximity probes
CA2648702A1 (en) * 2006-04-04 2007-10-11 Arcxis Biotechnologies, Inc. Cooperative probes and methods of using them
FR2900158A1 (en) * 2006-04-25 2007-10-26 Biomerieux Sa Probe for detecting a target sequence comprises a first nucleotide segment with a sterically hindering structure at its 5' end and a second nucleotide segment complementary to the target sequence
WO2007127454A2 (en) 2006-04-28 2007-11-08 Cythera, Inc. Hepatocyte lineage cells
US20100216657A1 (en) * 2006-05-16 2010-08-26 Arcxis Biotechnologies, Inc. Pcr-free sample preparation and detection systems for high speed biologic analysis and identification
US7833716B2 (en) 2006-06-06 2010-11-16 Gen-Probe Incorporated Tagged oligonucleotides and their use in nucleic acid amplification methods
JP2008029333A (en) * 2006-07-03 2008-02-14 Fujifilm Corp Primer for use in new gene amplification method
EP2639317B1 (en) 2006-09-11 2015-03-04 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
FR2906532B1 (en) 2006-09-28 2008-12-12 Biomerieux Sa NEW OLIGONUCLEOTIDE BRAND
WO2008051511A2 (en) 2006-10-20 2008-05-02 Applera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US9938641B2 (en) * 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
US8518646B2 (en) 2006-12-19 2013-08-27 Geneohm Sciences, Inc. Detection of Staphylococcus aureus and identification of methicillin-resistant Staphylococcus aureus
EP2134677B1 (en) 2006-12-20 2011-10-12 Bayer HealthCare LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
CA2674907C (en) 2007-01-31 2017-04-04 Celera Corporation A molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof
WO2008096146A1 (en) 2007-02-07 2008-08-14 Solexa Limited Preparation of templates for methylation analysis
US8906354B2 (en) 2007-02-28 2014-12-09 Bruker Biospin Corporation Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes
US8017104B2 (en) * 2007-02-28 2011-09-13 Carestream Health, Inc. Large stoke shift dye used for optical imaging
US8183359B2 (en) 2007-03-01 2012-05-22 Gen-Probe Incorporated Kits for amplifying DNA
WO2008151004A1 (en) 2007-05-31 2008-12-11 Yale University A genetic lesion associated with cancer
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
EP2700723B1 (en) 2007-08-06 2015-07-15 Orion Genomics, LLC Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
NZ583796A (en) * 2007-09-17 2011-12-22 Oncomethylome Sciences Sa Improved detection of mage-a expression
US7695963B2 (en) * 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
US8043978B2 (en) 2007-10-11 2011-10-25 Riken Electronic device and method for producing electronic device
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
WO2009155271A1 (en) * 2008-06-17 2009-12-23 Sigma-Aldrich Co. Real time polymerase chain reaction process using a universal detection system
CN101619335B (en) * 2008-07-01 2012-04-18 中国人民解放军军事医学科学院基础医学研究所 Method for preparing single chain DNA by using primer with stem-loop sample structure through PCR
FR2933410B1 (en) * 2008-07-04 2010-08-20 Biomerieux Sa NEW DETECTION PROBE
US8216786B2 (en) 2008-07-09 2012-07-10 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
GB0909333D0 (en) 2009-06-01 2009-07-15 Fu Guoliang Multiplex amplification and detection
EP2373808B1 (en) 2008-12-09 2015-11-25 Oxitec Limited Enhanced taqman probe based amplification
CA2751287A1 (en) 2009-02-06 2010-09-10 Yale University A snp marker of breast and ovarian cancer risk
US20100286926A1 (en) 2009-02-11 2010-11-11 Orion Genomics Llc Combinations of polymorphisms for determining allele-specific expression of igf2
WO2010101947A2 (en) * 2009-03-02 2010-09-10 Cooperative Diagnostics, Llc Rapid oligo probes
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
EA021100B1 (en) 2009-03-17 2015-04-30 МДхХЭЛС СА Improved detection of gene expression
WO2010121223A2 (en) * 2009-04-17 2010-10-21 California Institute Of Technology Electromagnetic molecular sensors and methods of using same
WO2010147848A2 (en) 2009-06-15 2010-12-23 Rd Biosciences, Inc. Kits and methods for selective amplification and detection of nucleic acid targets
AU2010265889A1 (en) 2009-06-25 2012-01-19 Yale University Single nucleotide polymorphisms in BRCA1 and cancer risk
CN102686728B (en) 2009-06-29 2018-09-18 卢米耐克斯公司 Chimeric primers with hairpin conformation and its application method
KR20110050327A (en) 2009-11-07 2011-05-13 주식회사 씨젠 T h d primer target detection
EP4276190A3 (en) 2009-12-03 2023-12-27 Quest Diagnostics Investments Incorporated Methods for the diagnosis of bacterial vaginosis
EP2516679B1 (en) 2009-12-21 2017-08-23 Seegene, Inc. Tsg primer target detection
WO2011078439A1 (en) * 2009-12-24 2011-06-30 Seegene, Inc. Real-time multiplexing detection of target nucleic acid sequences with elimination of false signals
US20110177512A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Method for assuring amplification of an abnormal nucleic acid in a sample
US8574832B2 (en) * 2010-02-03 2013-11-05 Massachusetts Institute Of Technology Methods for preparing sequencing libraries
EP2545384B1 (en) * 2010-03-12 2017-12-13 JPT Peptide Technologies GmbH Method for determining the concentration of a peptide
GB201004292D0 (en) * 2010-03-15 2010-04-28 Olink Ab Assay for localised detection of analytes
WO2011130728A1 (en) 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention diseases and conditions
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
WO2011154139A2 (en) 2010-06-07 2011-12-15 Roche Diagnostics Gmbh Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
CN103210092B (en) * 2010-06-14 2015-11-25 新加坡国立大学 The quantitative PCR of the oligonucleotide mediated reverse transcription of stem-ring of modifying and base intervals restriction
GB201011971D0 (en) 2010-07-15 2010-09-01 Olink Ab Methods and product
US8778614B2 (en) 2010-08-24 2014-07-15 Enzo Life Sciences, Inc. Assays for detecting modified compounds
US8557532B2 (en) 2010-08-30 2013-10-15 The University Of Utah Research Foundation Diagnosis and treatment of drug-resistant Ewing'S sarcoma
WO2012034007A2 (en) 2010-09-10 2012-03-15 Bio-Rad Laboratories, Inc. Size selection of dna for chromatin analysis
US9051606B2 (en) 2010-09-10 2015-06-09 Qiagen Gaithersburg, Inc. Methods and compositions for nucleic acid detection
WO2012049316A1 (en) 2010-10-15 2012-04-19 Olink Ab Dynamic range methods
GB201017978D0 (en) 2010-10-25 2010-12-08 Oxitec Ltd Multiplex amplification and detection
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
WO2012095748A2 (en) * 2011-01-14 2012-07-19 Smiths Detection - Watford Limited Single tube quantitative polymerase chain reaction (pcr)
GB201101621D0 (en) 2011-01-31 2011-03-16 Olink Ab Method and product
EP2675913B1 (en) 2011-02-15 2016-12-14 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic dna
WO2012112883A1 (en) 2011-02-18 2012-08-23 Yale University The kras-variant and endometriosis
WO2012129352A1 (en) 2011-03-21 2012-09-27 Yale University The kras variant and tumor biology
GB201107863D0 (en) 2011-05-11 2011-06-22 Olink Ab Method and product
US9109226B2 (en) * 2011-09-01 2015-08-18 New England Biolabs, Inc. Synthetic nucleic acids for polymerization reactions
WO2013035875A1 (en) 2011-09-08 2013-03-14 独立行政法人理化学研究所 Primer set, method for amplifying target nucleic acid sequence using same, and method for detecting mutated nucleic acid using same
EP2570487A1 (en) * 2011-09-16 2013-03-20 Lexogen GmbH Nucleic acid transcription method
DK2756098T3 (en) 2011-09-16 2018-09-03 Lexogen Gmbh Process for Preparing a Library of Nucleic Acid Molecules
WO2013041577A1 (en) 2011-09-20 2013-03-28 Vib Vzw Methods for the diagnosis of amyotrophic lateral sclerosis and frontotemporal lobar degeneration
US9352312B2 (en) 2011-09-23 2016-05-31 Alere Switzerland Gmbh System and apparatus for reactions
US9416153B2 (en) 2011-10-11 2016-08-16 Enzo Life Sciences, Inc. Fluorescent dyes
WO2013059044A1 (en) * 2011-10-18 2013-04-25 Celedon Alfredo Andres Detection units and methods for detecting a target analyte
GB201201547D0 (en) 2012-01-30 2012-03-14 Olink Ab Method and product
AU2013243300B2 (en) 2012-04-05 2018-12-06 Oregon Health & Science University Gene expression panel for breast cancer prognosis
BR112014024888B1 (en) 2012-04-06 2023-05-16 Geneohm Sciences Canada, Inc COMPOSITION AND METHOD TO DETECT METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
CN102796816B (en) * 2012-07-06 2014-04-16 陕西北美基因股份有限公司 Method for performing in-vitro accurate test on KRAS gene mutation
CN102796817B (en) * 2012-07-06 2014-06-25 陕西北美基因股份有限公司 Method for rapidly detecting mutation of KRAS gene
WO2014052487A1 (en) 2012-09-28 2014-04-03 Cepheid Two-primer pcr for microrna multiplex assay
CN104955963A (en) 2012-11-14 2015-09-30 欧凌科公司 Rca reporter probes and their use in detecting nucleic acid molecules
WO2014076209A1 (en) 2012-11-14 2014-05-22 Olink Ab Localised rca-based amplification method
US9411930B2 (en) 2013-02-01 2016-08-09 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
CA2899020C (en) 2013-02-01 2023-10-03 The Regents Of The University Of California Methods for genome assembly and haplotype phasing
CN105339505B (en) 2013-03-12 2021-08-10 生命技术公司 Universal reporter-based genotyping methods and materials
EP3564370B1 (en) 2013-03-15 2022-01-12 Labrador Diagnostics LLC Nucleic acid amplification
CN105431550A (en) * 2013-03-15 2016-03-23 雅培分子公司 Multiplex allele detection
US10450595B2 (en) 2013-03-15 2019-10-22 Theranos Ip Company, Llc Nucleic acid amplification
JP2016521120A (en) 2013-03-15 2016-07-21 セラノス, インコーポレイテッド Nucleic acid amplification
AU2014237563B2 (en) 2013-03-15 2020-06-11 Becton, Dickinson And Company Detection of neisseria gonorrhoeaes
KR102240332B1 (en) 2013-03-15 2021-04-14 아벨리노 랩 유에스에이, 인크. Methods for improved isolation of genomic dna templates for allele detection
ES2738602T3 (en) 2013-03-15 2020-01-24 Theranos Ip Co Llc Nucleic acid amplification
CA2917206C (en) * 2013-08-09 2021-09-21 Genebio Systems, Inc. Dna amplification via scissor-like structures (dasl)
GB2517700A (en) * 2013-08-27 2015-03-04 Lgc Ltd Oligonucleotides comprising a secondary structure and uses thereof
SG11201601611WA (en) 2013-09-06 2016-04-28 Theranos Inc Systems and methods for detecting infectious diseases
GB201320145D0 (en) 2013-11-14 2014-01-01 Olink Ab Localised RCA-based amplification method using a padlock-probe
EP3872192A1 (en) 2013-11-15 2021-09-01 Avellino Lab USA, Inc. Methods for multiplex detection of alleles associated with ophthalmic conditions
CN105452451B (en) 2013-12-06 2020-06-05 生物辐射实验室股份有限公司 Fusion polymerases
WO2015089243A1 (en) 2013-12-11 2015-06-18 The Regents For Of The University Of California Methods for labeling dna fragments to recontruct physical linkage and phase
GB201401885D0 (en) 2014-02-04 2014-03-19 Olink Ab Proximity assay with detection based on hybridisation chain reaction (HCR)
WO2015147370A1 (en) 2014-03-28 2015-10-01 Seegene, Inc. Detection of target nucleic acid sequences using different detection temperatures
WO2016014493A1 (en) 2014-07-22 2016-01-28 Bio-Rad Laboratories, Inc. Buffers for use with polymerases
EP4219710A3 (en) 2014-08-01 2023-08-16 Dovetail Genomics, LLC Tagging nucleic acids for sequence assembly
CA2955967A1 (en) * 2014-08-14 2016-02-18 Abbott Molecular Inc. Multifunctional oligonucleotides
WO2016050813A1 (en) * 2014-09-30 2016-04-07 Koninklijke Philips N.V. Method for detecting a spatial proximity of a first and a second epitope
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
CN107533590B (en) 2015-02-17 2021-10-26 多弗泰尔基因组学有限责任公司 Nucleic acid sequence Assembly
US11807896B2 (en) 2015-03-26 2023-11-07 Dovetail Genomics, Llc Physical linkage preservation in DNA storage
CA2982467C (en) 2015-04-24 2024-02-13 Becton, Dickinson And Company Multiplex detection of vulvovaginal candidiasis, trichomoniasis and bacterial vaginosis
KR20180096586A (en) 2015-10-19 2018-08-29 더브테일 제노믹스 엘엘씨 Methods for Genome Assembly, Haplotype Paging and Target Independent Nucleic Acid Detection
GB201518655D0 (en) 2015-10-21 2015-12-02 Olink Ab Method for generating proximity probes
ES2899242T3 (en) 2015-11-20 2022-03-10 Seegene Inc Method for calibrating a data set of a target analyte
WO2017105104A1 (en) 2015-12-15 2017-06-22 Seegene, Inc. Signal extraction for a target nucleic acid sequence
EP3402900A1 (en) 2016-01-12 2018-11-21 Interleukin Genetics, Inc. Methods for predicting response to treatment
CN105624296A (en) * 2016-01-28 2016-06-01 屈强 Universal fluorescent hairpin primers for detecting gene polymorphism on basis of ARMS (amplification refractory mutation system) fluorescent PCR (polymerase chain reaction) process
KR102300738B1 (en) 2016-02-05 2021-09-10 주식회사 씨젠 How to reduce the noise level of a data set for a target analyte
CA3014911A1 (en) 2016-02-23 2017-08-31 Dovetail Genomics, Llc Generation of phased read-sets for genome assembly and haplotype phasing
JP2019515035A (en) 2016-04-27 2019-06-06 ミラ ディーエックス, インコーポレイテッド Immunity-based treatment of KRAS variant cancer patients
EP3455356B1 (en) 2016-05-13 2021-08-04 Dovetail Genomics LLC Recovering long-range linkage information from preserved samples
WO2017207825A1 (en) 2016-06-03 2017-12-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Methods for the detection of a latent tuberculosis infection
KR102301305B1 (en) 2016-06-30 2021-09-13 주식회사 씨젠 Tube for amplifying nucleic acid and reaction vessel for amplifying nucleic acid
GB201621514D0 (en) 2016-12-16 2017-02-01 Q-Linea Ab Padlock probe detection method
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
WO2018175399A1 (en) 2017-03-24 2018-09-27 Bio-Rad Laboratories, Inc. Universal hairpin primers
TW201840856A (en) 2017-03-29 2018-11-16 大陸商中美冠科生物技術(太倉)有限公司 System and method for determining cetuximab sensitivity on gastric cancer
KR102602627B1 (en) 2017-04-28 2023-11-16 아벨리노 랩 유에스에이, 인크. Methods for detection of alleles associated with keratoconus
WO2019045532A2 (en) 2017-08-31 2019-03-07 Seegene, Inc. Evaluation of performance of components using a pair of dimer-forming primers
KR102345601B1 (en) 2017-09-29 2021-12-30 주식회사 씨젠 Detection of target nucleic acid sequences by PTO cleavage and extension-dependent extension analysis
CN111263819A (en) 2017-10-06 2020-06-09 卡特阿纳公司 RNA templated ligation
EP3735476B1 (en) 2018-01-05 2023-08-23 Seegene, Inc. Method for determining the presence or absence of m. tuberculosis, m. bovis and m. bovis bcg in a sample
KR102464501B1 (en) 2018-04-20 2022-11-17 주식회사 씨젠 Methods and apparatus for detection of a plurality of target nucleic acid sequences in a sample
KR102220701B1 (en) 2018-09-28 2021-03-03 (주)나노헬릭스 Multiplex identification method of pcr product using fluorescence-based multiple melting analysis
CN109797200B (en) * 2019-02-13 2022-07-19 中国科学院苏州生物医学工程技术研究所 Ratio type telomerase activity quantitative detection method
CA3142662A1 (en) 2019-06-06 2020-12-10 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
US20230119074A1 (en) * 2019-09-17 2023-04-20 Boe Technology Group Co., Ltd. Quantum dot ligand, quantum dot material and quantum dot light emitting device
GB201919029D0 (en) 2019-12-20 2020-02-05 Cartana Ab Method of detecting an analyte
GB201919032D0 (en) 2019-12-20 2020-02-05 Cartana Ab Method of detecting an analyte
BR112022018015A2 (en) * 2020-03-13 2022-12-06 Uh Oh Labs Inc LOOP PRIMER AND LOOP-TO-LOOP METHOD TO DETECT TARGET NUCLEIC ACID
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19
EP4150118A1 (en) 2020-05-14 2023-03-22 Becton Dickinson and Company Primers for immune repertoire profiling
JP2023547536A (en) 2020-11-05 2023-11-10 ベクトン・ディキンソン・アンド・カンパニー Multiplex detection of bacterial respiratory pathogens
AU2021376490A1 (en) 2020-11-05 2023-05-11 Becton, Dickinson And Company Rapid identification and typing of vibrio parahaemolyticus
AU2021374695A1 (en) 2020-11-05 2023-07-13 Becton, Dickinson And Company Multiplex detection and typing of vibrio cholerae
WO2023039433A1 (en) 2021-09-08 2023-03-16 Becton, Dickinson And Company Non-sequencing pcr-based method for detection of antibody-conjugated oligonucleotides
WO2023067110A1 (en) * 2021-10-20 2023-04-27 Tataa Biocenter Ab Methods and compositions for detection of mutant nucleic acid sequences
WO2024003792A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Viral detection assays
WO2024028818A1 (en) 2022-08-04 2024-02-08 Crispr Therapeutics Ag Method for detecting mycoplasma contamination
WO2024044352A1 (en) 2022-08-26 2024-02-29 The General Hospital Corporation Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998943A (en) * 1954-08-12 1961-09-05 Billy D Dobbins Antenna cap
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4199559A (en) * 1974-08-12 1980-04-22 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
IT1079045B (en) * 1977-05-16 1985-05-08 Syva Co DOUBLE RECEPTOR FLUORESCENT IMUUNOLOGICAL ANALYSIS
CA1190838A (en) * 1981-07-17 1985-07-23 Cavit Akin Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer
US5288609A (en) * 1984-04-27 1994-02-22 Enzo Diagnostics, Inc. Capture sandwich hybridization method and composition
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4996143A (en) * 1985-12-23 1991-02-26 Syngene, Inc. Fluorescent stokes shift probes for polynucleotide hybridization
CA1273552A (en) * 1985-12-23 1990-09-04 Michael J. Heller Fluorescent stokes shift probes for polynucleotide hybridization assays
US4889818A (en) * 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5079352A (en) * 1986-08-22 1992-01-07 Cetus Corporation Purified thermostable enzyme
DE3803275A1 (en) * 1988-02-04 1989-08-17 Dornier Medizintechnik PIEZOELECTRIC SHOCK WAVE SOURCE
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5118801A (en) * 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
WO1990012115A1 (en) * 1989-03-21 1990-10-18 Collaborative Research, Inc. A dna diagnostic test using an exonuclease activity
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP3080178B2 (en) * 1991-02-18 2000-08-21 東洋紡績株式会社 Method for amplifying nucleic acid sequence and reagent kit therefor
WO1992014845A1 (en) * 1991-02-26 1992-09-03 Worcester Foundation For Experimental Biology Diagnosing cystic fibrosis and other genetic diseases using fluorescence resonance energy transfer (fret)
JP3085409B2 (en) * 1991-03-29 2000-09-11 東洋紡績株式会社 Method for detecting target nucleic acid sequence and reagent kit therefor
CA2074214C (en) * 1991-07-23 2000-02-22 Will Bloch Improvements in the in situ pcr
ES2159282T3 (en) * 1991-11-07 2001-10-01 Nanotronics Inc HYBRIDIZATION OF POLINUCLEOTIDES CONJUGATED WITH CHROMOFORAS AND FLUOROFOROS IN ORDER TO GENERATE ENERGY TRANSFER SYSTEMS FROM DONATOR TO DONATOR.
US5567583A (en) * 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
EP0566751B1 (en) * 1992-03-23 1996-01-10 F. Hoffmann-La Roche Ag DNA detection method
EP0601889A2 (en) * 1992-12-10 1994-06-15 Maine Medical Center Research Institute Nucleic acid probes
US5593840A (en) * 1993-01-27 1997-01-14 Oncor, Inc. Amplification of nucleic acid sequences
WO1994017206A1 (en) * 1993-01-27 1994-08-04 Oncor, Inc. Method for amplifying nucleic acid sequences
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
CA2176348C (en) * 1993-11-12 2004-11-02 Sanjay Tyagi Hybridization probes for nucleic acid detection, universal stems, methods and kits
US5654419A (en) * 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5547861A (en) * 1994-04-18 1996-08-20 Becton, Dickinson And Company Detection of nucleic acid amplification
DE69427876T2 (en) * 1994-05-23 2002-04-11 Biotronics Corp METHOD FOR DETECTING A TARGETED NUCLEIC ACID
US5866336A (en) * 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5691145A (en) * 1996-08-27 1997-11-25 Becton, Dickinson And Company Detection of nucleic acids using G-quartets
US5681145A (en) * 1996-10-30 1997-10-28 Itt Automotive Electrical Systems, Inc. Low-noise, high-efficiency fan assembly combining unequal blade spacing angles and unequal blade setting angles

Also Published As

Publication number Publication date
ATE305476T1 (en) 2005-10-15
JP2001513623A (en) 2001-09-04
CA2260973A1 (en) 1998-01-22
US6117635A (en) 2000-09-12
WO1998002449A1 (en) 1998-01-22
DE69734283D1 (en) 2006-02-09
EP0912597B1 (en) 2005-09-28
DE69734283T2 (en) 2006-07-06
EP0912597A1 (en) 1999-05-06
US6090552A (en) 2000-07-18
ES2248852T3 (en) 2006-03-16
JP2003111599A (en) 2003-04-15
JP3597869B2 (en) 2004-12-08
EP0912597A4 (en) 2001-04-11
AU3728597A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
CA2260973C (en) Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5866336A (en) Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
WO1998002449A9 (en) Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US7824890B2 (en) Isothermal amplification of nucleic acids
CA2163388C (en) Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
AU2010290277B2 (en) TD probe and its uses
EP2606150B1 (en) Quantitative real-time pcr assay using fret dual-labeled primers
AU5882000A (en) Improved primers and methods for the detection and discrimination of nucleic acids
JP6166342B2 (en) Polymerase chain reaction detection system using oligonucleotides containing phosphorothioate groups
CA2747068C (en) Nucleic acid amplification with allele-specific suppression of sequence variants
JPH0870876A (en) Decomposition detecting method of oligonucleotide labeled with luminous label
WO2017205510A1 (en) Omega amplification
EP2256215A1 (en) Assay system using a nuclease activity of a nucleic acid polymerase
CA2392469A1 (en) Oligonucleotides and assemblies thereof useful in the detection of the presence or absence of target nucleic acid sequences in a sample
CA2781133C (en) Preferential amplification of mrna over dna using chemically modified primers
CA2705852C (en) Photoinduced electron transfer (pet) primer for nucleic acid amplification
AU2006200604A1 (en) Improved primers and methods for the detection and discrimination of nucleic acids

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170717